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Abstract 
Metalloproteinase family members such as MMPs and ADAMs have well-defined roles 
in host immunity. ADAMTS family members however remain largely uncharacterised in this 
context. Considering the potential use of ADAMTS enzymes as pharmacological targets, it is 
critical we understand the functional role of ADAMTS enzymes in cellular processes. This 
thesis describes the importance of two ADAMTS enzymes, ADAMTS5 and ADAMTS7, in 
regulating viral immunity.  
ADAMTS5 enzymatic activity has a well-characterised role in arthritis pathogenesis 
with extensive literature supporting these observations. Studies in this thesis have utilised the 
Adamts5 knockout mouse model to determine the role of ADAMTS5 in influenza virus 
immunity. In our studies, we found that the absence of ADAMTS5 in mice results in increased 
influenza virus associated disease characterised by perturbed CD8+ T cell immunity in the 
spleen and lung. Moreover, CD8+ T cells accumulated in the mediastinal lymph node (MLN), 
the site of CD8+ T cell activation. We suggest that accumulation of CD8+ T cells is linked to 
increased versican levels, a key substrate of ADAMTS5. Therefore, we propose that 
ADAMTS5 plays a crucial role in regulating CD8+ T cell migration from the MLN to 
periphery following influenza virus infection.  
ADAMTS7 has previously been identified in a human protease screen as having a key 
role in influenza virus pathogenesis. Chapter 5 of this thesis extends these observations in a 
Adamts7 knockout mouse model to further characterise ADAMTS7’s role in controlling the 
immune responses in vivo. Our results show that the absence of ADAMTS7 in mice negatively 
impacts dendritic cell (DC) activation and CD8+ T cell responses-, culminating in delayed viral 
clearance and increased susceptibility to disease.  
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Finally, we found that Adamts5-/- and Adamts7-/- mice were potentially more susceptible 
to Hendra virus infection, suggesting ADAMTS5 and ADAMTS7 are essential mediators for 
the removal of infectious diseases in mice. 
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Chapter 1 - Introduction 
Influenza is an acute, febrile, and highly contagious respiratory disease which causes 
significant global morbidity and mortality (1-3). Annually, influenza viruses kill between 
250,000 and 500,000 people (2-4), and, although influenza viruses can infect all age groups, 
it’s the elderly (> 65 years) and the young (< 2 years) who succumb more readily to disease (5, 
6). Moreover, influenza virus infection causes a substantial economic burden through increased 
healthcare costs and decreased workplace productivity, equating to a $USD 87.1 billion global 
economic burden per year (7). 
Though there are therapeutic treatments available for influenza virus infection, current 
strategies need to be constantly adapted to align with changes occurring in the influenza virus 
genome that can lead to pandemic potential (see section 1.2). The emergence of pandemic 
strains constantly reminds us that current therapies (vaccines and antivirals; see section 1.3) 
can be ineffectual at combating some novel influenza virus strains (8). Consequently, there is 
a strong need for new and reliable therapeutic targets.  
 
 
1.1 Influenza viruses 
Influenza viruses form part of the Orthomyxoviradea family of viruses, which contain 
five members: influenza A, B, C and D viruses, thogotovirus and isavirus (9). All three 
influenza virus types can infect humans, yet, it is influenza A and B viruses that contribute 
significantly to global mortality (10). Influenza A viruses contain 8 negative sense single 
stranded ribonucleic acid (RNA) segments that encode 12 main proteins (11, 12). These 
proteins can be separated into structural and non-structural (NS) proteins (Figure 1.1). The 
structural proteins include the matrix (M) 1 protein and the M2 ion transporter encoded by the 
M gene, the neuraminidase (NA) and haemagglutinin (HA) glycoproteins and the components 
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of the RNA-polymerase complex which include the polymerase basic (PB) 1, PB2 and Acid 
polymerase (PA), and the RNA nucleoprotein (NP) (11, 12). NS proteins include NS-1, the 
nuclear export protein (NEP), the PB1-frame 2 and the recently defined PA-X protein (13). 
Other proteins encoded by some influenza virus strains include the N-terminally truncated 
version of the polypeptide (14), the PB2-S1 (15) and the M42 (16).  
Of importance to virus classification and replication are the surface glycoproteins, the 
HA and NA, which assist with virus infection. Currently there have been 18 HA and 11 NA 
variants identified (17, 18). HA is a homo-trimeric protein that allows influenza viruses to 
attach to sialic acid receptors on lung epithelial cells and enter the host cell in order to replicate 
(17). Human influenza viruses bind to sialic acids in an α2-6 conformation, whereas avian 
influenza viruses bind α2-3 sialic acid receptors (19). The NA is a tetrameric protein which 
cleaves sialic acids attached to HA glycoproteins facilitating its release from the infected cell 
(11). Due to their location on the surface of influenza virus, HA and NA are more susceptible 
to selection pressures imposed by the host immune response. As such, the HA and NA undergo 
constant mutation. 
 
 
1.2 Antigenic drift and shift of influenza viruses 
A single exposure to influenza virus is usually sufficient to provide immunity against 
future infection by a homologous strain. However, mutations within the HA and the NA result 
in structural changes within the genome rendering influenza virus unrecognizable to the host 
immune system, thereby allowing re-infection (20). Mutations accumulating within the HA 
and NA sequence result in antigenic drift, eventually resulting in a new strain of influenza 
virus. Antigenic drift generally occurs every 2-3 years and causes seasonal epidemics (21). 
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Figure 1.1 Influenza A Viruses.  
Influenza A viruses contain 8 negative sense RNA gene segments bound to a RNA polymerase. 
These segments are enclosed by a lipid bilayer and M proteins. The HA and NA glycoproteins 
are found on the surface of the virus and facilitate virus attachment and release from a host 
cell. 
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Major changes in the HA or NA occurs through a process known as antigenic shift. 
Antigenic shift results in novel surface glycoproteins being expressed following virus 
reassortment (5). Some animals, such as pigs, contain both α2,3 and α2,6 sialic receptors 
(receptors for HA host cell attachment) which are accessible to both avian and human influenza 
viruses (22). Due to this, pigs can be co-infected with multiple viruses. Co-infection leads to 
genetic reassortment of influenza virus genes, resulting in the formation of novel influenza 
viruses (23, 24). These viruses sometimes express new proteins for which the human host 
population is often naïve. These new viruses have, on occasion, had the ability to become 
zoonotic and initiate new pandemics. Pandemics such as the 1918 “Spanish flu”, the 1957 
“Asian Flu”, and the 1968 “Hong Kong Flu” as well as the first pandemic of this century, the 
2009 H1N1 “Swine Flu”, have all resulted from antigenic shift mutations (23). Although 
seasonal epidemics can kill up to 500,000 people each year, the pandemics mentioned above 
are estimated to have caused 40 million (1918), 4 million (1957), 1 million (1968) and 300,000 
(2009) deaths, respectively (25, 26).  
More recently, global health organizations, such as the World Health Organization, 
have been concerned about the potential for high pathogenic H5N1 and low pathogenic H7N9 
avian influenza viruses to become zoonotic. H5N1 avian influenza viruses currently have a 
mortality rate of ~60 % in humans (3, 27), however little human to human transmission has 
been definitively determined (28). Additionally, H7N9, originally detected in chickens, has 
emerged in China and has an observed 27 % mortality rate in humans (29). Although, like 
H5N1 influenza viruses, little human-to-human transmission has been observed. Due to these 
potential pandemic threats, it is imperative that therapeutic agents are designed to be effective 
against a broad range of influenza virus strains as current strategies against these zoonotic 
agents have failed to ameliorate disease.  
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1.3 Intervention strategies targeting influenza viruses 
1.3.1 Antivirals 
Antivirals are therapeutic agents that limit replication of influenza viruses. M2 and NA 
inhibitors are two classes of antivirals used to reduce the impact of influenza virus infection. 
M2 inhibitors block the ion channel, stopping protons from entering the virion and preventing 
acidification of the viral interior (30). Amantadine and rimantadine were the two most 
commonly used forms of M2 inhibitors. However, resistance to these drugs has been observed 
in all influenza virus subtypes indicating that they are not be effective for controlling virus 
replication (31, 32).  
NA inhibitors block the enzymatic activity of the NA enzyme, preventing cleavage of 
the surface-attached HA receptors which become reattached during viral exit (33). NA 
inhibitors are analogues for sialic acids, and can block the NA active site (33). Here, they inhibit 
the NA-mediated cleavage of host cell sialic acids which have become bound to HA’s upon 
cell exiting, preventing budding from the infected cell (33). This results in viral accumulation 
at the cell surface and a reduction in the number of infectious virus particles released (34). 
Tamiflu (oseltamivir) and Relenza (zanamivir) are the two commonly prescribed NA 
inhibitors. Scientists initially predicted that little or no resistance would be observed towards 
these drugs, as the NA active site is essential for the virus life cycle. However, resistance 
towards NA inhibitors has been observed in some seasonal influenza A virus subtypes as well 
as in the recent 2009 H1N1 “swine flu” pandemic (35-37). 
 
1.3.2 Vaccinations 
Influenza vaccination was introduced in the 1950s, with both inactivated and live 
formulations now commercially available and used globally. The inactivated formulation is 
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prepared by taking the allantoic cavity of embryonated chicken eggs and inactivating the 
infectious supernatant using beta-proproriolactone or formaldehyde (20, 38). Additionally, 
virus can also propagated in cell culture [e.g. Madin Darby Canine Kidney (MDCK) and 
African green monkey kidney epithelial (VERO) cell lines (39, 40)], although this is not as 
common. Current inactivated vaccines afford protection against 3-4 circulating influenza virus 
strains, usually comprising 2 influenza A and 1-2 influenza B subtypes (41). As these 
formulations contain only inactivated virus it is suitable for those over 4 years of age, 
incorporating susceptible populations such as the elderly and pregnant women (20). 
The second type of commercially available formulation is the live attenuated influenza 
vaccine (LAIV) used throughout Europe and North America. This vaccination is a nasal spray 
which introduces a live attenuated virus to the nasal cavity. Unlike the inactivated vaccine, 
which affords only humoral immune response (IgG and IgA antibodies), the LAIV activates 
both the humoral and cellular immune responses (influenza-specific CD4+ and CD8+ T cells) 
(38, 42). The importance of these immune responses in influenza virus infection will be 
explained in greater detail in Section 1.7. This type of vaccination is currently only available 
in America and Europe and is recommended to individuals aged between 5 and 60. However, 
this year the Centre for Disease Control (America) recommended that the inactivated vaccine 
be prescribed over the LAIV, due to reduced effectiveness observed of this vaccine between 
2013 and 2016.  
Additionally, the constant evolution of influenza viruses necessitates an annual review 
of vaccine components (20). However, the circulating strain is not always identified leading to 
a mismatch, additionally the time taken to select the circulating strain can further result in 
mismatches. Due to this, as well as the specific characteristics of the persons vaccinated (e.g. 
health and age), influenza vaccines have a range of efficacy between 60-90% in people aged 
between 20 and 65 (43, 44). This efficacy drops to 40-60% in the elderly (>65 years) (44-47).  
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1.3.3 Novel therapeutic targets 
As described above, current therapeutic treatments mostly target the globular HA head. 
Becaused genetic drift and shift cause changes in the influenza virus genome (mostly at the HA 
globular head), current therapeutics may not always be effective against novel circulating 
influenza subtypes. Hence, discovering new therapeutic targets (including those that target the 
virus and the host) is important in this ongoing struggle to limit the burden of influenza virus 
infection. 
 
1.3.3.1 Immune evasion pathways 
Influenza viruses can use immune evasion mechanisms to facilitate infection and 
replication. These pathways include the Raf/MEK/ERK and NF-κB pathways (48). The 
Raf/MEK/ERK pathway is necessary for normal cell growth, differentiation and survival (49, 
50). Additionally, several studies have detected that upregulation of the Raf/MEK/ERK 
pathway is necessary for influenza virus replication (51). Inhibition of the pathway at the 
MAPK/ERK level leads to lower viral loads in infected MDCK cells (51) through impaired 
NEP function resulting in nuclear retention of viral RNA. Furthermore, in vivo inhibition of 
MEK1 and MEK2 (proteins activated in the Raf/MEK/ERK pathway) using the U0126 
inhibitor resulted in lower virus titres in influenza-infected mice (52).  
The NF-κB pathway is involved in the production of cytokines associated with host 
defense against infection. In vitro studies have indicated that inhibiting the NF-κB pathway 
following influenza virus infection reduces viral load (53, 54). This is caused by viral RNA 
retention in the nucleus. Activation of this pathway is required for normal cell lysis, but it also 
supports viral release (53). In the context of influenza virus infection, in vivo inhibition of the 
NF-κB pathway, using the BAY 11-7082 NF-κB inhibitor, resulted in decreased virus titres in 
influenza virus infected mice (52). These studies identify the potential for modulating host cell 
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factors such as Raf/MEK/ERK and NF-κB to prevent influenza virus replication. Importantly, 
the USA Federal Drug Administrator has already approved cancer treatments for human use 
known to inhibit these pathways simplifying their potential use as therapeutic agents against 
influenza virus infection (54-56).  
Influenza virus infection is a lytic disease and clearance requires both arms of the 
immune system (see section 1.6 and 1.7). Immune cells assist with the clearance of influenza 
virus infected cells through activation of the NADPH pathway resulting in the release of 
reactive oxygen species (ROS), including Nox2 a subunit of the NADPH complex involved in 
hydrogen peroxide and a hydroxyl radical production (57, 58). The release of ROS promotes 
antiviral activity and the timely removal of infection. Although ROS production is beneficial 
in normal immune responses, over-reactive release can result in excessive inflammation 
leading to lung damage, contributing to mortality. The NADPH inhibitors, gp91dstat and 
apocynin, are attractive therapeutics for the reduction of influenza-associated inflammation. 
Inhibition of ROS production in vitro reduced viral titres following H5N1 and H7N9 avian 
influenza virus infection of A549 epithelial cells (59). Use of apocynin in vivo during 
A/HongKong-X31 (X31) (H3N2) infection correlated with in vitro findings (58). Furthermore 
use of ROS scavengers upon 1918 influenza virus infection in mice further supports the use of 
ROS intervention strategies to ameliorate disease burden (60). These studies were supported in 
vivo where apocynin treatment resulted in increased recovery time and decreased in neutrophil 
infiltration in influenza virus infected mice (58, 59, 61).  
These studies highlight the potential importance of  modulating the host response to 
control influenza virus infection. The development of novel therapeutic agents that modulate 
host responses could be used in combination with existing antiviral treatments that target the 
virus to a) prevent virus replication, b) aid the immune system in clearing infection and c) 
prevent further transmission of influenza viruses. 
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1.4 Mouse models of influenza virus infection 
Mouse models are commonly used to assess influenza virus replication, virulence and 
the host immune responses. Mice on the DBA/2J, BALB/c and C57BL/6 backgrounds have 
been used in influenza virus related experiments, however it is of importance to note that mice 
are not natural hosts of influenza viruses (62). Nonetheless, mouse adapted influenza virus 
strains have been developed and can be used to assess the impact of infection on the host (63, 
64).  
Like humans, mice can be intranasally infected with influenza virus (63, 64). Intranasal 
infection of mice mimics human infection and allows the analysis of primary and secondary 
immunity. Upon intranasal infection, mice show typical signs of disease, including weight loss, 
hunching and ruffled fur (62, 63). The effects of influenza virus infection in mice can be 
measured through recording weight loss, assessing virus titers from respiratory organs and 
characterizing the innate and adaptive immune responses in various tissues (63). Whilst the 
ferret has been extensively used to assess transmission of human influenza viruses our ability 
to characterize innate and adaptive immunity is constrained by a lack of reagents for this 
species. Conversely, reagents to analyze influenza-specific innate and adaptive immunity in 
mice are readily available. One such example is tetramer staining which is used to enumerate 
influenza-specific CD8+ T cells in C57BL/6 and BALB/c mice (65-69). Moreover, the 
availability of knockout mice has contributed to our detailed understanding of influenza-
specific immunity.  
 
 
1.5 Influenzas virus pathogenesis in mice – an overview 
When mice are infected with a sub-lethal dose of influenza virus [e.g. X31 (H3N2)], 
mice start losing weight at 2-3 days post infection (dpi) (representing the peak of virus titres) 
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and continue this weight loss until 6-8 dpi (63). This time point normally represents the 
induction of the adaptive immune response (see section 1.7) from which point mice begin to 
regain weight, coinciding with a reduction of viral load and clearance of virus by day 10 (Figure 
1.2) (70). This is typically depicted as a U-shaped weight loss curve.  
Innate immune cells play a pivotal role in the clearance of influenza virus infection. 
These cells increase rapidly within the first 2 days of infection and peak at 4 dpi (71). DCs, a 
key cell type involved in antigen presentation, are numerically at their highest levels in the 
lung, 18 hours’ post infection (72-75). These cells then migrate to draining lymph nodes to 
activate naïve T cells (see section 1.6.5).  
Finally, T and B cells are required for the clearance of influenza virus infection (see 
section 1.7). Removal of influenza virus infected cells by the adaptive immune response shows 
a biphasic response (71). An initial clearance is observed at early time points, which is mediated 
by innate immune cells. The latter stages of clearance are dominated by T and B cells. 
Influenza-specific T cell responses peak between 7 and 10 dpi, whereases B cell numbers and 
Influenza-specific antibodies peak 14 dpi. Following the removal of infection, influenza-
specific T and B cells will undergo apoptosis, leaving behind small stable memory populations 
(68). 
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Figure 1.2. Immunity to Influenza Viruses.  
Influenza virus titres peak at 3 dpi and viral replication is restrained by the innate and adaptive 
immune system. This figure is not to scale. 
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1.6 The innate immune response to influenza virus infection 
The protection afforded by the innate immune system against influenza virus infection 
involves numerous defense mechanisms, such as mucins and surfactants that are secreted into 
the respiratory airways (76, 77). This is in addition to the accumulation of cells associated with 
the innate immune system [neutrophils, macrophages and natural killer (NK) cells] that induce 
apoptosis, removal of influenza virus infected respiratory epithelial cells and the eventual 
activation of the adaptive immune response (77). 
 
1.6.1 Detection of influenza viruses 
Upon infection, pattern recognition receptors recognize various aspects of pathogens 
including, carbohydrates, proteins and nucleic acids (78, 79). The main pattern recognition 
receptors that detect influenza virus are the retinoic acid-inducible gene 1 (RIG-I), toll-like 
receptors (TLRs) (TLR7 and 8) and Nucleotide-binding oligomerization domain-containing 
(NOD) receptors (78, 80).  
RIG-I receptors detect the single-stranded RNA 5’triphosphate of influenza virus in the 
cytosol of infected cells (81-83). Like RIG-I receptors, NOD-1 receptors recognise viral RNA 
in cytosolic compartments. TLR7 and 8 recognise single-stranded RNA in endosomes of 
influenza-infected cells (84-86). The recognition of viral components results in the release of 
pro-inflammatory cytokines (tumour necrosis factor (TNF) α, interleukin (IL) 1α and β, 6, 8, 
18, interferon (IFN) α, β and γ) that promote the activation of innate immune cells (87). 
Interestingly, the RIG-I receptor can be blocked by the NS-1 protein expressed in the influenza 
virus infected cell (88), preventing the RIG-I signaling cascade and the eventual release of pro-
inflammatory cytokines, such as IFNα and IFNβ (81, 89). 
 
  
 
13 
 
1.6.2 Neutrophils 
Neutrophils are typically the first immune cell type to arrive in influenza virus infected 
lungs, arriving as early as 6 hours post infection (90, 91). Neutrophils secrete a range of pro-
inflammatory molecules and immune mediators, such as ROS, defensins and TNFα. These 
mediators have potent antiviral activity towards influenza virus infected cells (92-94). 
Neutrophils also generate extracellular traps following virus infection. These traps contain an 
array of excreted enzymes (such as elastase, cathepsin G and histones) to trap pathogens before 
they enter cells (93).  
As neutrophil knockout mice are embryonic lethal, understanding the importance of 
this cell type during influenza virus infection has been experimentally achieved through the 
use of neutrophil targeting antibodies (95, 96). Neutrophil depleted mice infected with X31 
(H3N2) or A/PuertoRico/8/34 H1N1 (PR8) (H1N1) influenza viruses show increased weight 
loss, pneumonia and death, indicating that these cells are essential for clearance of influenza 
virus (91, 95). Although these studies confirm that neutrophils play a critical role in limiting 
disease severity in mice, excessive neutrophil infiltration results in an overproduction of 
inflammatory mediators (e.g. ROS, TNFα) resulting in increased lung damage and pathology 
(91, 97). However, the prolonged presence of neutrophils and extracellular traps exacerbate 
damage to infected tissue (92, 98) resulting in acute lung injury and acute respiratory distress 
syndrome. This syndrome is a complication of severe influenza virus infection and is 
characterised by alveolar damage and respiratory failure (99), which can lead to death.  
 
1.6.3 Macrophages 
Resident lung macrophages detect infection, become activated and remove influenza 
virus infected cells. Removal of influenza virus infected cells occurs through phagocytosis 
(100, 101) and the production of innate cytokines, such as IFNα and β and IL12 (102). As 
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macrophage, knockout mice are embryonic lethal, antibody depletion has been used to assess 
the contribution of macrophages to influenza virus immunity. Macrophage depletion results in 
uncontrolled virus replication, severe pneumonia and increased mortality in C57BL/6 mice 
infected with BJx109 (H3N2) influenza virus (100, 103, 104). In support of these findings in 
mice, macrophage depletion in pigs using dichloromethylene diphosphonate also causes 
increased weight loss, lower antibody titres and decreased CD8+ T cell numbers following 
A/New Caledonia/20/99 (H1N1) influenza virus infection (103). Macrophage depletion in 
mice also drives compensatory neutrophil infiltration into the lungs (105), leading to the over-
production of pro-inflammatory molecules that contribute to the destruction of lung tissue 
through the release of superoxide radicals (106). 
 
1.6.4 NK cells 
NK cells are recruited to the lungs between 2-5 dpi and can recognise and lyse infected 
cells (71, 107). NK cells can detect influenza viruses via two mechanisms. Firstly, they bind 
neutralizing antibodies that have recognised influenza virus (108). NK cells then lyse infected 
cells through a mechanism known as antibody dependent cell-mediated cytotoxicity, resulting 
in the perforation and death of influenza virus infected cells (108, 109). Alternatively, NK cells 
recognize influenza virus HA glycoprotein through NKp44 and NKp46 cell surface receptors. 
Recognition of virus infected cells by NK cells also results in the release of cytokines, such as 
IFNγ, TNFα and IL15, which initiate the migration of other inflammatory cells to influenza 
virus infected lungs (110, 111). The secretion of IL15 also positively stimulates NK cell 
activity and the expansion and maintenance of NK cells in mice infected with influenza virus 
(112). The role of NK cells in influenza virus immunity has been highlighted using the Ncr1-/- 
mouse model. In these mice the NCR-1 gene (NKp46 in humans), the NK cell receptor gene, 
was replaced with a green fluorescent reporter cassette (113). This mutation prevented the 
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recognition of PR8 (H1N1) influenza virus infected cells, culminating in to a lethal infection 
(113). 
 
1.6.5 DCs 
DCs play an important role in innate immunity and are crucial for activating the cell 
mediated immune response (see section 1.7.2) (74, 114). DC populations involved in clearance 
of influenza virus infection include conventional DCs, interstitial DCs, and plasmacytoid DCs. 
These DCs produce an array of cytokines (IL1, 6 and 12, TNFα and IFNs) that promote 
antiviral responses (115-117). However, it is the conventional DC subsets (CD11bhiCD103lo or 
CD11bloCD103hi) that present antigen to naïve T cells. Upon influenza virus infection, these 
DCs acquire influenza virus antigen from infected cells or they themselves become infected. 
These DCs then traffic to the lymph node (18 hour – 5-dpi). Here, the resident lymph node 
CD8+ DCs receive this antigen from the migratory population. Lymph node CD8+ DCs then 
present antigen to naïve CD8+ and CD4+ T cells via Major Histo-compatibility complex (MHC) 
Class I and Class II molecules (118), leading to their activation and expansion (119). Once T 
cells reach effector sites in the lung, airway CD103hi DCs continue antigen presentation to 
promote activation (120).  
Antibody depletion of CD11blo and CD11bhi DC subsets in mice further supports the 
importance of DCs in influenza pathogenesis (73). Depletion of CD11blo and CD11bhi DCs 
with clodronate-liposome results in delayed influenza virus clearance [A/JAPAN/305/57 
(H2N2)] and significant weight loss in mice (121), leading to ineffective T cell priming. 
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1.7 The adaptive immune response to influenza virus infection 
The adaptive immune response is critical for efficient elimination of influenza virus 
and involves humoral and cellular immunity. Two cell types critical to this arm of the adaptive 
immune response are B cells and T cells. Lack of B and T cells in Scid and Rag2-/- mice leads 
to mortality when infected with a sub-lethal dose of PR8 (H1N1) influenza virus (122, 123), 
identifying the importance of these cells in the clearance of influenza virus infection.  
 
1.7.1 Humoral immunity 
Natural responses towards influenza virus can also produce non-neutralising antibodies 
towards the M1, M2 and NP proteins (124, 125). These antibodies, rely on the Fc portion of 
the variable region in the antibody to recognise infected cells (126). This recognition, results 
in complement-mediated destruction or antibody-dependent cell-mediated cytotoxicity and 
ultimately death of the infected cell. However, these are not influenza-specific antibodies.  
At the resolution of influenza virus infection (> 10 days), B cells become the most 
predominant, responding cell and limit infection through the production influenza-specific 
antibodies (127). These antibodies mostly target the easily-accessible cell surface 
glycoproteins of the influenza virus, the HA and NA and to a lesser extent the M1 protein (128-
130). HA-specific antibodies bind the trimeric head of the HA and neutralise virus by 
preventing attachment to cells (128, 130). NA antibodies do not neutralise virus, but prevent 
further spread of infectious virus particles, in a similar fashion to NA inhibitors by blocking 
the virus release from cells (see section 1.3.2) (129). Influenza-specific antibodies can also 
activate the NK mediated antibody-dependent cell-mediated cytotoxic pathway to lyse and 
remove influenza-infected cells (129, 130). The importance of B cells in influenza virus 
clearance is evidenced in experiments using μMT-/- mice (131). μMT-/- mice lack mature B cells 
preventing an effective antibody response (131). Infection of μMT-/- knockout mice with X31 
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(H3N2) influenza virus results in delayed clearance, and infection with a sub lethal dose of 
PR8 (H1N1) influenza virus results in decreased survival compared to WT controls (129, 131). 
 
1.7.1.1 Influenza-specific antibody subtypes 
IgM antibodies that recognize the HA and NA glycoproteins are the earliest influenza-
specific antibody subtype produced by B cells (132) and facilitate complement mediated 
destruction of influenza virus infected cells (133). C5a, a molecule involved in the complement 
cascade, can be targeted using a peptide antagonist for its receptor, delaying influenza virus 
clearance (129, 134, 135). Secretory IgA antibodies are found in respiratory mucous and can 
facilitate binding of influenza viral proteins in order to prevent the formation and release of 
viral progeny (136, 137). Additionally, influenza-specific IgG antibodies move from the serum 
to the respiratory tract to neutralise influenza viruses and provide long-lasting protection 
against infection (138).  
 
1.7.1.2 Heterosubtypic immunity 
Homologous immunity describes protection afforded by antibodies raised against one 
strain of virus. Importantly, strong antibody-mediated protection can also be afforded against 
heterologous strains of influenza virus (termed heterosubtypic immunity) (139-141), although 
most antibodies produced towards influenza virus are not heterosubtypic. Recent studies have 
identified antibodies in influenza virus infected that target the HA glycoprotein stalk which 
have the ability to protect against multiple strains of influenza virus (142, 143). These 
antibodies are now the subject of intense research in the hope of generating a universal 
antibody-based vaccine.  
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1.7.2 Cell mediated immunity  
1.7.2.1 CD4+ T cells 
CD4+ T cells are known as “T helper cells” as they are involved in stimulating B cell 
proliferation and production of influenza-specific antibodies (144). B cells proliferate through 
the "help" CD4+ T cells provide by expressing cytokines such as IL4 and 13 (145, 146). The 
importance of CD4+ T cells in the immune response to influenza virus infection has been 
highlighted using MhcII-/- and CD4-/- mouse models. MhcII -/- mice infected with influenza virus 
are unable to efficiently activate CD4+ T cells (147) and show a diminished capacity to produce 
influenza-specific antibodies (148). Depletion of CD4+ T cells during the primary response also 
results in delayed CD8+ T and B cell responses upon secondary challenge (148). Additionally, 
CD4+ T cells are also vital for the establishment of heterosubtypic immunity. In a study 
assessing the importance of B cells and CD8+ T cells in heterosubtypic immunity, it was 
identified that CD4-/- mice lost more weight than CD8-/- mice upon heterologous and 
homologous challenge, although they did not succumb to disease (140). 
 
1.7.2.2 CD8+ T cells 
In the influenza virus mouse model, defined CD8+T cell precursor frequencies lead to 
the formation of a well-characterised immunological hierarchy for recognition of antigenic 
peptides. The CD8+ T cell response following influenza virus infection is focused on internal 
influenza proteins, with the NP366-374 and PA224-233 peptides the immunodominant antigenic 
determinants presented on MHC Class I molecules in the C57Bl/6 mouse model (66). 
Subdominant CD8+ T cells responses involve the PB1703-711, PB1-F262-70 and NS2114-121 
antigenic peptides (66). Primary infection with influenza virus results in co-dominant NP366-
374
+ and PA224-233
+ CD8+ T cells responses, whereas NP366-374
+ CD8+ T cell numbers are 6-10 
fold higher than PA224-233 CD8
+ T cell numbers following secondary infection (68, 149). 
  
 
19 
 
Throughout both primary and secondary infection, the subdominant antigenic responses 
(PB1703-711, PB1-F262-70 and NS2114-121) are lower than those observed for NP366-374
+ and PA224-
233
+ -specific CD8+ T cells responses. Cytotoxic CD8+ T cells directly kill influenza virus 
infected cells. Activated CD8+ T cells secrete cytokines, including IL2, 4, 5, 9, 10, 17, 21, 22, 
IFNγ, and TNFα, and chemokines, such as CCL3 and 4 and CXCL9 and 10, to promote 
macrophage and neutrophil infiltration and function (87). CD8+ T cells kill influenza virus 
infected cells by releasing perforin and granzyme (150) or through TRAIL or Fas ligand 
interactions to induce apoptosis in influenza virus infected cells (151, 152). When B cell 
depleted mice (μMT-/- mice) (131) have their CD4+ T cell compartment depleted (CD8+ T cell 
compartments remained intact) they were able to clear infection, albeit in a substantially 
delayed fashion low pathogenic influenza virus (153) infection highlighting a critical role for 
CD8+ T cell immunity. Depletion of both CD8+ and CD4+ T cell subsets in mice is lethal in the 
presence of influenza virus infection (154) indicating a need for both subsets. 
 
 
1.8 Host cellular factors in influenza virus infection 
Alongside the roles of the immune response in the clearance of influenza virus 
infection, tools such as short interfering RNA (siRNA) and short hairpin RNA (shRNA) 
screens have provided a mechanism for identifying which host cellular factors are also involved 
in the removal of disease. siRNAs are short double stranded RNA molecules comprising 17-
25 base pairs (155, 156) (Figure 1.3). Synthetic siRNAs can be introduced to silence target 
messenger RNA (mRNA) preventing protein expression within appropriate cell lines (156). 
The introduction of siRNA activates the RNA induced silencing complex (RISC) that binds to 
synthetic siRNA mediating the unwinding of siRNA double strands (155, 157). The siRNA 
and RISC composite  
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Figure 1.3. siRNA pathways.  
Double stranded RNA enters the cell and is recognised and cleaved by the Dicer enzyme, 
creating siRNA. siRNA combines with RISC which degrades the mRNA preventing translation, 
allowing silencing of the gene. siRNAs are loaded directly into RISC and then follows the 
normal RNAi pathway.  
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will then bind and cleave target mRNA. Cleaved mRNA is identified by the cell as aberrant 
and is destroyed, thus preventing translation of the gene (155, 156).  
The silencing of genes of interest using siRNAs and shRNAs has allowed the 
identification of the role key host genes play in important cellular responses, such as the 
immune response. Indeed, RNAi screens have been readily used to assess the role of host 
cellular factors in influenza virus replication (158-160). Although these studies have identified 
many important host cellular factors involved in controlling influenza virus infection, few 
overlapping genes have been observed (160). This can be attributed to differences in the cell 
lines, viruses and methodologies used (160, 161). For example, Brass et al (2009) used a human 
sarcoma cell line, PR8 (H1N1) influenza virus and HA immunostaining to identify IFITM3 as 
an inhibitor of influenza virus infection (162). On the other hand, Hao et al (2009), using a 
drosophila cell line, recombinant WSN (H1N1) virus and luciferase activity identified 
ATP6V0D1, COX6A1 and NXF1 as host genes that play a role in influenza virus replication 
(158). The lack of overlap and consistent identification of host genes in these screens suggests 
that they are context dependent (160, 161) and can be affected by cell line variations and virus 
strains in any given experiment. This is supported by Karlas et al and Konig et al (2009), who 
both used an identical cell line and virus and showed only 3 host genes (COPI complex, 
PRSS31 and CAMK2B) in common (159, 163).  
More recently, a siRNA screen assessed the role of human proteases in influenza virus 
replication virus. In this screen, all known 481 human proteases were assessed for their role in 
influenza virus replication (160, 161). Twenty-one proteases were identified that either 
increased or decreased influenza virus replication through the use of an in vitro human lung 
cell culture model (A549 cells) (161). The screen identified A Disintegrin-like and 
Metalloproteinase with Thrombospondin-1 repeats (ADAMTS) 7 as having a key role in 
influenza virus replication. Additionally, downstream analysis identified A Disintegrin-like 
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and Metalloproteinase (ADAM) 30, ADAMDEC1, matrix metalloproteinase (MMP) 13 and 
14 as having key roles in influenza virus replication (161). Moreover, a related enzyme to 
ADAMTS7, ADAMTS5, was also identified in this screen as having a role in influenza virus 
replication through downstream analyses (personal communication – Ralph Tripp, University 
of Georgia, Georgia, USA). These targets were validated multiple times and suggest a 
definitive role for these enzymes in influenza virus replication. 
 
 
1.9 Metalloproteinases 
Recent evidence suggesting a role for metalloproteinases in influenza virus infection is 
attributable to their known roles in inflammation, proliferation and migration in inflamed 
tissues, such as in arthritis (164, 165). The metzincin superfamily of metalloproteinases 
comprises MMPs, ADAMs and the ADAMTS enzymes (166, 167). These enzymes cleave 
many substrates including extracellular matrix (ECM) components and cytokines.  
 
1.9.1 Structure of metalloproteinases 
The zinc-dependant metalloproteinase (metzincin) superfamily includes 26 MMPs 
(168), 40 ADAMs and 19 ADAMTS metalloproteinases (169, 170) in mammals. All 
metzincins are synthesized as zymogens, containing a pro-domain and a catalytic domain for 
enzymatic activity, with each group having a distinctive C-terminus or ancillary domain 
(Figure 1.4) (171, 172). MMPs can be distinguished by the presence of a haemopexin-like 
domain that facilitates adhesion to their various substrates (173). MMPs can be further divided 
into collagenases, gelatinases, stromelysins or further separated by the presence or absence of 
a transmembrane domain (MT-MMPs or MMPs respectively), allowing them to exist either as 
membrane-anchored or secreted proteinases (Figure 1.4) (174). ADAMs and ADAMTS  
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Figure 1.4. The basic domain organisation of members of the metalloproteinase family. 
Structurally, metalloproteinases contain similar N-terminal domains. Differences in structure 
are observed at the C-terminus or the ancillary domain: ADAMTS enzymes contain a series of 
Thrombospondin-1 repeats, ADAMs are membrane-anchored through a transmembrane 
domain and MMPs contain haemopexin-like regions. 
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metalloproteinases vary from MMPs due to the presence of a Disintegrin-like domain (169). 
These domains interact with integrins which can facilitate localisation of excreted 
metalloproteinases to the ECM (175). ADAMs contain a transmembrane domain in the C-
terminus not present in ADAMTS enzymes. The transmembrane domain acts as a membrane 
anchor not unlike MT-MMPs. ADAMTS metalloproteinases contain a series of 
Thrombospondin-1 repeats within their ancillary domain (176). These Thrombospondin-1 
repeats function as binding domains for glycosaminoglycans (GAG) found on proteoglycans 
(177, 178). 
 
1.9.2 Activation of metalloproteinases 
The metzincin family of metalloproteinases is named due to the conserved methionine 
residue at the active site and the use of a zinc ion in the enzymatic reaction (179). Soluble 
metalloproteinases, including ADAMTSs and MMPs, are synthesized and secreted as inactive 
enzymes. They remain in a latent state until activation by pro-protein convertases, such as furin 
(180).  
Catalytic activation of MMPs allows cleavage of an array of ECM proteins including 
laminin (181), collagen (182, 183), proteoglycans (184) tenascin-R (185), growth factors (i.e. 
pro-nerve growth factor) (186) and cytokines (pro TNFα) (187, 188). Catalytic activation of 
ADAMs mostly occurs intra-cellular and so they are secreted in their active forms (189-191). 
Docking to the cellular membrane for MT-MMP’s and ADAMs provides specialised functions 
in cleavage of membrane-associated proteins (192). Shedding of membrane-associated proteins 
frees extracellular peptides into their active forms (i.e. TNFα) (193) or regulates gene 
expression through the generation of intracellular domains that translocate to the nucleus to act 
as transcription factors, such as Notch proteins (194). Like ADAMs, ADAMTS 
metalloproteinases are activated intracellularly and are secreted in their active forms (164, 
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195). A group of ADAMTS enzymes (ADAMTS1, 4, 5, 8, 9 and 15) can cleave aggrecan, 
versican, brevican, and neurocan and are termed “hyalectinases” (196-199).  
Metalloproteinases collectively cleave a vast amount of ECM substrates including 
proteoglycans, collagens as well as membrane-associated protein substrates, such as soluble 
chemokines (193, 200). 
 
1.9.3 Metalloproteinase regulation by tissue inhibitor of metalloproteinases 
(TIMPs) 
Dysregulated, catalytically-active metalloproteinases can enhance inflammatory 
disorders and other pathological conditions, causing excessive ECM destruction and tissue 
damage (105). However, metalloproteinase-mediated catalytic activity can be regulated and 
inhibited. α-macroglobulin, reversion-inducing cysteine-rich protein with Kazal motifs, and 
TIMPs can all regulate metalloproteinase activity, although TIMP inhibitors are the 
predominant regulators of metalloproteinase activity (201). All four of the TIMP (TIMP1 - 4) 
family members display broad inhibition of MMPs (201-205), with TIMP3 having the broadest 
activity, inhibiting all MMPs, ADAM10, 12, 17, 28 and 33 and ADAMTS1, 2, 4 and 5 (206-
208).  
The regulation of metalloproteinases by the TIMP family is important in pathological 
and physiological processes as they can effectively control metalloproteinase activity. As such 
novel therapeutics involving TIMP inhibitors are currently being studied for disease, such as 
cancer and arthritis. Additional roles for TIMPs are also being identified using TIMP knockout 
mice. Timp1-/- mice display delayed neuronal death leading to significant brain injury and 
delayed ECM repair following myocardial infarction (202, 209). Timp2-/- mice display motor 
defects that have been associated with tissue destruction and unregulated metalloproteinase 
activity (210). Timp3-/- mice are highly susceptible to arthritis (211), due to unrestrained 
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ADAMTS [such as ADAMTS4 and 5 (see section 1.7.1)] degradation of aggrecan, a 
proteoglycan found in joints (212, 213). Finally, Timp4-/- mice are highly susceptible to 
myocardial infarctions caused by excessive MMP activity (214). The use of TIMP knockout 
mice helps identify roles for these inhibitors in development and disease pathologies, as well 
as allowing the identification of potential therapeutic targets. 
Broad-spectrum synthetic metalloproteinase inhibitors have been used extensively to 
assess the effects of metalloproteinases in various disease models (215), including cancer (216-
218) and arthritis (219). Studies have consistently shown however that metalloproteinase 
inhibitors show poor efficacy due to a lack of specificity (220). In contrast and despite the 
findings above, specific metalloproteinase inhibitors still remain an attractive therapeutic 
strategy for a variety of diseases; most notably ADAMTS5 inhibitors that are currently in Phase 
III trials (http://clinicaltrials.gov/show/NCT00454298) for treatment of osteoarthritis (199) as 
cleavage of aggrecan by proteases, such as ADAMTS5 has been shown to exacerbate 
osteoarthritic disease (165, 221).   
In conclusion, a greater understanding of the functional mechanisms of 
metalloproteinases is required before therapeutic inhibition of metalloproteinases can become 
a viable treatment option for disease.  
 
 
1.10 The role of metalloproteinases in infection and immunity  
Here, I will discuss the known roles of metalloproteinases in infection and the current 
understanding for their role in facilitating immune responses. These responses are broadly 
outlined in Figure 1.5.  
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Figure 1.5. The role of metalloproteinases in mediating the immune response. 
The release of metalloproteinases is observed in diseases such as influenza virus infection (A). 
These enzymes can help control disease and can enhance the inflammatory process by cleaving 
chemokines and generating chemokine gradients to enhance immune cell migration (B). 
Furthermore, metalloproteinases can cleave components of the basement membrane, such as 
collagen and proteoglycans, allowing immune cell infiltration into the diseased tissues (C). 
For ease, MMPs denotes all metalloproteinases - MMPs, ADAMs and ADAMTS enzymes. 
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1.10.1 Detection of metalloproteinases throughout influenza virus infection 
Upon infiltration of the host, pathogens deploy several immune evasion strategies to 
enhance survival. This includes taking advantage of host cell machinery for replication. 
Metalloproteinase activity is commonly hijacked to enhance tissue destruction, cell lysis and 
enhance replication of progeny (222). Metalloproteinase expression and activity has been 
detected and described in many bacterial and viral infections [e.g. Helicobacter pylori, human 
immunodeficiency virus (223-225) and influenza virus infection (161, 222, 226-228)]. 
As discussed in section 1.8, ADAMTS7 metalloproteinase expression is critically 
important for influenza virus replication (161). Other studies have indicated that influenza virus 
infection results in a significant release of metalloproteinases, mainly MMP9 (222, 226, 227, 
229-231). The release of MMP9 predominantly occurs from infiltrating neutrophils and its 
release is stimulated by pro-inflammatory cytokines, such as TNFα, IL6 and IL1β (230). 
Neutrophil numbers are found to be at their highest in the lung between 3-5 dpi. MMP9 
expression levels coincide with neutrophil infiltration into the lung, peaking at 3-5 dpi (232). 
Influenza virus mediated enhanced expression of MMP9 is also observed in cell culture models 
(228). Here, MMP2 and 9 expression and activity can be stimulated by influenza virus infection 
of epithelial cell lines (228). 
 
1.10.2 Metalloproteinase control of cytokine cleavage 
Cytokine expression and signalling is essential for host cell immunity in response to 
infection (233). For the activation of immune responses cytokine signalling needs to occur, 
cytokines need to be released from the ECM and cleaved into their soluble forms, from here 
they can bind to their receptors and activate the signalling cascade. This process can be 
performed by metalloproteinases (193). TNFα is a pro-inflammatory cytokine that induces 
immune cell migration (233). A number of diseases including rheumatoid arthritis (234, 235) 
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and Crohn’s disease are also associated with TNFα expression (236). Cleavage of the TNFα’s 
C-terminus is required to release its soluble form and to induce pro-inflammatory effects (193). 
ADAM17, or TNFα convertase, is the major enzyme involved in this process. ADAM10, 
MMP1, 2, 3, 7, 9 and 12 can also cleave TNFα, but not as efficiently as ADAM17 (187, 237, 
238). Once cleaved TNFα can induce the expression of a number of metalloproteinases 
including MMP3, 9 and 14 and ADAMTS1, 4, 5 and 7 (239). Release of these 
metalloproteinases can have downstream effects on inflammation and immune cell functions, 
such as the release of pro-inflammatory cytokines. 
Chemokines, a subfamily of cytokines, attract immune cells towards damaged or 
infected tissue. Neutrophils are typically the first cell to respond to infection and infiltration 
may be supported by metalloproteinase activity. During allergic rhinitis, upregulated ADAM12 
cleaves and releases neutrophil chemoattractants (CXCL1 and 8) from the ECM, resulting in 
recruitment of neutrophils to the nasal cavity (240). Mmp7-/- and Mmp8-/- mice have also been 
utilised to discover the role for these metalloproteinases in neutrophil chemotactic gradients 
(241, 242). These metalloproteinases are involved in the cleavage of CXCL2 and syndecan-1, 
respectively, which control the release of chemokines and neutrophil chemotaxis (242). Whilst 
the studies discussed here do not relate to influenza viruses or infectious diseases it is important 
to note that cleavage of these cytokines by metalloproteinases would have a definitive role in 
the immune response to influenza virus infection, and it is imperative that we gain a thorough 
understanding of these roles.  
 
1.10.3 The role of metalloproteinases in immune cell migration 
ECM components can block migration and infiltration of innate and adaptive immune 
cells, preventing effective clearance of infection. Immune cell infiltration into the infected 
tissues requires traversing the basement membrane and physical barriers imposed by the ECM.  
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1.10.3.1 Innate immune cell migration 
Neutrophils are generally the first infiltrating cell population into infected tissue (90, 
91). Neutrophil infiltration of influenza virus infected lungs of mice correlated with 
upregulated levels of MMP2 and 9, leading to increased pathogenesis due to MMP9 mediated 
tissue damage (105). In support of this study, influenza virus infected Mmp9-/- mice have 
decreased neutrophil infiltration into the lung (105). Although, this reduced neutrophil 
infiltration affected the ability for Mmp9-/- mice to remove influenza virus infected cells (105), 
highlighting the importance of neutrophils in this infection. 
In several non-influenza virus infection models, it has been observed that macrophages 
must first traverse the basement membrane of inflamed tissues. MMP2, 9, and 14 (MT1-MMP) 
activity increase macrophage infiltration by degrading collagen components of the basement 
membrane (243-246). Depletion of plasminogen (an activator of MMP9) in mice resulted in 
decreased macrophage infiltration following thioglycolate-induced peritonitis, which 
contributed to increased aortic aneurysms (244). Moreover, Mmp2-/- mice show decreased 
infiltration, resulting in enhanced renal fibrosis because of decreased ECM remodelling (247). 
Finally, macrophage infiltration into the dermal layer was altered in Mmp14-/- mice with croton-
oil induced contact dermatitis (245). Whilst these discussed studies are not influenza-specific 
studies, collectively, these studies highlight the importance for MMPs in macrophage 
migration. In addition, the related enzymes, ADAMs (ADAM8, 9, 15 and 19) and ADAMTS 
(ADAMTS1, 4, 5 and 8) are highly expressed in macrophage-rich areas of atherosclerosis (248-
252), although, it is unclear if this expression confers improved infiltration capacity (239, 253). 
Migration of DCs is important for activation of the adaptive immune response (72, 73). 
DCs recognise and capture antigen in infected tissue before trafficking to draining lymph nodes 
to present antigen to cells of the adaptive immune system (72, 73). The ECM has been shown 
to block the migration of DCs in vitro, which could significantly impact their migration in vivo. 
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Indeed, the addition of extracellular MMPs (e.g. MMP9) enhanced the degradation of the ECM 
and improved DC migration in vitro (254). This result was supported in vivo, where 
lipopolysaccharide-induced DCs derived from Mmp9-/- mice show decreased infiltration into 
the draining lymph node (254). Reduced DC infiltration, as observed in Mmp9-/- mice, suggest 
that these mice might be susceptible to infection if the activation of the adaptive immune 
response is impeded due to delayed DC migration.   
 
1.10.4.2 Adaptive immune cell migration 
Research documenting the involvement of metalloproteinases in the migration of 
adaptive immune cells is relatively limited. Lymphopoiesis studies by Melamed and colleagues 
has shown that MMP9 secretion is altered during different stages of B cell development (255). 
Secretion of MMP9 is markedly increased in pro-B and pre-B cells and is rapidly reduced in 
immature, transitional and mature B cells (255). However, further studies are required to tease 
out the role for metalloproteinases in B cell development and migration. 
The migration of T cells towards targeted tissues (e.g. cancerous, infected) is vital for 
immunosurvelliance and homeostasis. T cell exodus from the blood stream involves an initial 
attachment of T cells, followed by degradation of the basement membrane ECM to allow entry 
into these targeted tissues. Basement membrane components, such as collagen, laminin, 
fibronectin and gelatin, can inhibit the T cell extravasation process (256-258). 
Metalloproteinases play a key role in the removal of these basement membrane components, 
particularly collagen, promoting the migration of T cells. Studies involving T cell migration 
have identified that T cells require the secretion of MMP2 and 9. Inhibiting these MMPs 
significantly reduced collagen degradation and impeded T cell movement in a transwell-
migration assay (256). In support, in vivo inhibition of the Wnt signalling, the major signalling 
pathway for the secretion of extracellular MMP2 and 9, in mice prevents ECM degradation 
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and, hence, T cell migration through the basement towards a dermally-induced cytokine (TNFα 
and IFNγ) signal (259).  
Like the aforementioned basement membrane components (collagen, laminin, 
fibronectin and gelatin), versican, an ECM proteoglycan, can also restrict T cell migration 
(257). Versican contains an N-terminal (immunoglobulin-like) domain, followed by a GAG 
domain and a C-terminal domain (Figure 1.6A) (260, 261). The final structure of versican can 
vary based on mRNA splicing within the GAG domain. This splicing can produce 4 isoforms 
termed V0, V1, V2 and V3. V0 contains both GAG-α and GAG-β domains, V1 has only the 
GAG-β domain, V2 has the GAG-α domains, and V3 is lacking GAG domains and is this not 
a proteoglycan but rather a glycoprotein (260). GAG domains contain attachment site for CS 
chains. Interaction of these domains with different binding partners [e.g. hyaluronan (262), 
tenascin-R (263), L-selectin (264, 265)] leads to various functional consequences for ECM 
structure and cell migration (261) (Figure 1.6B). In particular, the N-terminus of versican has 
been shown to bind hyaluronan, a non-sulphated GAG widely distributed in connective tissue, 
via a link protein to maintain ECM structure (266). The interaction of versican and hyaluronan 
can increase the viscosity of the ECM and has been shown to inhibit the amoeboid shape 
formed by migrating CD4+ T cells (257). When CD4+ T cells are stimulated with the 
immunostimulatory molecule Poly I:C, increased versican expression prevented cell 
“crawling” along the ECM scaffold (257). Further evidence is provided following analysis of 
versican expression in human cervical cancer samples. Increased versican expression in 
stromal cells was shown to inhibit CD8+ T cell invasion, which may impede the removal of 
cancerous tissue (258). MMP1, 2, 3, 7 and 9 and ADAMTS1,  
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Figure 1.6. The structure and binding partners of versican. 
(A). Versican (V0 isoform) contains a hyaluronan binding domain, two GAG domains (α and 
β domains), an epidermal growth factor receptor domain, a lectin-like domain and terminates 
in a complement-regulatory protein. Some of these domains can interact with extracellular 
factors (highlighted in the red boxes) which can influence cellular processes. Adapted from Wu 
et al (267). (B). A diagraphical representation of the interaction between versican, hyaluronan 
and CD44. Adapted from Ween et al (268). 
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4, 5, 9 and 15 can remodel and cleave versican (198, 269-272), however only MMP2 and 9 
mediated collagen-degradation has been associated with T cell migration (273). 
 
 
1.11 ADAMTS5 and ADAMTS7 
1.11.1 ADAMTS5 
ADAMTS5 (Figure 1.7) was first discovered in 1999 (196, 274), and has since been 
found in various cells and tissues throughout the body including the heart, brain, macrophages 
smooth muscle cells and lung epithelium (275). ADAMTS5 contains the typical C-terminal 
domains, including the catalytic, disintegrin-like and thrombospondin-1 domain. Additionally, 
ADAMTS5 contains one C-terminal thrombospondin-1 repeat with attached molecules within 
its cysteine rich and spacer domain. Binding sites found within the cysteine rich domain and 
spacer domain help localize ADAMTS5 to the ECM. Heparin, a highly sulfated GAG, has 
ADAMTS5 binding sites in the cysteine rich and spacer domains (196), allowing ADAMTS5 
to localize within the ECM. Hyaluronan, a non-sulfated GAG, binds to the disintegrin-like 
domain of ADAMTS5 (276) and localizes ADAMTS5 to the ECM through its interaction with 
CD44 (277), a cell-surface glycoprotein. 
Catalytically active ADAMTS5 has the ability to act on and cleave its extracellular 
substrates, predominately the hyalectan/lectican class of chondroitin sulphate proteoglycans: 
aggrecan, versican, brevican and neurocan (278, 279). Cleavage of versican by ADAMTS5 is 
essential for the removal of webbing in between digits through the remodeling of the ECM 
(280). In arthritis, hyaluronan interacts with aggrecan in the synovial joint to form large 
aggregates. Hyaluronan serves to lubricate the joint and aggrecan gives the joint its load bearing 
properties, compressibility and elasticity (165, 221, 281). As previously mentioned, cleavage 
of aggrecan by ADAMTS5 has been shown to exacerbate osteoarthritic disease (165, 221).  
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Adamts5-/- mice have been used to understand the role this enzyme in osteoarthritis. 
These studies indicated that Adamts5-/- mice are viable and were initially characterized as 
phenotypically normal based on gross phenotypical analysis of histological samples (213, 221). 
Upon closer investigation, Adamts5-/- mice have been shown to have decreased interdigital web 
regression (280), valve maturation (269), altered formation of multinucleated myotubes for 
skeletal muscle development (282) and these mice are resistant to osteoarthritis (213, 221).   
 
1.11.2 ADAMTS7 
ADAMTS7 (Figure 1.7) is expressed in the heart, lung, bone, cartilage, meniscus, 
skeletal muscle and fat (195, 283, 284). ADAMTS7 contains the typical conserved structural 
domains (the catalytic, disintegrin-like, thrombospondin, cysteine and spacer domains) in the 
N-terminus but differs in the number of C-terminal thrombospondin-1 repeats. ADAMTS7 has 
7 C-terminal thrombospondin-1 repeats separated by a mucin domain (195). Within the mucin 
domain are attachment sites for chondroitin sulphated GAGs, covalently bound to serine 
residues (195).  
Catalytically active ADAMTS7 has been identified in arthritis (285, 286), 
atherosclerosis (283) and cancer (287). In arthritis, increased levels of ADAMTS7 are believed 
to cleave cartilage oligomeric matrix protein, compromising cartilage function (288). 
ADAMTS7 is also observed to promote migration of vascular smooth muscle cells leading to 
vessel thickening in arthritis (289). Increased ADAMTS7 expression has also been detected in 
the urine of patients with prostate and bladder cancers (287). Some of these processes, such as 
arthritis and atherosclerosis, could be prevented when ADAMTS7 is inhibited by α2 
macroglobulin or granulin epithelin precursor (290, 291).  
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Figure 1.7. The structure of ADAMTS5 and ADAMTS7. 
ADAMTS5 and ADAMTS7 each contain conserved structural domains at the N-terminus but 
differ in the number of C-terminal thrombospondin-1 repeats. ADAMTS7 C-terminal repeats 
are separated by a mucin domain. The mucin domain of ADAMTS7 has covalently attached 
chondroitin sulphate and sialic acid chains. ADAMTS5 can bind hyaluronan and heparin in 
its ancillary of its domains. 
 
 
 
ADAMTS5 
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Studies in Adamts7-/- knockout mice, although limited, indicate that these mice are 
healthy and viable (283, 284). These studies show that Adamts7-/- mice have normal whole 
blood counts and gross morphology (284). It was identified that Adamts7-/- mice had decreased 
anxiety and increased lung function parameters (284). Phenotypic analysis has identified that 
these mice are less susceptible to artherogenesis and neointima formation and that ADAMTS7 
promotes vascular remodelling (283, 284). More studies in these mice are required to gain a 
greater understanding the role of ADAMTS7 in cellular processes.  
 
1.11.3 Evolutionary relationships of ADAMTS5 and ADAMTS7 
Evolutionary clades formed within the ADAMTS family spark interest due to their 
distinct substrate specificities. There are four evolutionary related groups within the ADAMTS 
family (see Figure 1.8); the proteoglycanases (ADAMTS1, 4, 5, 8, 9, 15 and 20), the pro-
collagenases (ADAMTS2, 3 and 14), an under-characterized clade (ADAMTS6, 7, 10, 12, 16, 
17, 18 and 19) and the Von-Willebrand cleaving protease (ADAMTS13). Clade members can 
form cooperative proteolytic networks (292). For example, ADAMTS compensation has been 
observed in collagen formation where ADAMTS14 continues to cleave procollagen in the 
absence of ADAMTS2, resulting in a less penetrant form of Ehlers Danlos syndrome (293). 
ADAMTS5 is closely related to ADAMTS1, 4, 8, 9, 15 and 20 (292). All six enzymes 
have the ability to cleave aggrecan and versican, being termed “aggrecanases” and 
“versicanases”, respectively (279). As aggrecan and versican make up the majority of the ECM, 
the removal of one ADAMTS enzyme without the compensatory effects of others may affect 
homeostasis including migration, differentiation and proliferation of cells (196, 261).  
ADAMTS7 and ADAMTS12 are derived from a single gene duplication, and only 
differ in length, with ADAMTS12 having a shorter mucin domain (195). Both 
metalloproteinases cleave cartilage oligomeric matrix protein, which has led to their 
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association with arthritis (291). ADAMTS12 has a novel role in inflammation and it would be 
of interest if similar inflammation properties could be induced by ADAMTS7. The relationship 
between ADAMTS12 and inflammation was originally identified in an allergen induced 
inflammation model. This study used an Adamts12-/- knockout mouse, which displayed 
exacerbated asthma pathologies (compared to their WT counterparts) related to increased 
neutrophil influx (294). Furthermore, laboratory-induced sepsis, pancreatitis and colitis all 
resulted in increased inflammatory responses in Adamts12-/- mice (295). This result was caused 
by observed delays in neutrophil apoptosis in these mice, suggesting that ADAMTS12 controls 
neutrophil death. As ADAMTS7 and ADAMTS12 are very closely related it is likely 
ADAMTS7 has similar pro-inflammatory effects. 
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Figure 1.8. The evolutionary relationships of ADAMTS family members. 
The ADAMTS family contains 19 members in mammals which all contain similar N-terminal 
structures but differ at the C-terminal end of the protease. There are four evolutionary clades; 
ADAMTS1, 4, 5, 8, 9, 15 and 20 (proteoglycanases) ADAMTS7, 10, 12, 16, 17, 18 and 19 
(poorly defined) ADAMTS13 (Von Willebrand factor) and ADAMTS2, 3 and 14 (pro-
collagenases) (292). 
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1.12 Hypothesis and Aims 
Given the identification of ADAMTS7 and ADAMTS5 (through downstream analysis) 
in the human protease siRNA screen in influenza virus infection (161), and the already 
established roles of related metalloproteinases in the immune response, we hypothesized that 
ADAMTS5 and ADAMTS7 would have dynamic roles in the outcome of influenza virus 
infection, through aiding cell migration and inflammatory properties. 
 
Therefore, the aims of this project are:  
 
1. To define the role of ADAMTS5 in vivo influenza virus infection.  
2. To determine the function ADAMTS7 in influenza virus infection  
3. To understand the role of ADAMTS5 and ADAMTS7 in other models of virus 
infection.   
 
This project aims to investigate the role that ADAMTS5 and ADAMTS7 in the immune 
response following infectious disease. We aim to assess the function of these enzymes in vivo 
using the well-established C57BL/6 mouse model to determine the mechanism by which these 
enzymes influence pathogenesis and immunity.  
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Chapter 2 - Materials and Methods 
2.1 Reagents 
2.1.1 Buffers and solutions 
Ammonium Tris Chloride: Ammonium Tris Chloride was prepared using 0.16 M HCl and 
0.17 M Tris-chloride (Amresco, Ohio, USA) dissolved in MilliQ water and the pH was adjusted 
to 7.65. MilliQ water was obtained using a MilliQ direct filtration device (Merck Millipore, 
Darmstadt, Germany). 
 
Bovine Serum Albumin (BSA): Ten % BSA (Invitrogen, California, USA) was prepared 
following the manufacturer’s instructions by tissue culture staff at the Commonwealth 
Scientific and Industrial Research Organisation (CSIRO), Australian Animal Health 
Laboratory (AAHL), Geelong, Australia. 
 
β-galactosidase staining solution: β-galactosidase staining solution was prepared using 5 mM 
potassium ferricyanide (C6N6FeK3) (Sigma-Aldrich, Missouri, USA), 5 mM potassium 
ferrocyanide (C6N6FeK4) (Sigma-Aldrich) and 1 mg/ml β-galactosidase powder (Amresco) in 
dimethyl sulfoxide (275). The final solution was prepared in MilliQ water. 
 
β-galactosidase wash buffer: β-galactosidase wash buffer was prepared using 0.1 M phosphate 
buffer (pH of 7.4), 2 mM MgCl2 (Sigma-Aldrich), 0.02 % NP-40 (Amresco) and 0.01 % Na 
deoxycholate (Sigma-Aldrich) in MilliQ water (275). 
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Collagenase tissue dissociation solution: Collagenase (Sigma-Aldrich) was diluted to 2 mg/ml 
in Hank’s Balanced Salt Solution (HBSS) (Invitrogen). HBSS was prepared by tissue culture 
staff at CSIRO AAHL, Geelong. 
 
CXCL12 T cell migration media: CXCL12 (BioLegend, California, USA) was diluted to 10 
ng/ml working concentrations in Roswell Park Memorial Institute (RPMI) (Invitrogen) media. 
 
Dulbecco’s Modified Eagle Medium (DMEM): DMEM (Invitrogen) was supplemented with 
10 % heat-inactivated foetal calf serum (FCS) (Hyclone Scientific, Delaware, USA), 2 mM L-
glutamine (Invitrogen), 100 µM minimum essential media, 100 µM non-essential amino acids 
(Invitrogen), 5 mM sodium pyruvate (ThermoFisher, Massachusetts, USA), 100 µg/mL 
penicillin, 100 µg/mL streptomycin (Invitrogen), 55 µM β-mercaptoethanol (Invitrogen) and 
100 µg/mL 4-(2-hydroxyethyl)-1-piperzineethansulfonic acid (HEPES) (MP Biomedicals, 
California, USA). HEPES solution was prepared using manufacturer’s guidelines by tissue 
culture staff at CSIRO AAHL, Geelong. FCS was heat inactivated in a 56 oC water bath by 
tissue culture staff at CSIRO AAHL, Geelong, Australia. 
 
Fluorescent Activated Cell Sorter (FACS) Buffer: FACS buffer was prepared using 10 % 
BSA and 10 % sodium azide (Sigma-Aldrich) in phosphate buffered saline (PBS) (Oxoid, 
Hampshire, United Kingdom). PBS was prepared following the manufacturer’s instructions by 
tissue culture staff at CSIRO AAHL, Geelong, Australia. 
 
Fixing buffer: Paraformaldehyde (Amresco) was prepared in PBS and diluted to a final 
concentration of 4 %. 
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Genotyping Extraction buffer: Extraction buffer was prepared using 25 mM NaOH and 0.25 
mM ethylenediaminetetraacetic acid (EDTA) in MilliQ water. 
 
Genotyping Neutralisation buffer: Neutralisation buffer contained 40 mM Tris-HCl in MilliQ 
water at a final pH of 5. 
 
Leibovitz-15 media: Leibovitz-15 media was prepared by dissolving two packets of 2 x 
Leibovitz-15 powder (Invitrogen) in MilliQ water. The mixture was then adjusted to a pH of 
6.8 and supplemented with 7 % NaCHO3, 1 M HEPES buffer, 100 µg/ml penicillin, 100 µg/ml 
streptomycin and 40 mg/ml gentamycin (58). 
 
Laurel Broth (LB): LB broth was prepared using 10 g/L Tryptone (BD Medical Supplies, 
North Ryde, Australia), 5 g/L yeast extract (Amresco), 10 g/L NaCl and 1 M NaOH in MilliQ 
water. In some experiments, LB was supplemented with 1 μg/ml ampicillin. 
 
Lysis Buffer: Lysis buffer was prepared using a digestion buffer [50 mM Tris-HCl, pH 8.0, 20 
mM NaCl, 1 mM EDTA and 1 % sodium dodecyl sulphate (SDS)] and a 20 mg/ml proteinase 
K buffer (Sigma-Aldrich) prepared in MilliQ water. 
 
Nuclease free water: Nuclease free water was purchased from Ambion (Burlington, Canada).  
 
RPMI-anti (serum-free media): RPMI media was supplemented with 24 µg/ml gentamycin, 
100 µg/ml penicillin and 100 µg/ml streptomycin. 
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RPMI growth media: RPMI media was supplemented with 10 % FCS, 2 mM L-glutamine 
(Invitrogen), 100 mM minimum essential media, 100 mM non-essential amino acids, 5 mM 
sodium pyruvate, 100 µg/mL HEPES buffer, 100 µg/mL penicillin, 100 µg/mL streptomycin 
and 55 µM β-mercaptoethanol. 
 
Trypan Blue: 0.4 % trypan blue (Invitrogen) diluted in PBS was prepared by tissue culture 
staff at CSIRO AAHL, Geelong. 
 
Trypsin-Versene: 0.25 % trypsin-EDTA (Invitrogen) diluted in PBS was prepared by tissue 
culture staff at CSIRO AAHL, Geelong. 
 
Trypsin Worthington: 0.1 % L-1-tosylamido-2-phenyletyl chloromethyl ketone was purchased 
from Worthington Biochemical Corporation (New Jersey, USA). Trypsin Worthington was 
prepared in PBS following the manufacturers’ instructions. 
 
Virus isolation buffer: Virus isolation buffer was prepared using 10 % BSA, 100 µg/ml 
penicillin and 100 µg/ml streptomycin in PBS (296).  
 
Western Blot loading dye: Loading dye was prepared using 0.5 M Tris-HCl (pH 6.8), 20 % 
(w/v) glycerol (Sigma-Aldrich), 10 % (w/v) SDS (Sigma-Aldrich), 55 mM β-mercaptoethanol 
and 10 % bromophenol blue (Sigma-Aldrich) in MilliQ water. 
 
Western Running Buffer: Running buffer contained 30.3 g/L Tris base (Amresco), 144 g/L 
glycine and 10 g/L SDS prepared in MilliQ water. Running buffer was diluted in MilliQ water 
for immunoblotting, to a final concentration of 10 %. 
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Western Transfer Buffer: Transfer buffer contained 29 g/L glycine, 58 g/L Tris base and 3.7 
g/L SDS prepared in MilliQ water. Transfer buffer was diluted in MilliQ water for 
immunoblotting, to a final concentration of 10 %. 
 
2.1.2 Cell lines 
All cell lines were supplied by the CSIRO AAHL tissue culture facility. Human 
Embryonic Kidney 293T (HEK293T) cells were maintained in DMEM growth media. MDCK 
cells were maintained in RPMI growth media.  
 
2.1.3 Viruses 
Mouse-adapted influenza virus strains X31 (H3N2) and PR8 (H1N1) were grown in 
eggs and titrated by plaque assay on MDCK cells (see section 2.5.9) (58, 59, 65). Hendra virus 
(HeV) (HeV/Australia/Horse/2008/Redlands) (HeV) was isolated by CSIRO AAHL staff from 
the spleen of a Redlands Bay HeV-infected horse (297). The isolated virus was then passaged 
in VERO cells by Bio-security Level (BSL) 4 staff at CSIRO AAHL three times, before 
titration using a Tissue culture infectious dose (TCID) 50 assay (297).  
 
2.1.4 Mice 
WT mice, on a C57BL/6 background, were obtained from the Animal Resources 
Centre, Western Australia. B6.129P2-Adamts5tm1Dgen/J (Adamts5-/-) on a C57BL/6 background 
were obtained from Jackson Laboratories (Maine, USA). Adamts7-/- and Versicanheart defect/+ 
(Vcanhdf/+) mice on a C57BL/6 background were a kind donation from Suneel Apte, Cleveland 
Clinic, Ohio, USA. Adamts7-/- and Vcanhdf mice were generated by insertion of a LacZ cassette 
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insertion into the gene of interest (298). All mice strains were housed at the Deakin University 
animal house.  
 
 
2.2 Cell Culture  
2.2.1 Thawing of HEK293T and MDCK cells 
Cryogenic tubes (Nunc, New York, USA) containing cells were thawed in a water bath 
at 37 oC. The cell suspension was then added into a T75 flask (Corning, Lowell, USA) 
containing RPMI or DMEM growth medium and incubated overnight as described above (see 
section 2.1.2). 
 
2.2.2 Maintenance of cells 
HEK293T and MDCK cells were passaged at 95 % confluence. Flask medium was 
aspirated and cells were washed with PBS. Cells were then treated with 0.125 % trypsin 
versene/5 mM EDTA at 37 oC.    
Growth medium was then added to inhibit trypsin activity. HEK293T and MDCK cells 
were typically passaged 1:10 into a new T75 flask containing growth medium (in DMEM and 
RPMI, respectively). Flasks were then incubated at 37 oC, with 5 % CO2. Growth medium was 
replenished every 48 hours. 
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2.3 Molecular methods 
2.3.1 RNA extraction 
Cell and tissue RNA was extracted using RNAzol (Invitrogen), following the 
manufacturer’s guidelines. RNA concentration was determined using the NanoVue 
spectrophotometer (GE Healthcare, Buckinghamshire, UK). RNA quality was determined 
using an A260/A280 nm ratio. A ratio of ≥ 1.8 was used to determine RNA sample purity. RNA 
samples were stored at -80 oC. 
 
2.3.2 Complementary deoxyribonucleic acid (cDNA) synthesis 
cDNA was synthesized from purified RNA (see section 2.3.1) using a SuperScript First 
strand cDNA synthesis kit (Invitrogen), as per the manufacturer’s instructions. cDNA 
concentration was determined using a NanoVue spectrophotometer. Purity was determined 
using an A260/A280 nm ratio of ≥ 1.8 (see Section 2.3.1). cDNA samples were stored at -80 oC. 
 
2.3.3 Polymerase chain reaction (PCR) Visualisation 
PCR products were resolved on 1.5 % (w/v) gels containing 1 x tris-acetate EDTA 
buffer (Amresco), and 1 x SYBR safe deoxyribonucleic acid (DNA) gel stain (Invitrogen) at 
100 volts for 35 minutes. DNA Molecular Weight Marker XIV (100 base pair ladder) (Roche, 
Castleville, Australia) was used to confirm the molecular weight of the expected PCR products. 
Gels were visualised under UV illumination on a ChemicDoc XRS (Bio-Rad, Gladesville, 
Australia) using Quantity ONE software for analysis. 
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2.3.4 Primer Design 
Primers for PCR experiments were designed using the Primer3Plus website; 
http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi. DNA oligonucleotides 
were acquired from Sigma-Aldrich and Gene Works (Table 2.1 and 2.2). The following 
parameters were generally used for optimal primer design: length (18 – 27 base pairs), melting 
temperature (57 – 63 oC) and Guanine-Cytosine base pair concentration (20 - 40 %). 
 
2.3.5 Plasmid DNA transformation 
Plasmids (2 µg) containing versican constructs were added to DH5α E. coli cells (2 x 
106 cells) (Promega, Wisconsin, USA) and incubated for 20 minutes on ice, followed by heat 
shock at 42 oC for 45 seconds and a further incubation on ice for 2 minutes. Under sterile 
conditions, LB was added and cells were incubated at 37 oC for 1 hour with agitation at 250 
revolutions per minute (rpm). Transformation mix was then plated onto LB agar plates 
containing 100 µg/mL ampicillin and incubated overnight at 37 oC. Under sterile conditions, 
single colonies were picked from the plates and grown overnight in 6 mL LB containing 
Ampicillin (50 µg/mL) at 37 oC and 250 rpm to amplify the selected colonies.  
 
2.3.6 Plasmid DNA minipreps 
DH5α bacterial cell cultures containing expression constructs were centrifuged at 3000 
rpm for 10 minutes to obtain bacterial cell pellets. A plasmid DNA miniprep kit (Qiagen, 
Hilden, Germany) was used to elute DNA following the manufacturer’s instructions. DNA was 
eluted in DNase-free water, and quantitated using the NanoVue spectrophotometer (see section 
2.3.1). DNA constructs were then stored at -20 oC.  
 
  
 
49 
 
 
 
 
Mouse Sequence 
Adamts5-/- 
Adamts5-/- allele 
Forward primer, 5’-GGG CCA GCT CAT TCC TCC CAC TCA T 
Common allele 
Reverse primer, 5’-CGC AGC TGA CTG CTC TTG TGC TTG 
WT allele 
Forward primer, 5’-GCA TAC CAC TCC AAA CTT AGA GAG G 
Adamts7-/- 
WT allele 
Forward primer, 5’-AAC TCC TTT CTG GAA TAC CCC ATC 
Reverse primer, 5’-GAG AGG AAT CAG GTT ACA ACT AGG 
β-galactosidase allele 
Forward primer, 5’-AAA CCG ACT ACA CAA ATC AG 
Reverse primer, 5’-GCT TCA TCC ACC ACA TAC AG-5’ 
Vcanhdf/+ 
Forward primer, 5’-AAC TCC TTT CTG GAA TAC CCC ATC 
Reverse primer, 5’-CCA TAA AGC CTG TGT GAA ATG CC 
 
Table 2.1. Mouse genotyping primers used in this study. 
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Target Sequence 
ADAMTS1 
Forward primer, 5’-CCT GTG AAG CCA AAG GCA TTG 
Reverse primer, 5’-TGC ACA CAG ACA GAG GTA GAG T 
ADAMTS4 
Forward primer, 5’-CAA GCA GTC GGG CTC CTT 
Reverse primer, 5’-GAT CGT GAC CAC ATC GCT GTA 
ADAMTS5 
Forward primer, 5’-GGC AGG ACA CCT GCA TAT TT 
Reverse primer, 5’-GCT ACT GCA CAG GGA AGA GG 
ADAMTS7 
Forward primer, 5’-CTG GTT GAT AAT GGG GGT TG 
Reverse primer, 5’-GGG CTA GGA GAC CAA GAT CC 
ADAMTS8 
Forward primer, 5’-GAC AGA AGA CTC CCG CAA AG 
Reverse primer, 5’-TTT CAC CAC CAC AAG GTT GA 
ADAMTS9 
Forward primer, 5’-TTG TTG TCT CCA TGT CCA AAA G 
Reverse primer, 5’-ATT GCT GAG GTT TGT CCT CAA T 
ADAMTS12 
Forward primer, 5’-CCA GGG TTA GTC ACC TGG AA 
Reverse primer, 5’-TTT CCT GGC CAT TAG GAG TG 
ADAMTS15 
Forward primer, 5’-GCT CAT CTG CCG AGC CAA T 
Reverse primer, 5’-CAG CCA GCC TTG ATG CAC TT 
ADAMTS20 
Forward primer, 5’-TTG AAA TCC TTC AGC ACA GCT A 
Reverse primer, 5’-GGT CCG TGC TGT TAA TTC TTT C 
 
Table 1.2. SYBR green quantitate PCR (qPCR) primers used in this study. 
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2.3.7 Transfections of plasmid constructs 
HEK293T cells were seeded in 6 well plates at a density of 3 x 105 cells/well in DMEM 
growth medium. The following day, flasks were individually transfected with versican or with 
an empty vector control using Lipofectamine RNAi 2000 (Invitrogen) (198, 282, 299), as per 
the manufacturer’s instructions. After 5 hours, transfection medium was replaced with serum 
free medium (RPMI-anti) for 48 hours at 5 % CO2 and 37 
oC. Conditioned media was collected 
after 48 hours of incubation (see section 2.3.8). 
  
2.3.8 Collection of conditioned media from transfections 
Transfected cells (section 2.3.7) were harvested and the suspension deposited into a 
falcon tube (Corning), followed by centrifugation at 3000 rpm for 5 minutes (198, 282). 
Supernatant containing the conditioned media was then removed and stored at -80 oC.  
 
2.3.9 Immunoblotting 
Immunoblotting was used to confirm the presence of constructs in conditioned media 
of transfected HEK293T cells (section 2.3.7). Prior to immunoblotting, western blot loading 
dye was added to conditioned media (section 2.3.8) and samples were boiled for 5 minutes and 
then placed on ice for 2 minutes. Samples were then separated using 8 % SDS – Polyacrylamide 
Gel Electrophoresis at 35 milli-amps for 60 minutes. Proteins were then transferred onto a 
nitrocellulose membrane at 150 milli-amps for 60 minutes and then detected using primary α-
GAG antibody (versican) or α-DPEAAE (versikine - the versican cleavage fragment) in 1 % 
skim milk in Tris Buffered Saline Triton X (1 ng/µL) (clone 9E10) (Sigma-Aldrich). Blots 
were rinsed in 5 % skim milk in Tris Buffered Saline Triton X and then a goat-α-rabbit 
secondary antibody conjugated to horse radish peroxidase added for detection (2 ng/µL) 
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(Sigma-Aldrich). Immunoblots were visualised using enhanced chemiluminescence reagent 
(GE Healthcare) on a ChemicDoc XRS (Bio-Rad, Gladesville, Australia) using Quantity ONE 
software for analysis. Immunoblots were analysed using ImageJ software. 
 
 
2.4 Animal maintenance 
2.4.1 Ethics Statement 
All influenza virus animal experiments were conducted following Deakin University 
Animal Welfare Committee approval (A80-2011, G38-2013 and G35-2014: see section 2.5). 
HeV studies were approved by the CSIRO AAHL Animal Ethics Committee under AEC1765 
and the Deakin University Animal Welfare Committee AEX09-2015 (see section 2.6). All 
procedures were conducted according to the guidelines of the National Health and Medical 
Research Council Australian code of practice for the care and use of animals for scientific 
purposes. For all infection models, a weight loss of 20 % initial body weight was considered a 
humane endpoint. 
 
2.4.2 Maintenance of mice 
Mouse cages were changed weekly by Deakin animal house staff. Cages (Tecniplast, 
Sydney, Australia) were sterilised by autoclaving in a Chipmunk autoclave (Atherton, 
Melbourne, Australia) at 121 oC. Tap water used for drinking was also sterilised. Food and 
water were provided ad libitum. 
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2.4.3 Breeding of Adamts5-/- mice 
Three 1st generation Adamts5-/- mouse breeding pairs (obtained at backcross 8) were 
set up and mated. Second generation pups were weaned from their parents at 3 weeks of age. 
Breeding pairs from 2nd generation mice were set up at 6 weeks of age. Third generation mice 
were weaned at 3 weeks of age and grown to 8 – 10 weeks of age prior to experimental analysis.  
 
2.4.4 Breeding of Adamts7-/- mice 
Three 1st generation Adamts7+/- mouse breeding pairs (obtained at backcross 8) were 
obtained and mated. Second generation pups were weaned from their parents at 3 weeks of age. 
Homozygote (Adamts7-/-) breeding pairs from 2nd generation mice were set up at 8 weeks of 
age. Third generation mice were weaned at 4 weeks of age and grown to 8 - 10 weeks of age 
prior to experimental analysis.  
 
2.4.5 Breeding of Vcanhdf/+ deficient mice 
Three Vcanhdf/+ mouse breeding pairs (backcrossed 8 times) were mated and weaned 
from their parents at 3 weeks of age. At 8 - 10 weeks of age mice were used in experimental 
analyses.  
 
2.4.6 Breeding of Adamts5-/-xVcanhdf/+ mice 
Adamts5-/-xVcan+/+ and Adamts5+/+xVcanhdf/+ breeding pairs were obtained and mated. 
Second generation pups were then weaned from their parents at 3 weeks of age. Second 
generation Adamts5+/-xVcan+/+ and Adamts5+/-xVcanhdf/+ mice were set up at 6 weeks of age. 
Third generation Adamts5-/-xVcanhdf/+ and Adamts5-/-xVcan+/+ mice were mated at 6 weeks of 
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age and offspring weaned at 3 weeks of age. Mice were then genotyped and maintained to 8 
weeks of age prior to influenza virus infection.  
 
2.4.7 Genotyping of mice 
To genotype mice, genomic DNA from ear tissue was placed in genotyping extraction 
buffer and incubated at 100 oC for 30 minutes. Samples were then placed on ice and allowed 
to cool, before the addition of equal volumes of genotyping neutralisation buffer. A PCR 
reaction was performed on genomic DNA using genotyping primers found in Table 2.1. A 
negative RNase-free water control was used to detect for potential DNA contamination. The 
PCR reaction was performed in the Bio-Rad thermocycler under the parameters found in Table 
2.3 and bands were visualised as described in section 2.3.3. Additional details to identify and 
analyse PCR products from the genomic targets in Adamt5-/- mice can be found at 
http://jaxmice.ax.org/strain/005772.html. 
 
2.4.8 Euthanasia 
Mice were euthanized using slow-fill inhalation of CO2 at various time points post 
infection or for colony maintenance. 
 
 
2.5 Influenza virus infection and analysis 
2.5.1 Intranasal influenza virus infection of mice 
Adamts5-/-, Adamts7-/-, Vcanhdf/+, Adamts5-/-xVcanhdf/+ and WT mice were individually 
numbered and assigned to groups for influenza virus infection. Mice were anaesthetised by 
inhalation of 1 - 3 % isoflurane in oxygen. X31 (H3N2) influenza virus (1x104 plaque forming  
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Mouse Strain PCR Parameters Cycles 
Adamts5-/- 
15 minutes at 95 oC 1 
94 oC for 30 seconds 
60 oC for 90 seconds 
72 oC for 30 seconds 
35 
72 oC for 10 minutes 1 
Adamts7-/- 
1 minute at 95 oC 1 
95 oC for 30 seconds 
58 oC for 1 minute 
72 oC for 1 minute 
35 
72 oC for 10 minutes 1 
Vcanhdf/+ 
5 minutes at 95 oC 1 
95 oC for 30 seconds 
56 oC for 30 seconds 
72 oC for 1 minute 
35 
72 oC for 10 minutes 1 
 
Table 2.3. PCR parameters followed for mouse genotyping. 
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Figure 2.1. Influenza virus infection models used throughout this study. 
Mice were either infected intranasally for primary acute responses or intraperitoneally for 
secondary challenge analyses. Seven weeks after intraperitoneal injection with PR8 (H1N1) 
influenza virus (1.5x107 pfu/mouse), mice were intranasally challenged with X31 (H3N2) 
influenza virus (1x104 pfu/mouse) and secondary challenge responses were measured at day 7 
post challenge. *Secondary memory was not analysed in this study. 
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units (pfu)/mouse) in PBS was then administered intranasally to each mouse (58, 65, 300). 
Body weights were recorded daily. Figure 2.1 details the influenza virus infection regime for 
in vivo influenza experiments undertaken in this study. 
 
2.5.2 Intraperitoneal influenza injection of mice 
Adamts5-/-, Adamts7-/- and WT mice were individually numbered and assigned to 
groups for influenza virus priming by intraperitoneal injection. Each mouse was 
intraperitoneally administered PR8 (H1N1) influenza virus (1.5 x 107 pfu/mouse) in PBS (65). 
Figure 2.1 demonstrates the experimental plan established for intraperitoneal influenza 
infection studies. 
 
2.5.3 Preparation of mouse tissue-single cell suspensions 
Mice were euthanized and lungs, spleen and MLN were removed from naïve or 
influenza virus infected mice and placed in HBSS. Figure 2.2 details the experimental assays 
performed on each tissue at various time points post infection. 
Lung tissue was weighed and disrupted using a variable speed homogeniser (Dremel, 
Melbourne, Victoria). The homogenised lung was then centrifuged and the supernatant 
removed and stored at -80 oC for use in plaque assays (see section 2.5.9). Any remaining lung 
tissue was used for RNA extraction (see section 2.3.1) and qPCR reactions (see section 2.5.7). 
Lung was also collagenase digested (2 mg/ml in HBSS) and incubated at 37 oC for 30 minutes 
to generate single cell suspensions. Cells were then filtered through a 70 µM strainer into a 50 
ml tube and washed with HBSS. Red blood cells were lysed using ammonium tris chloride 
buffer for 3 min at room temperature, washed twice in HBSS and resuspended in 1 mL RPMI 
growth medium for flow cytometric analysis (see section 2.5.4). 
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Figure 2.2. Experimental regimes following influenza virus infection. 
Tissues were removed from influenza virus infected mice at 3, 7, 10 and 30 dpi or at day 7 post-
secondary challenge. Virus titres in the lung were assessed using plaque assays. Immune cell 
responses were characterised using qPCR and flow cytometric analysis of immune cell 
populations using antibodies, tetramers and intracellular cytokine staining assays.  
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Spleen and MLN were pushed through a 70 µM strainer to generate single cell 
suspensions. Spleen cell suspensions were further enriched for T cells following B cell panning 
on plates coated with goat anti-mouse IgG and IgM antibody (Jackson ImmunoResearch, West  
Grove, PA) for 1 hour at 37 oC. The enriched suspension was then centrifuged at 1600 rpm for 
5 minutes and the supernatant removed. Five mL ammonium tris chloride buffer was added to  
the cell pellet for 3 minutes at room temperature to lyse red blood cells and the reaction 
neutralised through the addition of HBSS. Cell suspensions were washed and the cell pellet 
was resuspended in 3 mL RPMI growth medium. 
 
2.5.4 Immune cell phenotyping 
Single cell suspensions (see section 2.5.3) were added to a 96-well U-bottomed plate 
(Nunc), centrifuged (1500 rpm for 5 minutes) and then resuspended in 50 µL FACS buffer 
containing diluted antibodies (Table 2.4) for 30 minutes at 4 oC and analysed on a BD-LSRII 
(BD-USA). Results were analysed using Flowjo software version 7 (Flowjo LLC, Ashland, 
USA). Gating strategies for phenotyping analyses are displayed in Figure 2.3. 
 
2.5.5 Tetramer and intracellular cytokine staining (ICS) 
CD8+ lymphocyte populations from the spleen, lung and MLN were enumerated using 
fluorescently labelled tetrameric complexes directed against two immunodominant influenza-
specific CD8+ T cells epitopes (NP366-374-PE or PA224-233-PE) (purchased from University of 
Melbourne, Australia) for 1 hour at room temperature in FACS buffer, as previously described 
(68, 149). Cells were washed and stained with anti-mouse CD8α-PERCP and analysed on a 
BD-LSRII (BD Biosciences). In some cases, CD62L-FITC and CD44-APC antibodies were 
also added. NP366-374 and PA224-233 CD8
+ T cell function was further assessed using the ICS 
assay. Briefly, cells were cultured for 5 hours in a 96-well round bottom plates with influenza  
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Target (Mouse) Fluoro chrome Clone Company Isotype Dilution 
B220 PERCP RAB3-6B2 BD Rat 1/200 
CD3 APC 145-2C11 BD Hamster 1/400 
CD4α FITC RM4-4 BD Rat 1/400 
CD8α PE 53-6.7 BD Rat 1/400 
CD8α PERCP 53-6.7 BD Rat 1/200 
CD11b FITC M1/70 BD Rat 1/400 
CD11c APC HL3 BD Hamster 1/400 
CD44 APC IM7 BD Rat 1/400 
CD62L FITC MEL-14 BD Rat 1/400 
CD314 PE CX5 BD Rat 1/400 
F4/80 PERCP BM8 BioLegend Rat 1/200 
GR1 FITC RB6-8C5 BD Rat 1/400 
Ly6G PE 1A8 BioLegend Rat 1/400 
MHCII PE 2G9 BD Rat 1/400 
 
Table 2.4. Flow cytometry antibodies used in this study. 
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Figure 2.3. Gating strategy for immune cell phenotyping. 
(A) Flow cytometric analysis showing the gating strategy used to distinguish CD4+ and CD8+ 
T and B220+ B cells. (B) Flow cytometric analysis depicting the gating strategy used to 
distinguish CD11c+ DCs, CD11b+ macrophages and neutrophils. APCs = antigen presenting 
cells 
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NP366-374 (ASNENMETM) or PA224-233 (SSLENFRAYV) peptides in the presence of Golgi-
plug (BD Biosciences) and IL2. Cells were then permeabilised and stained with anti- mouse 
CD8α-PERCP, anti-mouse IFNγ-FITC and TNFα-APC (BD Biosciences) as previously 
described (300). Data was acquired on a BD-LSRII and analysed using Flowjo software. Gating 
strategies for tetramer and ICS staining are displayed in Figure 2.4. 
 
2.5.6 Magnetic enrichment of cells 
CD8+ and CD11c+ splenocytes (see section 2.5.3) were isolated using negative selection 
kits and magnetic beads (Stem Cell Technologies, Vancouver, Canada) on a fully automated 
cell separator (Stem cell Technologies).  
 
2.5.7 qPCR analysis for cytokine expression 
Lung cDNA, 1 µL probe and primers (TaqMan, Mulgrave, Australia) were added to 
detect cytokine gene expression (TNFα and, IFNγ) (Table 2.5). qPCR samples were prepared 
in MicroAmp Fast Optical 96-well reaction plates (Applied Biosystems, Austin, Texas, USA). 
Each reaction contained 10 µM forward primer, 10 µM reverse primer and 10 µM probe (see 
Table 2.5), 10 µL of TaqMan 2X master mix and 100 ng of sample cDNA. Adhesive film was 
applied to the plates prior to centrifugation at 1600 RPM for 1 minute. The plates were placed 
on a 7500 Fast Real-Time PCR system (Applied Biosystems) under the following PCR cycle 
conditions; 10 minutes at 95 oC, and 40 repeating cycle of 95 oC for 30 seconds, 60 oC for 1 
minute and 72 oC for 30 seconds. Ct values were measured and compared to cDNA 
concentrations determined using the Oligreen protocol (see section 2.5.8). 
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Figure 2.4. Gating strategy used for tetramer and ICS analyses. 
Flow cytometric gating strategy used to enumerate (A) tetramer+CD8+ T cells and (B) 
IFNγ+CD8+ T cells.  
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Table 2.5. TAQMAN primers purchased for this study 
 
 
 
 
 
 
 
 
 
 
 
 
Target Product Number 
TNFα Mm00443528_m1 
IFNγ Mm01168134_ml 
GAPDH Mm99999915_g1 
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2.5.8 OliGreen protocol 
 A known 20 x DNA standard (Invitrogen) was diluted to in 1 x elution buffer and a 
series of dilutions followed to prepare 8 known DNA standards. Five µl of the DNA standards 
and cDNA samples used in qPCRs (see section 2.5.7) were loaded into their respective wells 
in a black 96 well plate (Nunc). Ninety-five µL of 1 x elution buffer was added to each well as 
was a further 100 µL of 1 x Quant-iT™ OliGreen® single stranded DNA reagent (Invitrogen). 
The plate was then read on a Perkin Elmer plate reader to determine cDNA concentrations for 
normalisation of Ct values obtained from RT-qPCR reactions. 
 
2.5.9 Plaque assay 
MDCK cells (1.2 x 106 cells/well) were seeded in 6-well plates. The following day, 
confluent cell monolayers were washed with RPMI-anti. Ten-fold dilutions (10-1-10-6) of 
infected lung supernatant (see section 2.5.3) were prepared in RPMI-anti. The RPMI-anti on 
the 6-well plates was removed and replaced with diluted (10-1-10-6) virus supernatant and 
incubated at 5 % CO2 and 37 
oC for 45 minutes (rocking each plate every 15 minutes). 
Leibovitz-15 medium containing Trypsin Worthington and 1.8 % agarose in water were placed 
in a pre-heated 45 oC water bath. Following the 45 minute incubation, Leibovitz-15 agarose 
overlay was added to the MDCK monolayer and left to set at room temperature (301). Plates 
were then incubated at 5 % CO2 and 37 
oC for 3 days. Visible plaques formed in the agarose 
overlay were counted and virus titres determined. 
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2.6. HeV infection and analysis 
2.6.1. HeV inoculation in mice 
HeV infections were performed at BSL4, where CSIRO staff wore fully encapsulating 
suits with an external air supply. Eight-week-old Adamts5-/-, Adamts7-/- and WT female mice 
were anaesthetised through intraperitoneal injection with ketamine (75 mg/kg; Ketamil; Ilium, 
Smithfield, Australia) and medetomidine (1 mg/kg; Domitor; Novartis). Once anaesthetised, 
mice were intranasally inoculated with 50,000 TCID50 HeV (HeV 
Australia/Horse/2008/Redlands) in saline (296). Mice were euthanized at 6 dpi.  
Due to the nature of BSL4 agents and the detailed training required, these experiments 
were only performed twice, with 4 biological replicates.  
 
2.6.2 Tissue collection and processing      
At 6 dpi, mice were anaesthetised by CSIRO AAHL staff and blood was collected via 
cardiac puncture, placed into EDTA and serum separator tubes. Following cardiac puncture, 
brain, kidney, liver, lung and spleens were collected for virus isolation. Samples were then 
placed into virus isolation buffer containing aluminium silicate beads (Biospec Products Inc., 
USA) (296). Samples were homogenised for 30 seconds in a bead beater (Biospec Products 
Inc.), centrifuged for 1 minute at 1600 rpm and stored at -80 oC for subsequent processing (see 
section 2.6.3). The remaining tissues were processed following protocols outlined in section 
2.6.4 for flow cytometric analysis. Aliquots for flow cytometry were stored in liquid nitrogen. 
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2.6.3 RNA extraction and virus quantification of HeV samples by qPCR 
MagMAX lysis/binding solution (Ambion) was added to homogenised tissue samples 
(see section 6.2) by CSIRO AAHL staff for 2 hours and samples removed from BSL4 to BSL3. 
RNA was then extracted using the MagMAX-96 viral RNA isolation kit (Ambion). HeV 
Nucleocapsid (N) gene levels were assessed by qPCR (Table 2.6), following AgPath-ID one-
step reverse transcription-PCR kit instructions (Applied Biosystems, Victoria, Australia). 
Cycle threshold (CT) values below 39.6 were considered positive (296). Samples were 
normalised against the 18S housekeeping gene.  
 
2.6.4 Fixing of HeV infected cells for flow cytometry analysis 
Frozen cells (see section 2.6.2) were removed from liquid nitrogen at BSL4 and were 
immediately thawed at 37 oC in a water bath. Once thawed, CSIRO AAHL BSL4 staff 
aliquoted cells into a 96-well plate, centrifuged, then stained with conjugated anti-mouse 
antibodies (see Table 2.4) for 30 minutes at 4 oC (see section 2.5.4). Cells were then washed in 
FACS buffer and resuspended in 2 % paraformaldehyde at room temperature for 3 hours. After 
this time cells were no longer infectious and were removed to BSL3 laboratories for flow 
cytometric analysis. Cells were then washed twice and resuspended in 200 µL FACS buffer. 
Samples were run on the BD-Fortessa (BD, Biosciences) HTS system. Data was then analysed 
using Flowjo software.  
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Target Sequence (5’-3’) 
Hendra N 
Gene 
Forward primer, GATATITTTGAMGAGGCGGCTAGTT 
Reverse primer, 5’-CCCATCTCAGTTCTGGGCTATTAG 
Probe, 6FAM-CTACTTTGACTACTAAGATAAGA-MGB 
18S 
Forward primer, 5’-GGG AGG TAG TGA CGA AAA ATA ACA AT 
Reverse primer, 5’-TTG CCC TCC AAT GGA TCC T 
 
Table 2.6. TAQMAN primers designed for this study 
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2.7 Mouse tissue experiments 
2.7.1 β-galactosidase staining of tissues 
MLN and lungs were removed from naïve and infected WT, Adamts5-/- and Adamts7-/- 
mice and fixed in 4% paraformaldehyde prepared in β-galactosidase wash buffer. Tissues were 
then washed in this buffer and incubated overnight in β-galactosidase staining solution at 37 
oC. The next day, MLN and lungs were rinsed in wash buffer and fixed in 4 % 
paraformaldehyde (prepared in wash buffer) at 4 oC overnight (275). After a brief rinse in wash 
buffer tissues were imaged then embedded in PBS before processing (see section 2.7.2).  
 
2.7.2 Histology  
Tissues from WT and Adamts5-/- mice were fixed in 4 % paraformaldehyde at 4 oC 
overnight. Following processing (2 hours in 30 % EtOH, 2 hours in 70 % EtOH, 2 hours in 90 
% EtOH, 4 hours in histolene (Grale, Victoria, Australia) and 8 hours in paraffin (Sigma-
Aldrich), tissues were paraffin-embedded and sectioned. Seven µM sections were mounted on 
a slide and left to dry at 37 oC overnight. Sections were then used for immunohistochemistry 
(see section 2.7.3). 
 
2.7.3 Immunohistochemistry 
Seven µM sections were stained with anti-GAGβ (versican) (1/1000) (Merck-
Millipore) or anti-DPEAAE (versikine) (1/500) (ThermoFisher) antibodies in Tris Buffered 
Saline Tween 20 at 4 oC overnight. The following day, tissues were washed with 10 % Tris 
Buffered Saline Tween 20 to remove excess antibody and incubated with Alexa-Fluor594 goat-
α-mouse antibody (Life-Technologies, California, USA) (198, 275, 282). Sections were re-
washed in 10 % Tris Buffered Saline Tween 20 (3 x 10 min) and nuclei stained with DAPI 
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(ThermoFisher). Sections were viewed under a confocal microscope at 60X magnification 
(Leica, Wetzlar, Germany). 
 
2.7.4 Ex vivo migration assays 
Migration assays were performed in 12-well 5 µm chamber inserts (Corning), as 
previously described (256). Inserts were coated with versican conditioned medium (see section 
2.3.8) and recombinant mouse CXCL12 T cell migration medium (10 ng/ml) was added to the 
lower chamber of the transwell to promote migration. Adamts5-/- or WT enriched (section 2.5.8) 
CD8+ T cells (105) were loaded into the upper chamber. The cells were allowed to migrate for 
4 hours at 37 oC and 5 % CO2 before the removal of non-migrating cells in the upper chamber. 
The transwell membrane was then stained with haematoxylin (Sigma-Aldrich) to enumerate 
the number of migrated cells.  
 
2.7.5 DC proliferation assays 
DCs (CD11c+) and CD8+ T cells were isolated from the spleen of naïve WT and 
Adamts7-/- mice as previously described (see Section 2.5.6). DCs (1x104 cells) were then 
infected with PR8 (H1N1) influenza virus (multiplicity of infection (MOI) 0.6) and incubated 
at 37oC for 6 hours (68, 72, 154, 302). After 6 hours, CD8+ T cells (5x103 cells) were added to 
infected DCs and activation of both cell subsets was assessed 48 hours later via flow cytometry 
and results were analysed using Flowjo software version 7. 
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2.8 Statistical analyses 
Normal distribution data is expressed as mean ± standard error of the mean 
(SEM); n represents the number of mice per group. Statistical differences between two groups 
were analysed by Student's t-test. Statistical differences between multiple groups were analysed 
by one-way ANOVA with Bonferroni post-test analysis. All statistical analyses were 
performed using GraphPad Prism 5 for Windows. In all cases, probability levels less than 0.05 
(*p<0.05) were indicative of statistical significance. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
72 
 
Chapter 3 – ADAMTS5 and the clearance of influenza virus 
infection 
3.1 Overview 
ADAMTS5 is one of the most highly-characterised and well-known metalloproteinases 
in the ADAMTS family. ADAMTS5 has been shown to cleave the hyalectan class of 
chondroitin sulphate proteoglycans, including aggrecan, brevican, neurocan and versican (299, 
303-305). Hyalectans/chondroitin sulphate proteoglycans are large aggregating 
macromolecules that hydrate tissue by attracting water molecules and confer rigidity to the 
extracellular space. Cleavage of these ECM components by ADAMTS5 has been associated 
with arthritis and developmental defects in vitro (281). The role of ADAMTS5 has been further 
defined in vivo by taking advantage of ADAMTS5 knockout mice (Adamts5-/- mice). These 
mice were previously generated through the insertion of a LacZ cassette into the ADAMTS5 
gene (275), thereby preventing the translation of the enzymatically active ADAMTS5 protein. 
In these mice, the LacZ cassette, which contains β-galactosidase, can be used as a surrogate 
reporter of ADAMTS5 expression. β-galactosidase staining in tissues from Adamts5-/- mice has 
helped characterise tissue expression patterns of ADAMTS5 (275). Expression of ADAMTS5 
has been detected in the cartilage, joints lungs, heart and spleen (275, 306).  
The presence of ADAMTS5 in the embryonic lung, and more importantly within the 
alveoli (284), suggests that ADAMTS5 may have an unidentified role in the control of lung 
homeostasis. In support of this unknown role, personal communication from data obtained in 
a siRNA screen assessing proteinase activity in influenza virus infection, identified ADAMTS5 
as a downstream modulator of influenza virus pathogenesis (Prof Ralph Tripp, University of 
Georgia, Georgia, USA). The presence of ADAMTS5 in the alveolar space and its 
identification in a downstream analysis of the siRNA screen indicates that ADAMTS5 may be 
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required for the clearance of influenza virus infection, possibly through its matrix remodelling 
capabilities. 
Aside from determining the expression pattern of ADAMTS5, research has focused on 
ADAMTS5’s role in the development of arthritis. Adamts5-/- mice are resistant to aggrecan 
cleavage in articular cartilage, and are thus protected from experimentally induced arthritis 
(213, 221). These observations have led to ADAMTS5 becoming a major drug target for 
arthritis therapy. Moreover the Adamts5-/- mouse model has also been used to identify 
ADAMTS5’s key role in embryonic and skeletal muscle development, including limb and 
cardiac morphogenesis (269, 282). In these studies, Adamts5-/- mice were observed to have 
reduced myoblast fusion resulting in weakened muscles (282). Additionally, Adamts5-/- mice 
were found to have enlarged heart valves due to reduced proteoglycan turnover, and hence 
ECM accumulation occurs in these vessels (269). 
In this current study, we utilise the Adamts5-/- mouse model to assess the role of 
ADAMTS5 in the immune response to influenza virus infection. Herein, we describe a novel 
association between the ADAMTS family, influenza virus pathogenesis and immunity. To 
characterise these results Adamts5-/- mice were intranasally infected with X31 (H3N2) 
influenza virus to assess primary infection or primed with PR8 (H1N1) and challenged with 
X31 (H3N2) to characterise secondary challenge in the absence of ADAMTS5.  
 
 
3.2 Adamts5-/- mice are immunologically "normal" 
ADAMTS enzymes are widely distributed in human adult tissues and play a key role 
in normal cellular function (275, 279, 306). Although Adamts5-/- mice are viable and 
phenotypically normal, based on gross analysis (213, 221), detailed characterisation has 
revealed decreased interdigital web regression leading to fused digits (299), irregular cardiac 
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valve maturation (269) and abnormal formation of multinucleated myotubes required for 
skeletal muscle development in these mice (282). In contrast, the immune cell populations in 
Adamts5-/- mice are yet to be analysed. To determine this, we removed spleen and lung from 
Adamts5-/- and WT mice and enumerated immune cell populations in these tissues as these 
would be used as points of comparison following influenza virus infection. In the spleen, we 
observed no differences in innate immune cells neutrophils (Ly6GhiGR1hi) (Figure 3.1A), NK 
cells (CD314+CD3-) (Figure 3.1B), macrophages (CD11bhiF4/80hi) (Figure 3.1C), DCs 
(CD11chiMHCIIhi) (Figure 3.1D), B cells (B220+) (Figure 3.1E) and CD4+ T cells (CD4+CD3+) 
and CD8+ T cells (CD8+CD3+) (Figure 3.1F). Similar results were observed between WT and 
Adamts5-/- mice in the lung (Figure 3.2). These data support previously published evidence 
suggesting that Adamts5-/- mice develop normally and indicates that Adamts5-/- mice develop 
normal immune cell populations. As such, we conclude that Adamts5-/- mice are 
immunologically “normal”. 
 
 
3.3 Adamts5-/- mice are more susceptible to influenza virus infection 
To investigate the role of ADAMTS5 during influenza virus infection, we initially 
examined in vivo weight loss and viral burden following primary infection with X31 (H3N2) 
influenza virus. Influenza virus replication in C57.BL6 mice normally peaks at 3 dpi, and virus 
is cleared by 7-10 dpi (70, 72). In these experiments, we intranasally infected Adamts5-/- mice 
and WT controls with 104 pfu/mouse adapted X31 (H3N2) influenza virus, and observed 
enhanced weight loss in Adamts5-/- mice across two experimental time points (p < 0.05 on 8 
and 9 dpi) period when compared to WT controls (Figure 3.3A). At the peak of virus replication 
(3 dpi), Adamts5-/- mice had higher virus titres in the lung when compared to WT controls (p = 
0.045) (Figure 3.3B). Delayed virus clearance was observed in Adamts5-/- mice  
  
 
75 
 
 
 
 
Figure 3.1. Naïve Adamts5-/- mice have normal immune cell subsets in the spleen. 
Spleens were removed from naïve WT and Adamts5-/- mice and immune cell subsets were 
characterized by flow cytometry. (A) Neutrophils (Ly6GhiGR1hi), (B) NK cells (CD314+CD3-), 
(C) macrophages (CD11bhiF4/80hi), (D) DCs (CD11chiMHCIIhi), (E) B cells (B220+) and (F) 
T cells (CD4+CD3+ or CD8+CD3+). The results are expressed as means ± SEM (n = 5, Figures 
are representative of 3 independent experiments). 
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Figure 3.2. Naïve Adamts5-/- mice have normal immune cell subsets in the lung.  
Lungs were removed from naïve WT and Adamts5-/- mice and immune cell subsets were 
enumerated by flow cytometry. (A) Neutrophils (Ly6GhiGR1hi), (B) NK cells (CD314+CD3-), 
(C) macrophages (CD11bhiF4/80hi), (D) DCs (CD11chiMHCIIhi), (E) B cells (B220+) and (F) 
T cells (CD4+CD3+ or CD8+CD3+). The results are expressed as means ± SEM (n = 5 
representing 3 experiments). 
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Figure 3.3. Adamts5-/- mice are more susceptible to influenza virus infection.  
Adamts5-/- and WT mice were intranasally infected with 104 pfu/mouse X31 (H3N2) influenza 
virus. (A) Percent of initial body weight loss was measured throughout the time course of 
infection. Virus titres in lung homogenates were determined at (B) 3 and (C) 7 dpi. The results 
are expressed as means ± SEM, and statistical significance (relative to WT controls) was 
determined by Student’s t test (* = p ≤ 0.05, n = 5 representing 3 experiments). 
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at 7 dpi (p = 0.013) when compared to WT controls (Figure 3.3C). These data clearly suggest 
that Adamts5-/- mice do not clear influenza virus infection as effectively as WT controls. 
 
 
3.4 Adamts5-/- mice have similar APC numbers in the lung 
Increased lung virus titres observed in Adamts5-/- mice at 3 and 7 dpi suggests that 
defective innate immune cell responses may be influencing pathogenesis, leading to enhanced 
virus titres and weight loss (Figure 3.3). Initially, we chose to enumerate macrophages and DCs 
(APCs) in the lung, the primary site of infection and a key site for antigen uptake (73). We 
originally hypothesized that a defect in APC numbers in the lung could result in enhanced virus 
titres (as observed at 3 dpi) and increased weight loss at later time points (Figure 3.3), as there 
may have been reduced or delayed antigen presentation and priming of T cells in Adamts5-/- 
mice. Our initial observations indicated that there were no differences in APCs (macrophages 
and DCs) in the lung of WT and Adamts5-/- mice at 3 and 7 dpi (Figure 3.4), although there was 
a trend for reduced macrophages at 3 and 7 dpi, p = 0.06 and p = 0.08 respectively. This data 
suggests that APC numbers were not directly contributing to increased weight loss and virus 
titres.  
 
 
3.5 Lack of ADAMTS5 expression results in the accumulation of T cells in 
the MLN 
As there was evidence of delayed viral clearance in Adamts5-/- knockout mice (Figure 
3.3) and no differences in the numbers of APCs (Figure 3.4), we wanted to determine if 
perturbations in the adaptive immune response contributed to disease. B and T cells are 
required for efficient clearance of influenza virus infection (see section 1.7). Disruption in 
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either population may contribute to delayed viral clearance observed in Adamts5-/- mice. We 
initially enumerated total T and B cells numbers in the spleen and lung at 7 and 10 dpi as these 
time points correspond to key time points in adaptive immunity following influenza virus 
infection. At 7 dpi, reduced numbers of total CD4+ (p = 0.004) and CD8+ (p = 0.001) T cells 
were observed in the spleen of Adamts5-/- mice when compared to WT controls (Figure 3.5A). 
Similar findings were observed in the lung, where total B cells (p = 0.043), CD4+ (p = 0.032) 
and CD8+ (p = 0.04) T cell numbers were lower in Adamts5-/- mice when compared to WT 
controls (Figure 3.5C and D). Interestingly there was a striking difference and contrasting 
accumulation of total B cells, CD4+ and CD8+ T cell numbers in pooled MLN in Adamts5-/- 
mice when compared to WT mice (Figure 3.5E and F).  
We then continued our analysis of adaptive immune cell populations at 10 dpi, the peak 
of influenza-specific CD8+ T cell immunity. Results at this time point were similar to those 
observed at 7 dpi (Figure 3.5). Adamts5-/- mice had fewer B cells (p = 0.07), CD4+ (p = 0.012) 
and CD8+ (p = 0.008) T cells in the spleen when compared to WT controls (Figure 3.6A and 
B). Enumeration of total adaptive immune cell populations in the lung suggested that Adamts5-
/- mice had fewer B cells (p = 0.11) and CD4+ (p = 0.007) and CD8+ (p = 0.006) T cells when 
compared to WT controls (Figure 3.6C and D). In contrast Adamts5-/- mice had higher numbers 
of total B cell, CD4+ and CD8+ T cells in pooled MLN samples when compared to WT controls 
(Figure 3.6E and F). 
These experimental observations suggest that Adamts5-/- mice have fewer total adaptive 
immune cells in peripheral tissue following infection, but accumulate cells in the MLN. These 
results link ADAMTS5 expression with altered adaptive immunity in the MLN, and suggests 
the presence of ADAMTS5 aids the egress of cells from the MLN to the lung and spleen.  
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Figure 3.4. APCs numbers are comparable in influenza virus infected Adamts5-/- and WT 
mice.  
Adamts5-/- and WT mice were intranasally infected with 104 pfu/mouse X31 (H3N2) influenza 
virus and APC numbers were assessed in the lung at 3 and 7 dpi. Macrophages 
(CD11bhiF4/80hi) in the lung at (A) 3 and (B) 7 dpi. DCs (CD11chiMHCIIhi) in the lung at (C) 
3 and (D) 7 dpi. The results are expressed as means ± SEM, and statistical significance 
(relative to WT controls) was determined by Student’s t test (n = 5 representing 3 experiments).  
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Figure 3.5. CD8+ T cells accumulate in the MLN of Adamts5-/- mice 7 dpi.  
Adamts5-/- and WT mice were intranasally infected with 104 pfu/mouse X31 (H3N2) influenza 
virus and total adaptive immune cell populations were assessed in the spleen, lung and MLN 
7 dpi. Total B cells (B220+) in the (A) spleen, (C) lung and (E) MLN. Total T (CD4+ or CD8+ 
CD3+) cells in the (B) spleen, (D) lung and (F) MLN. Spleen and lung data are expressed as 
means ± SEM, and statistical significance (relative to WT controls) was determined by 
Student’s t test (* = p ≤ 0.05, *** = p ≤ 0.005, n = 5 representing 3 experiments). MLN data 
are expressed as pooled means (n = 5 mice/group). 
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Figure 3.6. CD8+ T cells continue to accumulate in the MLN of Adamts5-/- mice 10 dpi.   
Adamts5-/- and WT mice were intranasally infected with 104 pfu/mouse X31 (H3N2) influenza 
virus and total adaptive immune cell populations were enumerated in the spleen, lung and MLN 
10 dpi. Total B cells (B220+) in the (A) spleen, (C) lung and (E) MLN. Total T (CD4+ or CD8+ 
CD3+) cells in the (B) spleen, (D) lung and (F) MLN. Spleen and lung data are expressed as 
means ± SEM. Statistical significance (relative to WT controls) was determined by Student’s t 
test (* = p ≤ 0.05, ** = p ≤ 0.001, n = 5 representing 3 experiments). MLN data are expressed 
as pooled means (n = 5 mice/group).  
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3.6 Influenza-specific CD8+ T cell responses in the periphery of Adamts5-/- 
mice 
Our data clearly demonstrated the accumulation of total CD8+ T cells in the MLN of 
Adamts5-/- knockout mice (Figure 3.5 and 3.6). We wanted to further confirm that this 
accumulation also included influenza-specific CD8+ T cells.  
To assess influenza-specific CD8+ T responses we enumerated antigen specific CD8+ 
T cells using tetrameric complexes that recognise the immunodominant NP366-374 
(ASNENMETM) or PA224-233 (SSLENFRAYV) CD8
+ T cell epitopes at 7 and 10 dpi (65). At 
7 dpi, fewer NP366-374 (p < 0.005) and PA224-233 (p = 0.13) CD8
+ T cells were detected in the 
spleen of Adamts5-/- mice when compared to WT controls (Figure 3.7A), although the 
differences in PA224-233
+CD8+ T cells was not statistically significant. Similarly, in the lung, 
fewer NP366-374 (p = 0.019) and PA224-233 (p = 0.006) CD8
+ T cells were found in Adamts5-/- 
mice when compared to WT controls (Figure 3.7C). Furthermore, and as suspected, NP366-374 
and PA224-233 CD8
+ T cells accumulated in the pooled MLN of Adamts5-/- mice (Figure 3.7E). 
These results were recapitulated at 10 dpi, where fewer NP366-374 and PA224-233 CD8
+ T cell 
numbers were detected in the spleen and lung of Adamts5-/- mice when compared to WT 
controls (Figure 3.8A and C). In pooled MLN samples, pooled samples suggested that NP366-
374 CD8
+ and PA224-233 CD8
+ T cells were increased in Adamts5-/- mice when compared to WT 
controls (Figure 3.8E).  
The ICS assay was used to assess the functionality of influenza-specific CD8+ T cells 
in the spleen, lung and MLN at 7 and 10 dpi where CD8+ NP366-374 or PA224-233 T cells expressed 
IFNγ (300). Using this assay, we identified that Adamts5-/- mice had reduced numbers of NP366-
374
+IFNγ+ (p = 0.044) and PA224-233+IFNγ+ (p = 0.03) CD8+ T cells in the spleen at 7 dpi (Figure 
3.7B). Similarly, Adamts5-/- mice had reduced numbers of NP366-374
+IFNγ+ and PA224-233+IFNγ+ 
CD8+ T cells in the lung at 7 dpi (Figure 3.7D), although this was not statistically significant. 
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In pooled MLN samples, Adamts5-/- mice had increased numbers of NP366-374
+IFNγ+ and PA224-
233
+IFNγ+ CD8+ T cells 7 dpi (Figure 3.7F). At 10 dpi, the peak of influenza-specific CD8+ T 
cell immunity, Adamts5-/- mice had fewer NP366-374
+IFNγ+ and PA224-233+IFNγ+ CD8+ T cells in 
the spleen and lung when compared to WT controls (Figure 3.8B and D). Pooled MLN samples 
indicated an increase in the numbers of NP366-374
+IFNγ+ and PA224-233+IFNγ+ CD8+ T cells when 
compared to their WT counterparts (Figure 3.8F).  
The data presented herein suggests that influenza-specific CD8+ T cell immunity was 
significantly impaired in the spleen and lung of Adamts5-/- mice at 10 dpi and provides a 
possible explanation for the increased viral titres and weight loss observed in Adamts5-/- mice 
(Figure 3.3).  
 
 
3.7 Adamts5-/- mice have reduced numbers of influenza-specific memory 
CD8+ T cells 
Activation of adaptive immune cells during acute influenza virus infection results in the 
expansion and eventual contraction of cells following elimination of a pathogen (307, 308). 
During this process a small subset of adaptive immune cells will become memory T cells (68) 
that will be available to rapidly respond to re-infection (307, 308). We hypothesised that the 
reduced numbers of influenza-specific CD8+ T cells observed in the peripheral tissue during 
acute infection of Adamts5-/- mice may also reflect the influenza-specific CD8+ T cell memory 
pool. Our observations in influenza virus infected Adamts5-/- mice indicated that effector CD8+ 
T cells accumulated in the MLN (Figure 3.5 – 3.8). Hence, we wanted to assess if this defect 
affected memory responses. Here, we assessed influenza-specific memory CD8+ T cells in the 
spleen of Adamts5-/- mice that had fully recovered from virus infection (30 dpi). 
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Figure 3.7. Influenza-specific CD8+ T cell immunity in Adamts5-/- mice 7 dpi.  
Spleen, lung and MLN from influenza virus infected Adamts5-/- and WT mice were assessed for 
influenza-specific immunity 7 dpi. Tetramer+CD8+ T cells in the (A) spleen, (C) lung and (E) 
MLN. IFNγ+CD8+ T cells in the (B) spleen, (D) lung and (F) MLN. The results are expressed 
as means ± SEM, and statistical significance (relative to WT mice) was determined by Student’s 
t test (* = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.005, n = 5 representing 3 experiments). MLN 
data are expressed as pooled means (n = 5 mice/group). 
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Figure 3.8. Influenza-specific CD8+ T cell immunity in Adamts5-/- mice 10 dpi.  
Spleen, lung and MLN from influenza virus infected Adamts5-/- and WT mice were assessed for 
influenza-specific immunity 10 dpi. Tetramer+CD8+ T cells in the (A) spleen, (C) lung and (E) 
MLN. IFNγ+CD8+ T cells in the (B) spleen, (D) lung and (F) MLN. The results are expressed 
as means ± SEM, and statistical significance (relative to WT mice) was determined by Student’s 
t test (* = p ≤ 0.05, ** = p ≤ 0.01, n = 5 representing 3 experiments). MLN data are expressed 
as pooled means (n = 5 mice/group). 
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Our data suggest that Adamts5-/- mice and WT controls had similar numbers of total CD4+ and 
CD8+ T cells in the spleen (Figure 3.9A). However, fewer NP366-374 (p < 0.005) and PA224-233 
(p < 0.005) tetramer+ CD8+ T cells were quantified in Adamts5-/- mice when compared to WT 
controls (Figure 3.9B). Similarly, fewer NP366-374
+IFNγ+ (p = 0.023) and PA224-233+IFNγ+ (p = 
0.008) CD8+ T cells were observed in Adamts5-/- mice when compared to WT mice (Figure 
3.9C). Detailed subsetting of influenza-specific CD8+ memory populations revealed that fewer 
NP366-374
+CD8+ effector memory (CD62LhiCD44hi) (p = 0.037) cells were isolated from the 
spleens of Adamts5-/- mice when compared to WT counterparts (Figure 3.10). Although, there 
was no statistical significance between PA244-233
+CD8+ memory cells in Adamts5-/- and WT 
mice (Figure 3.10). This data suggests that only NP366-374
+ memory CD8+ T cells populations 
are significantly affected by the lack of ADAMTS5 expression.  
 
 
3.8 Reduced influenza-specific NP366-374+CD8+ T cell responses in Adamts5-/- 
mice following secondary challenge 
Due to the lower number of NP366
+CD8+ T memory cells observed in Adamts5-/- mice 
(Figure 3.10) following primary infection, we hypothesized that this would significantly impact 
the ability of Adamts5-/- mice to mount an effective recall response. To determine if this was 
indeed true, we intraperitoneally primed Adamts5-/- and WT mice with PR8 (H1N1) influenza 
virus (1.5 x 107 pfu/mouse) and then intranasally challenged these mice with the serologically 
distinct X31 (H3N2) (104 pfu/mouse) influenza virus 6 weeks later. The X31 (H3N2) and PR8 
(H1N1) influenza viruses are laboratory adapted influenza virus strains that contain the same 
internal gene segments, but differ in external HA and NA proteins (H3N2 and H1N1, 
respectively). Priming with PR8 (H1N1) and challenging with X31 (H3N2) facilitates boosting  
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Figure 3.9. Influenza-specific CD8+ T cell immunity in Adamts5-/- mice 30 dpi.  
Adamts5-/- and WT mice were intranasally infected with 104 pfu/mouse X31 (H3N2) influenza 
virus. Spleens were removed and immunity assessed 30 dpi. (A) Total CD4+ or CD8+ CD3+ T 
cells, (B) tetramer+ CD8+ T cells and (C) functional (IFNγ+) CD8+ T cells were enumerated. 
The results are expressed as means ± SEM, and statistical significance (relative to WT mice) 
was determined by Student’s t test (* = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.005, n = 5 
representing 3 experiments). 
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Figure 3.10. Adamts5-/- mice have fewer NP336-374+ influenza-specific memory CD8+ T cells.  
Adamts5-/- and WT mice were intranasally infected with 104 pfu/mouse X31 (H3N2) influenza 
virus and influenza-specific NP366-374
+ or PA224-233
+ effector memory CD8+ T cells 
(CD62LhiCD44hi) were enumerated in the spleen. The results are expressed as means ± SEM, 
and statistical significance (relative to WT mice) was determined by Student’s t test (* = p ≤ 
0.05, n = 5 representing 3 experiments). Amd snfns,e ,sfgmgmh,t smfmmrmrmwlwmrrfmdm 
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of CD8+ T responses during secondary infection, as the immunodominant CD8+ T cell 
responses are encoded within the NP366-374 and PA224-233 internal gene segments. Using this 
challenge model, weight data indicated that Adamts5-/- mice lost more weight when compared 
to WT controls, with significant differences occurring at 5, 6 and 7 dpi (p = 0.045, p = 0.031 
and p = 0.047, respectively) (Figure 3.11A).  
Next we enumerated adaptive immune cells, where we found comparable total B cell 
and CD4+ T cell numbers in Adamts5-/- and WT mice in the spleen (Figure 3.12A and B). 
However, total CD8+ T cell numbers (p = 0.045) were lower in the spleens of Adamts5-/- mice 
when compared to WT controls (Figure 3.12B). In the lung, B cells (p = 0.031), CD4+ T cells 
(p = 0.101) and CD8+ T cells (p = 0.03) were all reduced in Adamts5-/- mice when compared to 
WT mice (Figure 3.12C and D). As with primary infection, increased numbers of B cells (p = 
0.007), CD4+ (p = 0.036) and CD8+ (p = 0.013) T cells were observed in the MLN of challenged 
Adamts5-/- mice when compared to WT controls (Figure 3.12E and F). 
Besides the expansion of CD8+ T cells, the C57BL/6 mouse model also displays a 
typical secondary challenge responses dominated by influenza-specific NP366-374
+CD8+ T cells, 
where a 6-fold increase is observed when compared to PA224-233 CD8
+ T cells (66, 67, 149). 
Given that total CD8+ T cell numbers were reduced in the periphery (lung and spleen) of 
Adamts5-/- mice during secondary challenge (Figure 3.12B and D), we also expected influenza-
specific immunity in Adamts5-/- mice to be compromised. Indeed, NP366-374
+tetramer+ T cell 
numbers were reduced in the spleen (p = 0.049) and lung (p = 0.048) of Adamts5-/- mice (Figure 
3.13A and C). No differences in PA224-233
+ tetramer+ (p = 0.11) and PA224-233
+IFNγ+ (p = 0.63) 
CD8+ T cell numbers were observed in the spleen (Figure 3.13B), although these cell numbers 
were reduced in the lung of Adamts5-/- mice when compared to WT controls (Figure 3.13D).  
As with primary infections, NP366-374
+ (p < 0.005) and PA224-233
+ (p < 0.005) CD8+ T 
cell numbers were increased in the MLN of Adamts5-/- mice when compared to WT controls 
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during secondary challenge (Figure 3.13E). However, functional NP366-374
+IFNγ+CD8+ (p = 
0.03) T cells were reduced in the MLN of Adamts5-/- mice (Figure 3.13F). This was peculiar, 
as numbers obtained in tetramer and ICS assays are normally similar (66, 67, 149). Finally, no 
differences in PA224-233
+IFNγ+ CD8+ T cell numbers were detected between Adamts5-/- and WT 
mice in the MLN (Figure 3.13F), suggesting that ADAMTS5 is required for normal NP366-
374
+CD8+ secondary challenge responses. 
This mechanism was confirmed by analysing differences between the staining profiles 
of NP366-374
+CD8+ secondary challenge responses. Staining suggested that increased NP366-
374
+CD8+ T cells were found in the MLN of Adamts5-/- mice (Figure 3.14A) and mean 
fluorescent intensity (MFI) staining further supported this (Figure 3.14B). However, IFNγ 
staining was reduced in this tissue (Figure 3.14C) and was again supported by MFI (Figure 
3.14D). 
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Figure 3.11. Adamts5-/- mice show increased weight loss following secondary challenge. 
 Adamts5-/- and WT mice were intraperitoneally primed with 1.5 x 107 pfu/mouse PR8 (H1N1) 
influenza virus and then intranasally challenged 6 weeks later with 104 pfu/mouse X31 (H3N2) 
influenza virus. Weight loss in (A) percent initial body weight and (B) grams lost was measured 
throughout the time course of secondary challenge. The results are expressed as means ± SEM, 
and statistical significance (relative to WT mice) was determined by Student’s t test (* = p ≤ 
0.05, n = 4 representing 3 experiments). 
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Figure 3.12. B and T cell responses in influenza virus infected Adamts5-/- mice following 
secondary infection.  
Adamts5-/- and WT mice were intraperitoneally primed with 1.5 x 107 pfu/mouse PR8 (H1N1) 
influenza virus and then intranasally challenged 6 weeks later with 104 pfu/mouse X31 (H3N2) 
influenza virus. Total B cells (B220+) in the (A) spleen, (C) lung and (E) MLN. Total T cells 
(CD3+CD4+ or CD3+CD8+) in the (B) spleen, (D) lung and (F) MLN. Data are expressed as 
means ± SEM, and statistical significance (relative to WT controls) was determined by 
Student’s t test (* = p ≤ 0.05, ** = p ≤ 0.01, n = 4 representing 3 experiments).  
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Figure 3.13. Influenza-specific immunity in Adamts5-/- mice following secondary acute 
infection.  
Adamts5-/- and WT mice were intraperitoneally primed with 1.5 x 107 pfu/mouse PR8 (H1N1) 
influenza virus and then intranasally challenged 6 weeks later with 104 pfu/mouse X31 (H3N2) 
influenza virus. Spleen, lung and MLNs were removed and influenza-specific immunity 
assessed 7 dpi. Tetramer+CD8+ T cells in the (A) spleen, (C) lung and (E) MLN. IFNγ+CD8+ 
T cells in the (B) spleen, (D) lung and (F) MLN. The results are expressed as means ± SEM, 
and statistical significance (relative to WT mice) was determined by Student’s t test (* = p ≤ 
0.05, ** = p ≤ 0.01, *** = p ≤ 0.005, n = 4 representing 3 experiments). 
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Figure 3.14. Influenza-specific immunity staining in the MLN of Adamts5-/- mice following 
secondary acute infection.  
Adamts5-/- and WT mice were intraperitoneally primed with 1.5 x 107 pfu/mouse PR8 (H1N1) 
influenza virus and then intranasally challenged 6 weeks later with 104 pfu/mouse X31 (H3N2) 
influenza virus. MLNs were removed and influenza-specific immunity assessed 7 dpi. (A) NP366-
374
+CD8+ T cells and (B) MFI of tetramer staining. (C) IFNγ+CD8+ T cells in the MLN and 
(D) MFI of ICS staining. The results are expressed as means ± SEM, and statistical significance 
(relative to WT mice) was determined by Student’s t test (n = 4 representing 3 experiments). 
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3.9 Discussion 
Increasing evidence in the literature highlights the importance of zinc-dependent 
metzincins in the regulation of immune responses. Dysregulated MMPs and ADAMs have been 
strongly associated with perturbations in the immune response, such as cytokine expression 
and immune cell infiltration (256, 309, 310). Here, we show for the first time that ADAMTS5, 
a member of the ADAMTS family, plays a key role in the immune response to influenza virus 
infection. Our research suggests that ADAMTS5 activity is required for effective CD8+ T cell 
responses in influenza virus infected Adamts5-/- mice during acute infection, as these mice 
displayed fewer CD8+ T cell populations in the periphery (Figure 3.5 – 3.8), yet, increased 
CD8+ T cells were observed in the MLN at 7 and 10 dpi (Figure 3.5 – 3.8). ADAMTS5 may 
be required for effective migration of CD8+ T cells, given that CD8+ T cell egress from the 
MLN seemed to be delayed (Figure 3.5 – 3.8). In support of this hypothesis, other studies have 
suggested that the related zinc-dependent metzincins, the MMPs, are essential for immune cell 
trafficking (244, 256, 310). Like ADAMTs enzymes, MMPs contain a catalytic domain that 
utilises a conserved zinc binding sequence (HEXXHXXXGXX) for catalysing reactions (167) 
and have a broad range of cleavage substrates [collagen, laminin, proteoglycan etc. (224, 311, 
312)]. This contrasts with the highly specific cleavage moieties associated with ADAMTS 
enzyme activity (proteoglycans). It is therefore not surprising that the MMPs have been 
identified in a vast number of physiological processes (311), including those of the immune 
responses. Indeed, MMP9 is highly intertwined with the trafficking of immune cells (105, 244, 
259). These studies have utilised the highly-characterised Mmp9-/- mouse. In fact, influenza 
virus infected Mmp9-/- mice have decreased neutrophil infiltration into the lung (105). This is 
caused by reduced collagen degradation and infiltration through the basement membrane. 
Additionally, the ECM has been shown to block the migration of DCs in vivo. In this study, 
lipopolysaccharide-induced DCs derived from Mmp9-/- mice show decreased infiltration into 
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the draining lymph node (254). Here ECM components, such as collagen and elastin, blocked 
the crawling of CD4+ T cells along the ECM, inhibiting their migration. Collagen and elastin 
form key ECM components of basement membranes and so reduced MMP enzymatic activity 
would, in turn, lead to the accumulation of these components and the inhibition of immune cell 
migration and tissue infiltration. Versican, a key ADAMTS5 substrate, is widely expressed in 
tissues and is not predominately associated with the basement membrane (unlike MMP 
substrates). ECM components, such as versican, provide a “sticky” surface for T cells allowing 
cell surface adhesion (257). We therefore speculate that the cleavage and removal of versican 
blockades via the action of proteoglycanases, such as ADAMTS5, is required to prevent 
excessive T cell adhesion and facilitate their migration towards the peripheral tissue. 
Lymph node accumulation studies using the FTY720 inhibitor (an agonist of 
sphingosine receptors) indicate that accumulation of CD8+ T cells in the lymph node may 
inhibit the functionality and availability of memory CD8+ T cells (313, 314). In these studies, 
mice were treated orally with FTY720 and found that FTY720-treated mice had reduced T cell 
infiltration towards lymphocytic choriomeningitis infection (314). It was found that T cells 
accumulated in the lymph node of these mice. Our studies, showed a similar result to those 
observed with FTY720 inhibitor studies, where T cells accumulated in the MLN in the absence 
of ADAMTS5 in the MLN during acute infection (Figure 3.5 and 3.6), although we did not 
assess if this was linked to sphingosine receptors Unlike the FTY720 studies, which found 
similar numbers of memory T cells in the periphery (314), we found fewer memory NP366-
374
+CD8+ T cell numbers in the spleen of Adamts5-/- mice (Figure 3.10). It would be of interest 
to further understand memory immune cell populations (e.g. central and effector memory cell 
subsets) in Adamts5-/- mice and if increased apoptosis is specific for NP366-374
+CD8+ T cells 
(given that memory PA224-233
+CD8+ T cells were not affected) in the MLN through techniques 
such as propidium iodide and annexin V staining (apoptosis markers) (315, 316).   
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Differential epitope-specific responses have been documented between CD8+NP366-374 
and CD8+PA224-233 T cells of WT C57/BL.6 mice based on antigen processing and presentation 
as DCs have been shown to favour expansion of NP366-374
+CD8+ T cells during secondary 
infection (317). Our observations show that CD8+NP366-374
+ T cells are impacted in mice 
lacking ADAMTS5, however CD8+PA224-233
+
 T cells remain unchanged (Figure 3.13). Because 
of this, it may be beneficial to assess DC processing and presentation of the in Adamts5-/- mice 
for both epitopes to try to pinpoint a reason for this discrepancy. 
Two interesting results were observed during secondary challenge responses in 
Adamts5-/- mice. Briefly, in a normal secondary responses, NP366-374
+
 CD8
+ T cells are the 
immunodominant influenza-specific CD8+ T cell type, their number being 6 times larger than 
the PA224-233 influenza-specific CD8
+ T cells in the MLN and spleen (66, 67, 149). Although 
our ICS and tetramer numbers reflect those in previous studies (65, 66, 318), our study we 
found that NP366-374
+CD8+ T cells were increased in the MLN of Adamts5-/- mice (Figure 
3.13E), but the ability of these cells to produce IFNγ+ was significantly altered in the MLN of 
Adamts5-/- mice (Figure 3.13F). Some metalloproteinases act as transcription factors for 
signalling pathways to regulate the expression and extracellular release of both cytokines and 
chemokines, enhancing the immune response. For example, MMP12 can regulate the 
expression of IFNα in mice infected with cocksackie virus (309). In these studies, Mmp12-/- 
mice showed delayed inflammation (309). IFNα is known to inhibit viral replication by 
inducing antiviral activity in surrounding cells. In this study it was found that macrophage-
secreted MMP12 enters cocksackie virus infected cells, where it then enters in the nucleus 
(309). In the nucleus, intracellular MMP12 binds to the NF-κB promoter allowing secretion of 
IFNα (309). Additionally, extracellular MMP12 cleaved the IFNα receptor, preventing IFNα 
binding. Regulation of IFNα production by MMP12 following infection could not only limit 
pathogen replication, but also prevent excessive inflammation. In support of this study, 
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ADAMTS7 has been shown to govern TNFα expression via a positive-feedback loop through 
modulation of the NF-κb pathway in an osteoarthritis-induced mouse model (285). In this 
study, ADAMTS7 transgenic mice showed increased cartilage destruction due to elevated 
TNFα expression. Given ADAMTS7’s control in TNFα expression, it is likely that related 
family members, such as ADAMTS5, may also be controlling cytokine/chemokine 
expression/release. Further, ADAMTS5 may be involved in regulating IFNγ production and 
secretion in the rapid and heightened memory recall response, hence promoting functional 
CD8+ T cell responses in influenza virus infected mice, however more studies are required to 
determine this.  
The second interesting result for discussion is the unchanged PA224-233 responses in the 
spleen of WT and Adamts5-/- mice following secondary challenge. This is in contrast to NP366-
374 responses that were consistently reduced in the spleen and lung of Adamts5
-/- mice during 
memory and secondary challenge (Figure 3.10 and 3.13). This result indicates that ADAMTS5 
is involved in sustaining memory NP366-374
+CD8+ T cell responses (but not PA224-233
+ CD8+ T 
cell responses) (Figure 3.9 and 3.10) and may be contributing to the reduced numbers of NP366-
374
+CD8+ T cell responses observed in secondary challenge 
 
 
3.10 Conclusion 
These data indicate that Adamts5-/- mice are more susceptible to influenza virus 
infection and CD8+ T cell immunity is critically compromised in these mice. The next chapter 
will assess the mechanism behind immune cell accumulation in the MLN of Adamts5-/- mice.  
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Chapter 4 - ADAMTS5-mediated cleavage of versican enhances 
CD8+ T cell migration 
4.1 Overview 
Chapter 3 described how the lack of ADAMTS5 in mice resulted in decreased 
influenza-specific CD8+ T cells in the periphery (spleen and lung) following influenza virus 
infection. Importantly, we observed that these cells accumulated in the MLN of Adamts5-/- 
mice. Given these findings we hypothesized that ADAMTS5 degradation of the ECM 
facilitates migration of CD8+ T cells from the lymph node to the periphery.  
ADAMTS5 cleaves a number of ECM proteoglycans, including brevican, neurocan, 
aggrecan and versican (221, 269). Of these proteoglycans, versican has been detected within 
most tissues (261), whilst the other ECM proteoglycans show selective tissue expression [e.g. 
the joints, brains and the central nervous system, respectively (319, 320)]. Importantly, versican 
has a role in the normal functioning of the immune response. Its GAG chains interact with 
receptors on the surface of immune cells, including CD44, TLR2 and selectins, and providing 
essential signals to influence inflammation and effector function, such as cytokine release (264, 
265, 267, 321-323). Versican also interacts with other ECM components, such as hyaluronan, 
fibronectin and tenascin, which are important in inflammatory responses (Figure 1.6) (324-
326). Interaction between these ECM components promotes/inhibits leukocyte migration (257, 
327-329). Interestingly, versican has been shown to inhibit the attachment of CD4+ T cells to 
hyaluronan, disrupting migration and immune responses (257). A similar result has also been 
observed with CD8+ T cells, whereby versican inhibited cells from entering stromal tissue to 
attack cervical cancer cells in human patients (258, 330). 
The remodeling and proteolysis of versican has been carried out by MMP1, 2, 3, 7 and 
9 and ADAMTS1, 4, 5, 8, 9, 15 and 20 physiological processes such as wound healing and 
  
 
101 
 
embryonic development (198, 269-272). Versican proteolysis, however, has never been 
associated with the migration of immune cells. This chapter examines versican expression in 
influenza virus infected Adamts5-/- mice and highlights the importance of the 
ADAMTS5/versican interaction for CD8+ T cell migration. Additionally, this chapter utilizes 
a versican reduced (Vcanhdf/+) mouse model to understand the role of ADAMTS5 and versican 
in the immune response to influenza virus infection.  
 
 
4.2 Versican accumulation in the MLN of Adamts5-/- mice 
Versican, a key ECM proteoglycan and cleavage substrate of ADAMTS5, impedes the 
trafficking of immune cell populations, such as T cells (257, 258). We hypothesised that a lack 
of versican degradation to versikine (the versican cleavage fragment) in the MLN of Adamts5-
/- mice could result in the accumulation of versican, a large ECM proteoglycan, in the MLN, 
resulting in inhibition of T cell movement to effector sites and the periphery. We therefore 
assessed versican and versikine expression in the MLN and lung of influenza virus-infected 
Adamts5-/- and WT mice at 10 dpi. MLN tissue from influenza virus infected mice was paraffin 
embedded, sectioned and stained with anti-GAG-β (versican) and anti-versikine antibodies. 
Fluorescence imagery of sections revealed increased levels of versican in the MLN of Adamts5-
/- mice when compared to WT controls (Figure 4.1A) and correlated with decreased versikine 
levels in Adamts5-/- mice (Figure 4.1C), suggesting reduced cleavage of versican into versikine 
in the MLN. qPCR analysis (Figure 4.1B and D) also confirmed that versican expression was 
increased in the pooled MLN of Adamts5-/- mice.  
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Figure 4.1. Versican accumulation in the MLN of Adamts5-/- mice.  
WT and Adamts5-/- mice were intranasally infected with 104 pfu/mouse X31 (H3N2) influenza 
virus and MLNs were removed 10 dpi. MLNs were sectioned and stained for the expression of 
versican and versikine. (A) Versican staining in the MLN of influenza virus infected WT and 
Adamts5-/- mice. (B) Fold change data (vs WT) of versican expression in the MLN of influenza 
virus infected Adamts5-/- mice. (C) Versikine staining in the MLN of WT and Adamts5-/- mice. 
(D) Fold change data (vs WT) of versikine expression in the MLN of influenza virus infected 
Adamts5-/- mice. Blue = nucleus, Red = versican/versikine (n = 5 mice/group). B and D are 
expressed as pooled data from 5 mice. 
 
 
 
  
 
103 
 
Immunofluorescence and qPCR data of the lung tissue showed no differences in the 
levels of versican (Figure 4.2A and B) and versikine (Figure 4.2C and D) observed between 
WT and Adamts5-/- mice.  
Because of these contrasting differences in versican accumulation in the MLN and lung, 
we suspected that the level of ADAMTS5 expression in these tissues varied. To gain a better 
understanding of ADAMTS5 expression in the MLN and lung, we performed β-galactosidase 
staining of whole MLN and found that β-galactosidase was highly expressed throughout the 
MLN (Figure 4.3A), but localised expressed was observed in the lung (Figure 4.3B), of 
Adamts5-/- mice. β-galactosidase staining was used here because Adamts5-/- mice were 
generated through the insertion of a LacZ cassette into the ADAMTS5 gene (275), thereby 
preventing the translation of the enzymatically active ADAMTS5 protein. In these mice, the 
LacZ cassette, which contains β-galactosidase, can be used as a surrogate reporter of 
ADAMTS5 expression. Interestingly, the lung displayed β-galactosidase staining within the 
trachea of both WT and Adamts5-/- mice (Figure 4.3B). We believed this expression is because 
of bacterial colonisation (which express β-galactosidase) within the trachea, hence why both 
mice have staining. This data suggests that the enzymatic activity of ADAMTS5 on its substrate 
versican is critically important in the MLN, but not in the lung. 
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Figure 4.2. Versican and versikine expression is similar in the lungs of WT and Adamts5-/- 
mice. 
WT and Adamts5-/- mice were infected intranasally with 104 pfu/mouse X31 (H3N2) influenza 
virus and lungs removed 10 dpi. Lungs were sectioned and stained for the expression of 
versican and versikine. (A) Versican staining in the lung of influenza virus infected WT and 
Adamts5-/- mice. (B) Fold change data (vs WT) of versican expression in the lung of influenza 
virus infected Adamts5-/- mice.  (C) Versikine staining in the lung of WT and Adamts5-/- mice. 
(D) Fold change data (vs WT) of versican expression in the lung of influenza virus infected 
Adamts5-/- mice.  Blue = nucleus, Red = versican/versikine. The results are expressed as means 
± SEM (n = 5 mice/group). 
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Figure 4.3. ADAMTS5 is highly expressed in the MLN.  
MLN and lungs were removed from influenza virus infected WT and Adamts5-/- mice 10 dpi and 
stained for β-galactosidase (ADAMTS5) expression. β-galactosidase staining in the (A) MLN 
and (B) lung. n = 5 mice/group. 
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4.3 Versican inhibits ex vivo CD8+ T cell migration 
Accumulation of versican in the MLN of influenza virus infected Adamts5-/- mice 
highlighted a potential role for versican-mediated impediment of immune cell trafficking out 
of this tissue. As such, we examined if the absence of ECM remodelling by ADAMTS5 was 
linked to impaired CD8+ T cell migration. Ex vivo transwell assays were employed to assess 
the migration of CD8+ T cells as previously described (244, 256). In our assay, the surface of 
the upper transwell chamber was coated with versican-enriched conditioned medium from 
transfected HEK293T cells (198, 282) prior to the addition of a T cell chemoattractant 
(CXCL12) to the lower transwell chamber. CD8+ T cells isolated from the spleens of influenza 
virus infected Adamts5-/- or WT mice were then added to the upper chamber of the transwell 
and migration through the versican-overlay was assessed. The data demonstrates that CD8+ T 
cells isolated from Adamts5-/- influenza-infected mice showed impaired migratory capacity 
through the versican overlay (p < 0.005) when compared to WT controls (that express 
ADAMTS5) (Figure 4.4A). 
Our transwell studies suggested that in the absence of ADAMTS5, CD8+ T cell 
migration was perturbed. We next decided to assess ADAMTS expression levels in CD8+ T 
cells. This data indicates that WT CD8+ T cells express ADAMTS5 (Figure 4.4B) and that 
enzymatic activity may be a key requirement for CD8+ T cell migration through versican. We 
confirmed this by determining the ability of CD8+ T cells to cleave versican. In this study, 
splenic CD8+ T cells from WT and Adamts5-/- mice were incubated with HEK293T versican 
conditioned medium and versican cleavage by CD8+ T cells was assessed via western blot 
(299). Higher levels of versikine (p < 0.005) were detected in samples from WT CD8+ T cells 
when compared to Adamts5-/- CD8+ T cells (Figure 4.4C and D).  
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Figure 4.4. ADAMTS5 degradation of versican facilitates ex vivo CD8+ T cell migration. 
Splenic CD8+ T cells were isolated from WT and Adamts5-/- mice and migration and versican 
degradation assessed. (A) Migration of CD8+ T cells through a versican overlay is shown by 
graphical representation. (B) Expression of ADAMTS1, 4, 5, 9, 15 and 7 in CD8+ T cells by 
qPCR analysis. (C) Western blot analysis of versican cleavage fragments generated by WT and 
Adamts5-/- mice. (D) Densitometric quantification of Figure 4.4C using ImageJ software. The 
results are expressed as means ± SEM, and statistical significance (relative to WT) was 
determined by a student’s t test (*p < 0.05, *** p < 0.005 relative to WT; n = 3 mice/group 
representing 3 individual experiments). 
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4.4 Immunity in influenza virus infected Vcanhdf/+ mice is similar to WT mice 
Results in Figure 4.4 suggest that ADAMTS5 is required for CD8+ T cell migration. 
However, the transwell assays used represent an ex vivo system and so to further define the 
effect of versican reduction on CD8+ T cell migration we utilised an in vivo mouse model. The 
role of versican in embryonic development, specifically heart ventricle formation, has been 
previously described using a versican reduced mouse model (298). In this model, a complete 
knockout of both versican alleles causes a hdf and results in embryonic lethality. Because of 
this, a heterozygote mouse model [Vcanhdf/+ (versican reduced)] has been used previously to 
describe versican’s role in embryonic heart development (298, 331). To assess the impact of 
versican reduction on influenza-specific immunity we intranasally infected these Vcanhdf/+ and 
WT control mice with X31 (H3N2) influenza-virus (104 pfu/mouse). Given that versican is 
reduced in Vcanhdf/+ mice and ADAMTS5 enzymatic activity is still intact, we anticipated that 
CD8+ T cell egress from the MLN would be increased, due to decreased levels of versican that 
inhibit migration, resulting in increased numbers of these cells in the periphery.  
Weight loss was documented throughout the time course of infection and immune cell 
numbers enumerated in these mice 10 dpi in the spleen, lung and MLN. No differences in 
weight loss were observed between influenza virus infected Vcanhdf/+ and WT control mice 
(Figure 4.5). Enumeration of total T cell populations in the spleen showed that influenza-
infected Vcanhdf/+ mice had fewer total CD4+ T cells (p = 0.03) and CD8+ T cells (p = 0.007) 
when compared to WT mice (Figure 4.6A). However, CD4+ T cells and CD8+ T cells were 
comparable between Vcanhdf/+ and WT mice in the lung (Figure 4.6B). In the pooled MLN 
samples T cell numbers were reduced in Vcanhdf/+ mice when compared to WT controls (Figure 
4.6C).   
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Figure 4.5. Weight loss in influenza virus infected Vcanhdf/+ mice.  
WT and Vcan+/hdf mice were infected intranasally with 104 pfu/mouse X31 (H3N2) influenza 
virus and % initial body weight measured throughout infection. Results are expressed as means 
± SEM (n = 5 mice/group representing 3 experiments). 
 
 
 
 
 
 
 
 
 
 
 
  
 
110 
 
 
 
Figure 4.6. Influenza virus infected Vcanhdf/+ mice have fewer total T cells in the spleen and 
MLN.  
WT and Vcanhdf/+ mice were infected intranasally with 104 pfu/mouse X31 (H3N2) influenza 
virus. Spleens, lungs and MLNs were removed 10 dpi and total T cell numbers enumerated. 
Total T cells (CD3+CD4+ and CD3+CD8+) in the (A) spleen (B) lung and (C) MLN. Spleen 
and lung results are expressed as means ± SEM, and statistical significance (relative to WT 
controls) was determined using a Student’s t test (*p ≤ 0.05, **p ≤ 0.01, n = 5 mice/group 
representing 3 experiments). MLN results are expressed as pooled MLNs from 5 mice. 
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Although a reduction in total T cell numbers in the spleen and MLN of influenza-
infected Vcanhdf/+ mice was noted (Figure 4.6), the number of influenza-specific CD8+ T cells 
was still to be analysed. To assess this, we enumerated NP366-374
+ and PA224-233
+
 influenza-
specific CD8+ T cells using tetramer technology and quantified functional CD8+ T cells (IFNγ+ 
cells) in the spleen, lung and MLN using the ICS assay. 
Our results indicated that fewer influenza-specific NP366-374
+
 (p = 0.045) and PA224-233
+
 
(p = 0.035) CD8+ T cells were detected in the spleen of Vcanhdf/+ mice when compared to WT 
controls (Figure 4.7A). However, no statistical differences in functional CD8+ T cells were 
observed in the spleen (Figure 4.7B). In the lung, we observed an increased number of in NP366-
374 (p = 0.009) and PA224-233 (p = 0.056) tetramer
+ CD8+ T cells (Figure 4.7C), although no 
differences in functional NP366-374 (p = 0.057) and PA224-233 (IFNγ+) CD8+ T cells were detected 
(Figure 4.7D). In the MLN, fewer tetramer+ and IFNγ+ cells were found in Vcanhdf/+ mice 
(Figure 4.7E and F), suggesting that reducing versican in mice leads to reduced influenza virus-
specific responses in the spleen and MLN, with comparable numbers in the lung.  
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Figure 4.7. Influenza-specific CD8+ T cells in Vcanhdf/+ mice.  
Spleens, lungs and MLNs were removed from influenza virus infected WT and Vcanhdf/+ mice 
and influenza-specific immunity enumerated 10 dpi. Tetramer+CD8+ T cells in the (A) spleen, 
(C) lung and (E) MLN. IFNγ+CD8+ T cells in the (B) spleen, (D) lung and (F) MLN. Spleen 
and lung results are expressed as means ± SEM, and statistical significance (relative to WT 
controls) was determined by Student’s t test (*p ≤ 0.05, **p ≤ 0.01, n = 5 mice/group 
representing 3 experiments). MLN results are expressed as pooled MLNs from 5 mice. 
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4.5 Immunity in influenza infected Adamts5-/- mice with reduced versican 
Influenza virus infection of Vcanhdf/+ mice demonstrated that reduction in one allele of 
versican did not fully result in increased immune cell migration to the periphery, i.e. fewer cells 
in the MLN and increased numbers in the lung and spleen, as initially suspected. To further 
validate the interaction between enzyme and substrate, and in an attempt to rescue the WT 
phenotype, we crossed Adamts5-/- mice with Vcanhdf/+ mice to produce Adamts5-/-xVcanhdf/+ 
offspring (see section 2.4.6). We then intranasally infected Adamts5-/- mice, Adamts5-/-
xVcanhdf/+ mice and WT controls with X31 (H3N2) influenza virus (104 pfu/mouse) and 
assessed weight loss and immune responses in spleen, lung and MLN at 10 dpi. Our weight 
loss data indicates that Adamts5-/-xVcanhdf/+ mice had a similar % initial body weight profile as 
WT controls (Figure 4.8), whereas Adamts5-/- mice lost significantly more weight. Enumeration 
of immune cell populations in the spleen indicated that Adamts5-/-xVcanhdf/+ and WT mice had 
similar numbers of total T cells (Figure 4.9A). This correlated with data in the lung (Figure 
4.9B) and pooled MLN (Figure 4.9C). 
We also enumerated influenza-specific CD8+ T cells and found increased NP366-374 and 
PA224-233 CD8
+ T cell numbers following tetramer staining in the spleens of Adamts5-/-
xVcanhdf/+ mice at 10 dpi when compared to Adamts5-/- mice (Figure 4.10A), partially restoring 
the WT phenotype. These results correlated with IFNγ production in the spleen (Figure 4.10B). 
Comparable results were found in the lung (Figure 4.10C and D). We also assessed influenza-
specific CD8+ T cell numbers in pooled MLN to determine if CD8+ T cell egress towards the 
lung could be restored. Careful analysis revealed comparable numbers of influenza-specific 
CD8+ NP366-374
+
 and PA224-233
+ (by tetramer and ICS) in the MLN of Adamts5-/-xVcanhdf/+ 
(versican reduced) and WT control mice (Figure 4.10E and F). These important and highly 
novel findings highlight the importance of the ADAMTS5 enzyme-versican substrate 
interaction as a key process in the regulation of virus-specific immunity. 
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Figure 4.8. WT and Adamts5-/-xVcanhdf/+ mice have similar weight loss profiles.  
WT, Adamts5-/- and Adamts5-/-xVcanhdf/+ mice were infected intranasally with 104 pfu/mouse 
X31 (H3N2) influenza virus and % of initial body weight was measured. The results are 
expressed as means ± SEM. Statistical significance was determined by a One-way ANOVA (p 
≤ 0.05 relative to WT mice, #p ≤ 0.05 relative to Adamts5-/-xVcanhdf/+ mice, n = 5 mice/group 
representing 3 experiments). 
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Figure 4.9. Influenza virus infected WT and Adamts5-/-xVcanhdf/+ mice have similar numbers 
of total T cells.  
WT, Adamts5-/- and Adamts5-/-xVcanhdf/+ mice were infected intranasally with 104 pfu/mouse 
X31 (H3N2) influenza virus. Spleens, lungs and MLNs were removed from infected mice 10 dpi 
and total T cell numbers were enumerated. Total T cells (CD3+CD4+ and CD3+CD8+) in the 
(A) spleen (B) lung and (C) MLN. Spleen and lung results are expressed as means ± SEM, and 
statistical significance was determined by One-way ANOVA (**p ≤ 0.01, *p ≤ 0.05, **p ≤ 0.01, 
n = 5 mice/group representing 3 experiments). MLN results are expressed as pooled MLNs 
from 5 mice. 
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Figure 4.10. WT and Adamts5-/-xVcanhdf/+ mice have comparable influenza-specific CD8+ T 
cell numbers  
Spleens, lungs and MLNs were removed from influenza virus infected WT, Adamts5-/- and 
Adamts5-/-xVcanhdf/+ mice and influenza-specific immunity enumerated 10 dpi. Tetramer+CD8+ 
T cells in the (A) spleen, (C) lung and (E) MLN. IFNγ+CD8+ T cells in the (B) spleen, (D) lung 
and (F) MLN. Spleen and lung results are expressed as means ± SEM, and statistical 
significance was determined by a One-way ANOVA (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.005 n = 
5 mice/group representing 3 experiments). MLN results are expressed as pooled MLNs from 5 
mice. 
 
 
  
 
117 
 
4.6 Discussion 
Migration of CD8+ T cells from draining lymph nodes to the periphery is critically 
important for elimination of pathogens Inhibition of immune cell migration results in increased 
susceptibility to influenza virus infection, as observed in our Adamts5-/- mice. We have 
demonstrated that the accumulation of versican in the MLN of Adamts5-/- mice prevents the 
establishment of normal T cell effector function in the periphery and results in the exacerbation 
of influenza virus infection. 
Versican GAG chains interact directly or indirectly with molecules on the surface of T 
cell lymphocytes, such as CD62L and CD44 (257, 264, 265, 332), providing attachment points 
for T cell rolling and trafficking. Previous studies have shown that the N-terminal globular 
domain of versican prevents CD4+ T cell migration and lymphocyte rolling (257). Moreover, 
versican overexpression has been associated with decreased infiltration of CD8+ T cells into 
the stromal compartments of cervical cancer patients (258). ECM components, such as 
versican, provide a “sticky” surface for T cell adherence and antigen presentation. However, 
inhibited degradation of “sticky” surfaces leads to unwanted accumulation of these cells in 
lymph nodes, compromising effector function in the periphery. We therefore propose that 
cleavage and removal of versican blockades via the action of proteoglycanases, such as 
ADAMTS5, is critical for efficient T cell/ECM interaction to encourage migration to effector 
sites in the periphery and for the subsequent resolution of infection.  
Our studies suggest that CD8+ T cells in Adamts5-/- mice become trapped in the MLN 
after infection. We attribute this phenomenon to the accumulation of versican, because of 
reduced degradation of the substrate itself. ADAMTS5 expression is required for the cleavage 
of versican and migration through this proteoglycan, as demonstrated by our in vitro migration 
assays (Figure 4.4A). Our studies in the Adamts5-/-xVcanhdf/+mice support the notion that 
versican accumulation in Adamts5-/- mice is preventing the migration of CD8+ T cells 
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suggesting that a reduction in versican could rescue the phenotypes observed in Adamts5-/- mice 
(Figure 4.8 - 4.10). However, it is important to note that the migration of influenza-specific 
CD8+ T cells, and other immune cells (e.g. CD4+ T cells), was not completely impeded in 
Adamts5-/- mice. ADAMTS5 may therefore be working in concert with other 
metalloproteinases to facilitate T cell migration. The proteoglycanases, ADAMTS1, 4, 8, 9, 15 
and 20, as well as MMP1, 2, 3, 7 and 9, are capable of producing versican fragments in a similar 
fashion to ADAMTS5 (164, 184, 198, 282, 331). It is reasonable to suspect that there is 
redundancy built into the trafficking system as related family members may be providing some 
compensatory function in the absence of ADAMTS5 allowing some (although highly 
restricted) T cell migration into the peripheral tissue (Figure 3.5 - 3.8). Indeed, Figure 4.4B 
indicates that ADAMTS4, 9 and 15 expression was increased in CD8+ T cells from Adamts5-/- 
mice. Cooperative versican cleavage has been observed in embryogenesis, where ADAMTS1, 
5, 9 and 20 are required for interdigital web regression (299), and so their compensatory 
presence in the regulation of immune cell migration cannot be discounted. This is also the case 
for collagen degradation, where MMP2 and 9 both contribute to T cell migration (256, 273). 
This is similar for macrophage migration, where MMP10 degrades collagen to facilitate its 
migration through the basement membrane (333). Further studies with related family members 
are required to ascertain their specific contribution to versican cleavage and influenza-specific 
immunity in the Adamts5-/- mouse.  
The effect of other ECM components on T cell activation and migration in influenza 
virus infected Adamts5-/- mice are not described in this chapter. Versican was chosen for closer 
analysis because of its global tissue expression pattern (334). It would not be surprising if other 
proteoglycans targeted by ADAMTS5 influence viral pathogenesis and immunity in other 
systems. An altered ADAMTS5/versican/hyaluronan complexes within the Adamts5-/- mouse 
model may be affected. Hyaluronan is a large polysaccharide and a key structural component 
  
 
119 
 
of the ECM, contributing to normal tissue hydrodynamics, including proliferation and 
migration (335). Versican binds to hyaluronan through its G1 domain, allowing versican 
localisation to the ECM (336). Recent studies indicate that hyaluronan can act as a signalling 
molecule for inflammatory cells, such as macrophages (337-339). Hyaluronan also binds 
molecules on the surface of T cells (340), including CD44 and CD62L, both of which are 
important for migration, proliferation and activation of T cells (341). In addition, hyaluronan 
can affect the inflammatory properties of activated T cells. High molecular weight hyaluronan 
displays anti-inflammatory properties that suppress the functionality and proliferation capacity 
of regulatory T cells, preventing excessive inflammation (342). Importantly, hyaluronan 
released on the surface of DCs contributes to the activation of naïve T cells by helping cell 
attachment during the antigen presentation (343, 344). Whilst we did not fully address 
hyaluronan expression in the Adamts5-/- mice, preliminary qPCR data in our laboratory 
indicates that hyaluronan synthases (HAS1, 2 and 3 - enzymes involved in the synthesis of 
hyaluronan), were significantly altered in influenza-specific CD8+ T cells isolated from 
Adamts5-/- mice. 
 
 
4.7 Conclusion 
In summary, our data show that the ADAMTS5 ECM enzymatic activity is important 
for lymphocyte trafficking following influenza virus infection (especially for CD8+ T cell 
immunity). In conclusion, interventions that facilitate increased ADAMTS5 expression used 
in conjunction with current approved antivirals and or vaccines offer a new approach for 
combating unexpected emerging influenza virus pandemic threats.  
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Chapter 5 - ADAMTS7 and the immune response to influenza 
virus infection 
5.1 Overview 
ADAMTS7 remains a relatively uncharacterised member of the ADAMTS family. 
ADAMTS7’s functional role as an ECM enzyme is limited to cleavage of the cartilage 
oligomeric matrix protein and thrombospondin-1 in arteries (284, 291). Degradation of these 
substrates in vitro has given ADAMTS7 a causal role in atherosclerosis and arthritis (286, 288, 
345). The limited number of in vivo studies dissecting the functional role of ADAMTS7 have 
utilised both Adamts7-/- mice and ADAMTS7 transgenic mice (283-285). Adamts7-/- mice 
generated through the insertion of a LacZ cassette into the ADAMTS7 gene, thereby preventing 
the translation of the enzymatically active ADAMTS7 protein (283). Staining for the β-
galactosidase reporter gene expression in Adamts7-/- mouse tissue identified the presence of 
high levels of ADAMTS7 in the heart, brain, lung, intestine and adrenal glands (283). Moderate 
expression of ADAMTS7 was observed in the kidney, brown fat and skeletal muscle (283). 
Additional phenotypic screens, (morphology, behaviour, haematology, energy consumption, 
neurological and clinical chemistry) were performed on Adamts7-/- mice with no overt 
differences detected between WT and Adamts7-/- mice (284). As such, Adamts7-/- mice are 
thought to be phenotypically normal (283, 284). Whereas removing ADAMTS7 resulted in no 
overt phenotypes, overexpressing ADAMTS7 within the chondrocytes of WT mice (for the 
assessment of ADAMTS7’s role in arthritis) resulted in decreased weight, bone volume and 
skeletal length in the first 4 weeks of life in these mice (285). 
The presence of ADAMTS7 in the lung, and more importantly within the bronchioles 
(284), suggests that ADAMTS7 may have an unidentified role in lung homeostasis. Many 
respiratory tract infections, such as influenza virus modify the integrity of the lung following 
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virus replication. The expression and function of many host cellular factors, including 
ADAMTS7, may be altered, leading to increased/decreased susceptibility to infection. Indeed, 
a siRNA screen assessing human proteinase activity following influenza virus infection 
established ADAMTS7 as an important contributor to influenza virus pathogenesis with its 
actions modulated through the NF-κB pathway (161). In this screen, all known 481 human 
proteases were assessed for their role in influenza virus replication (160, 161). Twenty-one 
proteases were identified that either increased or decreased influenza virus replication through 
the use of an in vitro human lung cell culture model (A549 cells) (161). These targets were 
confirmed multiple times through downstream analysis (M gene qPCR, NP expression, 
haemagglutination assays) and suggest a definitive role for ADAMTS7 in influenza virus 
replication.  
Inflammatory cytokines, including TNFα, have been shown to induce the expression of 
ADAMTS7 in inflammatory diseases, such as arthritis (291). This expression is caused by 
TNFα activating the NF-κB pathway, whose components bind to the promoter region of the 
ADAMTS7 gene, allowing protein translation. Further, this study identified that when 
ADAMTS7 was overexpressed in chondrocytes, elevated levels of TNFα occur, suggesting a 
positive feedback loop for TNFα and ADAMTS7 (285). This is important as TNFα expression 
is critical in the control of influenza virus infection. TNFα creates an anti-viral state 
surrounding epithelial cells and encourages the development and proliferation of immune cells, 
such as DCs and macrophages (152). Additionally, TNFα is involved in maintaining the 
viability and functionality of immune cells, such as DCs (117).  
The relationship identified between TNFα and ADAMTS7 is of particular interest given 
that ADAMTS7’s structural homolog, ADAMTS12, has been shown to play a significant role 
in inflammation (295, 346). Adamts12-/- mice show signs of severe neutrophilia and 
cytokinemia (e.g. IL6) in inflammatory disease; i.e. colitis, pancreatitis and sepsis, resulting in 
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delays in recovery (295). Given the association of ADAMTS12 with inflammation and the 
previously identified role of ADAMTS7 in the control of TNFα expression and influenza virus 
replication (285), we hypothesised that ADAMTS7 may have an unidentified role in viral 
immunity. The results in this chapter describe a novel association between influenza virus 
infection, immunity and ADAMTS7 expression. Here we found that Adamts7-/- mice were 
more susceptible to intranasal X31 (H3N2) influenza virus infection due to perturbations in the 
immune response described herein.  
 
 
5.2 Adamts7-/- mice are immunologically “normal” 
Adamts7-/- mice were generated through the insertion of a LacZ cassette within the 
ADAMTS7 allele (283, 284), preventing expression of protein. Previously published 
observations using Adamts7-/- mice indicate that these mice are phenotypically normal based 
on gross morphological and histological analysis (284). The immune cell populations in 
Adamts7-/- mice however are yet to be characterised. To define immune cell populations in 
uninfected mice, we removed spleens and lungs and generated single cell suspensions for 
comparison with WT controls using flow cytometry. These tissues were chosen as these would 
be used as points of comparison in future influenza virus infection experiments. In the spleen, 
we observed no differences in neutrophils (Ly6GhiGR1hi) (Figure 5.1A), NK cells 
(CD314+CD3-) (Figure 5.1B), macrophages (CD11bhiF4/80hi) (Figure 5.1C), DCs 
(CD11chiMHCIIhi) (Figure 5.1D), B cells (B220+) (Figure 5.1E) and total CD4+ T (CD4+CD3+) 
and CD8+ T cells (CD8+CD3+) (Figure 5.1F) between WT and Adamts7-/- mice. Similar results 
were observed between WT and Adamts7-/- mice in the lung (Figure 5.2). This data supports 
previously published data suggesting that Adamts7-/- mice develop normally. 
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Figure 5.1. Naïve Adamts7-/- mice have normal immune cell subsets in the spleen. 
Spleens were removed from naïve WT and Adamts7-/- mice and immune cell subsets were 
characterized by flow cytometry. (A) Neutrophils (Ly6GhiGR1hi), (B) NK cells (CD314+CD3-), 
(C) macrophages (CD11bhiF4/80hi), (D) DCs (CD11chiMHCIIhi), (E) B cells (B220+) and (F) 
T cells (CD4+CD3+ or CD8+CD3+). The results are expressed as means ± SEM (n = 5, Figures 
are representative of 3 independent experiments). 
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Figure 5.2. Naïve Adamts7-/- mice have normal immune cell subsets in the lung.  
Lungs were removed from naïve WT and Adamts7-/- mice and immune cell subsets were 
enumerated by flow cytometry. (A) Neutrophils (Ly6GhiGR1hi), (B) NK cells (CD314+CD3-), 
(C) macrophages (CD11bhiF4/80hi), (D) DCs (CD11chiMHCIIhi), (E) B cells (B220+) and (F) 
T cells (CD4+CD3+ or CD8+CD3+). The results are expressed as means ± SEM, and statistical 
significance (relative to WT controls) was determined by Student’s t test (n = 5, Figures are 
representative of 3 separate experiments). 
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5.3 Adamts7-/- mice are more susceptible to influenza virus infection 
The identification of ADAMTS7 as a key contributor to influenza virus infection in 
vitro (161) justifies further investigation of its role in vivo. To study the role of ADAMTS7 we 
examined in vivo weight loss and determined lung virus titres following X31 (H3N2) intranasal 
infection (104 pfu/mouse) of Adamts7-/- and WT control mice. Adamts7-/- mice lost more weight 
than WT controls (p < 0.05 on 5, 6 and 10 dpi) (Figure 5.3A). Moreover, at the known peak of 
virus replication in this model (3 dpi), Adamts7-/- mice showed higher lung virus titres when 
compared to WT controls (p < 0.005) (Fig 5.3B). Delayed virus clearance was also observed 
in Adamts7-/- mice at 7 dpi (p < 0.005) when compared to WT controls (Figure 5.3C). These 
data clearly demonstrate that Adamts7-/- mice do not clear influenza virus as effectively at WT 
controls. 
 
 
5.4 Adamts7-/- mice have reduced DCs in the lung following influenza virus 
infection 
Increased lung virus titres and weight loss in Adamts7-/- mice suggested the possibility 
of defective immune cell responses. To further understand the mechanism involved we 
enumerated innate immune cell populations in the lung, the primary site of virus replication 
(73). We hypothesized that a defect in innate immune cell numbers in the lung could result in 
enhanced virus titres (as observed at 3 dpi) and increased weight loss at later time points (Figure 
5.3), resulting in delayed clearance of infection. Our data indicated that there were no 
differences in neutrophils, NK cells and macrophages in the lung of WT and Adamts7-/- mice 
(Figure 5.4A-C). Upon assessment of DC numbers in the lung, we found that DC numbers  
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Figure 5.3. Adamts7-/- mice are more susceptible to influenza virus infection.  
Adamts7-/- and WT mice were intranasally infected with 104 pfu/mouse X31 (H3N2) influenza 
virus. (A) Percent of initial body weight was measured throughout the time course of infection. 
Virus titres in lung homogenates were determined at (B) 3 and (C) 7 dpi. The results are 
expressed as means ± SEM, and statistical significance (relative to WT controls) was 
determined by Student’s t test (* = p ≤ 0.05, *** = p ≤ 0.005, n = 5, Figures are representative 
of 3 separate experiments). 
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Figure 5.4. DC numbers are reduced in the lung of influenza virus infected Adamts7-/- mice.  
Adamts7-/- and WT mice were intranasally infected with 104 pfu/mouse X31 (H3N2) influenza 
virus and innate immune cell numbers were assessed 3 dpi in the lung. (A) Neutrophils 
(Ly6GhiGR1hi), (B) NK cells (CD314+CD3-), (C) macrophages (CD11bhiF4/80hi) and (D) DCs 
(CD11chiMHCIIhi) in the lung. Data are expressed as means ± SEM (* = p ≤ 0.05, n = 5, 
Figures are representative of 3 separate experiments). 
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were significantly lower (p = 0.017) in Adamts7-/- mice when compared to WT controls (Figure 
5.4D). 
 
 
5.5 Lack of ADAMTS7 reduces adaptive immunity 
Given evidence of delayed viral clearance in Adamts7-/- knockout mice (Figure 5.3) and 
fewer DCs in the lung (Figure 5.4), we wanted to determine how this would impact on adaptive 
immunity. B and T cells are required for efficient clearance of influenza virus infection (see 
section 1.7). Disruption in either population has been shown to contribute to delayed viral 
clearance. We initially enumerated total B and T cell numbers in the spleen and lung at 7 and 
10 dpi as these time points correspond to key time points in adaptive immunity following 
influenza virus infection. At 7 dpi, fewer total B cells (p = 0.017) were observed in the spleen 
of Adamts7-/- mice (Figure 5.5A). No differences were observed in total T cell numbers between 
WT and Adamts7-/- mice in the spleen (Figure 5.5B). In the lung, we found no difference in 
total B cell and CD4+ numbers but saw a reduction in total CD8+ T cell numbers (p = 0.045) 
in Adamts7-/- mice when compared to WT controls (Figure 5.5C and D). When assessing 
adaptive immune cell populations in pooled MLN, we identified a trend for fewer total B and 
T cells in pooled MLN samples of Adamts7-/- mice when compared to WT controls (Figure 
5.5E and F).  
We then continued our analysis at 10 dpi, the peak of influenza virus-specific T cell 
immunity. At this time point Adamts7-/- mice had fewer total B and T cells in the spleen and 
fewer total T cells in the lung when compared to WT controls (Figure 5.6A-D). In pooled MLN 
samples Adamts7-/- mice had similar numbers of total B cell and a trend higher for CD4+ and 
CD8+ T cells when compared to WT controls (Fig 5.6E and F). These experimental  
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Figure 5.5. Reduced total T cells 7 dpi in influenza virus infected Adamts7-/- mice.  
Adamts7-/- and WT mice were intranasally infected with 104 pfu/mouse X31 (H3N2) influenza 
virus and total adaptive immune cell populations were assessed in the spleen, lung and MLN 
7 dpi. B cells (B220+) in the (A) spleen, (C) lung and (E) MLN. T (CD4+ or CD8+) CD3+ cells 
in the (B) spleen, (D) lung and (F) MLN. Spleen and lung data are expressed as means ± SEM, 
and statistical significance (relative to WT controls) was determined by Student’s t test (* = p 
≤ 0.05, n = 5, Figures are representative of 3 separate experiments). MLN data are expressed 
as pooled means (n = 5 mice/group). 
 
 
  
 
130 
 
 
 
Figure 5.6. Reduced total T cells 10 dpi in influenza virus infected Adamts7-/- mice.  
Adamts7-/- and WT mice were intranasally infected with 104 pfu/mouse X31 (H3N2) influenza 
virus and total adaptive immune cell populations were assessed in the spleen, lung and MLN 
10 dpi. B cells (B220+) in the (A) spleen, (C) lung and (E) MLN. T (CD4+ or CD8+) CD3+ cells 
in the (B) spleen, (D) lung and (F) MLN. Spleen and lung data are expressed as means ± SEM, 
and statistical significance (relative to WT controls) was determined by Student’s t test (* = p 
≤ 0.05, *** = p ≤ 0.005, n = 5, Figures are representative of 3 separate experiments). MLN 
data are expressed as pooled means (n = 5 mice/group). 
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observations suggest that Adamts7-/- mice have fewer total adaptive immune cells in the 
periphery following influenza virus infection. 
 
 
5.6 Influenza-specific CD8+ T cell immunity in Adamts7-/- mice following 
primary influenza virus infection 
Our data suggests that Adamts7-/- mice have reduced DC numbers in the lung (Figure 
4.4D) that may contribute to the observed CD8+ T cells discrepancies in the lung and spleen 
(Figure 5.5 and 5.6). Fewer DC numbers will compromise influenza antigen uptake and antigen 
presentation in the MLN, culminating in reduced T cell activation and clonal expansion of 
influenza-specific CD8+ T cells (72). Hence, we anticipated that influenza-specific CD8+ T cell 
responses would be heavily impacted in Adamts7-/- mice, due to the reductions in DC numbers. 
To assess influenza-specific CD8+ T responses in Adamts7-/- mice we enumerated antigen 
specific CD8+ T cells using tetrameric complexes that recognise the immunodominant NP366-
374 (ASNENMETM) or PA224-233 (SSLENFRAYV) CD8
+ T cell epitopes at 7 and 10 dpi (65). 
At 7 dpi, a trend for fewer NP366-374 and PA224-233 CD8
+ T cells were detected in the spleen 
(Figure 5.7A) and significantly fewer influenza-specific CD8+ T cells in the lung of Adamts7-
/- mice when compared to WT controls (Figure 5.7C). A trend for higher NP366-374 and PA224-
233 CD8
+ T cells was found in pooled MLN samples in Adamts7-/- and WT mice (Figure 5.7E). 
These results were further supported at 10 dpi, where statistically fewer NP366-374 and PA224-233 
CD8+ T cell numbers were noted in the spleen and lung of Adamts7-/- mice when compared to 
WT controls (Figure 5.8A and C). NP366-374 and PA224-233 CD8
+ T cell numbers in pooled MLN 
samples mirrored data at 7 dpi suggesting an accumulation of cells (Figure 5.8E). 
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Figure 5.7. Influenza-specific CD8+ T cell immunity in Adamts7-/- mice 7 dpi.  
Spleen, lung and MLN from influenza virus infected Adamts7-/- and WT mice were assessed for 
influenza-specific immunity 7 dpi. Tetramer+CD8+ T cells in the (A) spleen, (C) lung and (E) 
pooled MLN. IFNγ+CD8+ T cells in the (B) spleen, (D) lung and (F) pooled MLN. The results 
are expressed as means ± SEM, and statistical significance (relative to WT mice) was 
determined by Student’s t test (* = p ≤ 0.05, n = 5, Figures are representative of 3 separate 
experiments). MLN data are expressed as pooled means (n = 5 mice/group). 
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Figure 5.8. Influenza-specific CD8+ T cell immunity in Adamts7-/- mice 10 dpi.  
Spleen, lung and MLN from influenza virus infected Adamts7-/- and WT mice were assessed for 
influenza-specific immunity 10 dpi. Tetramer+CD8+ T cells in the (A) spleen, (C) lung and (E) 
pooled MLN. IFNγ+CD8+ T cells in the (B) spleen, (D) lung and (F) pooled MLN. The results 
are expressed as means ± SEM, and statistical significance (relative to WT mice) was 
determined by Student’s t test (* = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.005, n = 5, Figures 
are representative of 3 separate experiments). MLN data are expressed as pooled means (n = 
5 mice/group). 
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The ICS assay was used to assess functionality (IFNγ expression) of influenza-specific 
NP366-374 or PA224-233 CD8
+ T cells in the spleen, lung and pooled MLN at 7 and 10 dpi (300). 
As expected, the data obtained mostly mirrored the tetramer results where fewer IFNγ+CD8+ T 
cells were observed in the spleen and lungs of Adamts7-/- mice when compared to WT controls 
(Figure 5.7 and 5.8). The data presented herein suggests that influenza-specific CD8+ T cell 
immunity was significantly impaired in the spleen and lung of Adamts7-/- mice at 10 dpi and 
provides a possible explanation for increased weight loss and delayed viral clearance observed 
in Adamts7-/- mice (Figure 5.3).  
 
 
5.7 ADAMTS7 is required for efficient NP366-374 CD8
+ T cell memory 
We suspected that fewer influenza-specific effector CD8+ T cells during primary 
infection would impact the number of memory CD8+ T cells and downstream recall/secondary 
responses in Adamts7-/- mice. We therefore assessed NP366-374 and PA224-233 CD8
+ T cell 
numbers at 30 dpi in Adamts7-/- mice. Fewer NP366-374 and PA224-233 tetramer
+ CD8+ T cells 
were found in the spleen of Adamts7-/- mice when compared to WT controls (Figure 5.9A) and 
a strong but similar trend for NP366-374
+IFNγ+ and PA224-233+IFNγ+ CD8+ T cells although this 
was not statistically significant (Figure 5.9B). Further analysis of influenza-specific CD8+ T 
cell memory indicated that Adamts7-/- mice had fewer memory (CD62LhiCD44hi) NP366-374
+
 
CD8+ T cells (p = 0.013) in the spleens of Adamts7-/- mice when compared to WT controls 
(Figure 5.10). Although there was no difference in memory (CD62LhiCD44hi) PA224-233
+
 CD8
+ 
T cells between WT and Adamts7-/- mice. 
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Figure 5.9. Influenza-specific CD8+ T cell immunity in Adamts7-/- mice 30 dpi.  
Adamts7-/- and WT mice were intranasally infected with 104 pfu/mouse X31 (H3N2) influenza 
virus. Spleens were removed and influenza-specific immunity was assessed 30 dpi. (A) 
Tetramer+ CD8+ T cells and (B) functional (IFNγ+) CD8+ T cells are displayed. These results 
are expressed as means ± SEM, and statistical significance (relative to WT mice) was 
determined by Student’s t test (* = p ≤ 0.05, ** = p ≤ 0.01, n = 5, Figures are representative 
of 3 separate experiments). 
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Figure 5.10. Adamts7-/- mice have reduced numbers of influenza-specific memory CD8+ T 
cells.  
Adamts7-/- and WT mice were intranasally infected with 104 pfu/mouse X31 (H3N2) influenza 
virus and influenza-specific memory (CD62LhiCD44hi) CD8+ T cells were enumerated in the 
spleen 30 dpi. The results are expressed as means ± SEM, and statistical significance (relative 
to WT mice) was determined by Student’s t test (* = p ≤ 0.05, n = 5, Figures are representative 
of 3 separate experiments). 
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5.8 Lack of ADAMTS7 impacts secondary CD8+ T cell responses in mice 
Due to perturbed CD8+ T cell memory responses in Adamts7-/- mice, we speculated that 
recall following secondary influenza virus infection may also be affected. To study this, we 
intraperitoneally primed Adamts7-/- and WT control mice with 1.5 x 107 pfu PR8 (H1N1) 
influenza virus and 6 weeks later we intranasally challenged the same mice with 104 pfu/mouse 
X31 (H3N2) influenza virus as previously described (300). Both viruses share the same NP 
and PA internal gene segments to enable boosting of NP366-374 and PA224-233 CD8
+ T cell 
responses. Using this challenge model, we identified that Adamts7-/- mice lost more weight than 
WT controls (in grams lost and % initial body weight) at 6 and 7 dpi (p = 0.043 and 0.0047, 
respectively) (Figure 5.11A and 5.11B). Weight, in grams, throughout the time course of 
infection is also shown in Figure 5.11C. 
To see if this weight loss correlated with poor immunity we assessed total T cell 
numbers in the spleen, lung and MLN of Adamts7-/- and WT mice using flow cytometry. Our 
studies indicate that total CD4+ and CD8+ T cell numbers were significantly lower in the 
spleens and lungs of Adamts7-/- mice when compared to WT controls (Figure 5.12A and B). 
No differences in these cell populations were detected in MLN samples (Figure 5.12C).  
In the C57BL/6 influenza virus mouse model, a typical secondary recall response shows 
6 fold higher numbers of NP366-374 CD8
+ T cells when compared to PA224-233 CD8
+ T cells (66, 
67, 149). Given total CD8+ T cell numbers in the spleen and lung were reduced in Adamts7-/- 
mice following secondary challenge (Figure 5.12), we predicted influenza-specific CD8+ T cell 
immunity in Adamts7-/- mice to be compromised. However, tetramer and ICS staining showed 
that only CD8+ NP366-374
+
, T cell responses in the spleen and lung were reduced, with no 
differences detected for PA224-233
+ tetramer+ and PA224-233
+IFNγ+ CD8+ T cell numbers when 
compared to WT controls in these tissues (Figure 5.13A - D). 
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Figure 5.11. Adamts7-/- mice show increased weight loss following secondary challenge.  
Adamts7-/- and WT mice were intraperitoneally primed with 1.5 x 107 pfu/mouse PR8 (H1N1) 
influenza virus and then intranasally challenged 6 weeks later with 104 pfu/mouse X31 (H3N2) 
influenza virus. Weight loss in (A) percent initial starting weight, (B) grams lost and (C) weight 
was measured throughout the time course of secondary challenge. The results are expressed 
as means ± SEM, and statistical significance (relative to WT mice) was determined by Student’s 
t test (* = p ≤ 0.05, ** = p ≤ 0.01, n = 5, Figures are representative of 3 separate experiments). 
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Figure 5.12. T cell responses in influenza virus infected Adamts7-/- mice following secondary 
challenge.  
Adamts7-/- and WT mice were intraperitoneally primed with 1.5 x 107 pfu/mouse PR8 (H1N1) 
influenza virus and then intranasally challenged 6 weeks later with 104 pfu/mouse X31 (H3N2) 
influenza virus. Total CD4+ T cells and CD8+ T cells were enumerated in the (A) spleen, (B) 
lung and (C) MLN 7 dpi. Data are expressed as means ± SEM, and statistical significance 
(relative to WT controls) was determined by Student’s t test (* = p ≤ 0.05, ** = p ≤ 0.01, *** 
= p ≤ 0.005, n = 5, Figures are representative of 3 separate experiments). 
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In the MLN, no differences in antigen specific and functional CD8+ T cells were found 
following tetramer staining, but CD8+ NP366-374
+
 were reduced in Adamts7
-/- mice (Figure 5.13E 
and F). 
 
 
5.9 ADAMTS7 is required for DC priming of CD8+ T cells 
Experimental results in Adamts7-/- mice following influenza virus infection suggest that 
ADAMTS7 may play a role in regulating DC numbers that could influence reduced CD8+ T 
cell numbers as observed in Figure 5.4, 5.5 and 5.6. To further clarify this observation and 
understand the underlying mechanism controlling activation of CD8+ T cells, splenic DCs from 
Adamts7-/- mice and WT controls were magnetically enriched (98% population purity) and 
infected with PR8 (H1N1) influenza virus (MOI 0.06). After 6 hours of infection we co-
cultured infected DCs with CD8+ T cells from either Adamts7-/- and WT mice. After 48 hours, 
we assessed the activation of all cell types using flow cytometry. As expected, we detected 
comparable percentages of DCs in all samples (Figure 5.14A), indicating that a similar number 
of DCs were loaded into each sample.  
When we examined how influenza virus infection affected the activation of DCs we 
found that activated DCs (CD11chiCD86hiMHCIIhi cells) were reduced in Adamts7-/- DCs when 
compared to WT DC (Figure 5.14B). Additionally, although the same number of CD8+ T cells 
(10,000 cells) were added to the DC/T cell co-culture, a reduced proportion of total CD8+ T 
cells (p < 0.005) were found in the samples containing Adamts7-/- DCs after the 48 hours of 
influenza virus infection (Figure 5.14C). This culminated in reductions in the percentage of 
activated CD8+ T cells (CD8+CD69hiCD44hi) (p < 0.005) in samples containing Adamts7-/- DCs 
(Figure 5.14D).  
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Figure 5.13. Influenza-specific immunity in Adamts7-/- mice following secondary challenge.  
Adamts7-/- and WT mice were intraperitoneally primed with 1.5 x 107 pfu/mouse PR8 (H1N1) 
influenza virus and then intranasally challenged 6 weeks later with 104 pfu/mouse X31 (H3N2) 
influenza virus. Spleen, lung and MLNs were removed and influenza-specific immunity 
assessed 7 dpi. Tetramer+CD8+ T cells in the (A) spleen, (C) lung and (E) MLN. IFNγ+CD8+ 
T cells in the (B) spleen, (D) lung and (F) MLN. The results are expressed as means ± SEM, 
and statistical significance (relative to WT mice) was determined by Student’s t test (* = p ≤ 
0.05, ** = p ≤ 0.01, *** = p ≤ 0.005, n = 5, Figures are representative of 3 separate 
experiments). 
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Figure 5.14. The removal of ADAMTS7 inhibits DC activation.  
Splenic DCs were stimulated with PR8 (H1N1) influenza virus (MOI 0.06) and CD8+ T cells 
added 6 hours later. After 48 hours of co-culture, DC and CD8+ T cell activation was assessed 
by flow cytometry. Percentage of (A) DCs (CD11chi) and (B) activated DCs 
(CD11chiMHCIIhiCD86hi). Percentage of (C) CD8+ T cells (CD8+) and (D) activated CD8+ T 
cells (CD8+CD69hiCD44hi). The data are expressed as means ± SEM, and statistical 
significance was determined by a One-way ANOVA (** = p ≤ 0.01, *** = p ≤ 0.005 relative 
to WT DC: WT T, ## = p ≤ 0.01, ### = p ≤ 0.005 relative to WT DC: TS7 T, n = 5, Figures are 
representative of 3 individual experiments). TS7 denotes ADAMTS7. T denotes CD8+ T cell. 
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The final question we addressed in this chapter was to ask why Adamts7-/- DCs were 
not effectively activating CD8+ T cells (Figure 5.14D). We suspected this was related to 
ADAMTS7’s ability to regulate TNFα expression (285), as previously described. TNFα is an 
integral cytokine for DC maturation and maintenance (347, 348). Indeed, TNFα-/- mice have 
more immature DCs upon adenovirus infection (347). We compared lung cytokine levels in 
naïve and influenza virus infected mice. We could not detect basal levels of TNFα expression 
by qPCR in the lungs of Adamts7-/- mice (Figure 5.15A). Following influenza virus infection, 
the lungs of Adamts7-/- mice showed lower TNFα expression when compared to WT 
counterparts (Figure 5.15A). Interestingly, other cytokines, such as IFNγ, were not affected by 
the lack of ADAMTS7 (Figure 5.15B). This data suggests that a reduction of TNFα expression 
in the lungs of Adamts7-/- during influenza virus infection, could be contributing to reductions 
in DC numbers observed in these mice. However, the cells expressing TNFα needs to be further 
confirmed.  
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Figure 5.15. TNFα expression is reduced in Adamts7-/- lung tissue.   
Lungs were removed from influenza virus-infected Adamts7-/- and WT mice at 0 and 3 dpi. 
Expression of (A) TNFα and (B) IFNγ was assessed by qPCR. The data are expressed as means 
± SEM, and statistical significance (relative to WT controls) was determined by a Student’s T 
test (*** = p ≤ 0.005, n = 5, Figures are representative of 3 separate experiments). 
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5.10 Discussion  
DC mediated-activation of naïve CD8+ T cells is critically important for the 
establishment of full effector function and the eventual clearance of pathogens (72, 74, 75, 
302). Our research suggests that the absence of ADAMTS7 disrupts DC maturation and CD8+ 
T cell activation following primary influenza virus infection (Figure 5.5, 5.7 and 5.8) and 
results in poor memory and secondary responses (Figure 5.10- 5.13).  
Decreased DC numbers observed in the lungs of naïve and influenza virus infected 
lungs of Adamts7-/- mice may be a causal factor for reduced influenza-specific CD8+ T cell 
numbers in the periphery at later dpi, and suggests that there is perturbed priming of CD8+ T 
cells in Adamts7-/- mice. Unfortunately, our study only enumerated DC populations in the lung, 
and future work should asses DC populations in other tissues, such as the thymus, of naïve and 
infected Adamts7-/- mice to determine if there are differences in these populations. This is 
particularly important in naïve mice, as differences in DC populations in a naïve setting may 
contribute to defects in infected mice for both DC populations and T cell priming. Additionally, 
only total DC populated were assessed, i.e. CD11chiMHCIIhi cells, and it would be of interest 
to further identify the DC subsets thought to be involved in antigen presentation in the influenza 
virus mouse model. Currently there is ongoing debate surrounding which DC subset is critical 
for antigen presentation following influenza virus infection. CD11bhiCD103lo and 
CD11bloCD103hi migratory DCs (DCs that migrate from the influenza virus infected lung to 
the MLN) were identified in separate studies as the sole DC subset involved in antigen 
presentation in the C57BL/6 mouse model (349, 350). This confusion is further compounded 
by studies that suggest both CD11bhiCD103lo and CD11bloCD103hi migratory DC subsets 
preferentially promote CD8+ T cell differentiation, excluding all others (119, 120). Lymph 
node resident CD8+ DCs are also involved in antigen presentation (72, 73, 351). This subset is 
thought to receive antigen from the migratory DCs for presentation to naïve CD8+ T cells in 
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the lymph node (352, 353). Because of the lack of clarity surrounding DC subsetting and CD8+ 
T cell activation, it would be of benefit to assess all DC subsets suspected to be involved in 
antigen presentation (CD11bhiCD103lo, CD11bloCD103hi and CD8+). We suspect that it is 
unlikely that only one DC subset is involved in antigen presentation and that they work together 
to activate naïve CD8+ T cells.  
Moreover, memory CD8+ T cells do not respond to all antigen-presenting DC subsets 
after influenza virus infection (75). Unlike naïve CD8+ T cells, which respond to antigen 
presentation from CD8+, CD11bhi and CD103hi DCs, memory CD8+ T cell undergo clonal 
expansion following interactions with the CD8+ DC subset following challenge (75). Because 
of this it would be beneficial to assess if CD8+ DCs numbers were lower in Adamts7-/- mice 
following secondary challenge, given that immune cell responses were compromised during 
secondary challenge (Figure 5.13). 
In this chapter, we have identified a key defect in Adamts7-/- mice with respect to total 
DC numbers. Additionally, we identified a defect in DC activation when these cells lack 
ADAMTS7 (Figure 5.14B). However, it would be beneficial to further characterise this 
activation model. In this model, we used splenic DCs at 48 hours’ post influenza virus 
infection. It may be better to assess activation of DCs from MLN tissues, given that this is the 
site of antigen presentation in the influenza virus infection model. Though, this would be very 
difficult given the size of the MLN. Additionally, assessing earlier time points may allow us to 
assess at which time point activation is occurring in WT and Adamts7-/- DCs, respectively. 
It is also important to discuss that TNFα expression, a key cytokine in the immune 
response to influenza virus infection, was perturbed in Adamts7-/- mice (Figure 5.15A). Basal 
levels of TNFα were not detectable in Adamts7-/- mice and low expression only observed at 3 
dpi. Although DCs are not the main cell type responsible for TNFα production in influenza-
infected lungs, TNFα, produced by surrounding cells (such as NK and T cells), is involved in 
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the maintenance, maturation, activation and functionality of DCs. With lower levels of TNFα 
in Adamts7-/- mice it is unsurprising that DC numbers were also reduced (Figure 5.4C), 
although this requires further analysis and would greatly benefit from assessing TNFα 
expression in cells which highly express TNFα (i.e. NK and T cells). 
A key theme in Chapter 3 and 4 was the role ADAMTS5 played in the migration of 
CD8+ T cells from the MLN into the periphery. ADAMTS5 potently degrades ECM 
proteoglycans (versican, aggrecan, brevican and neurocan) (176, 213, 282), but knowledge 
surrounding which ECM components ADAMTS7 could be cleaving to facilitate immune cell 
migration is unknown in the matrix biology field. ADAMTS7 does not cleave versican 
(personal communication, Dr Daniel McCulloch, Deakin University) and the only known ECM 
components that ADAMTS7 cleaves is the cartilage oligomeric matrix protein and 
thrombospondin-1 proteins (284). Given these proteins are unlikely to be involved in migration 
of immune cells (due to selective expression in cartilage tissues), ADAMTS7 may be cleaving 
alternative ECM components to facilitate immune cell migration. Additionally, reduced TNFα 
expression in the lung of Adamts7-/- mice, as previously mentioned, could be the reason DC 
migration is inhibited (354). In vivo tracking of DC migration would provide an invaluable tool 
for assessing ADAMTS7’s role in this process. Ho et al. has labelled the lipid coat of influenza 
virus with a fluorescent dye (DiD) to assess infection, replication and uptake by DCs. 
Alongside intranasal infection of mice with this fluorescent virus, they intranasally inoculated 
mice with CFSE dye to track the migration of DCs that had taken up DiD influenza antigen 
(350). Alongside this, to further assess TNFα’s role in DC migration in Adamts7-/- mice, we 
could administer exogenous TNFα to Adamts7-/- mice during influenza virus infection to see if 
we could rescue the WT phenotype. 
Finally, although Adamts7-/- mice has been previously characterised as “normal”, it is 
important to gain a further understanding of naïve and pathogen induced-induced immunity in 
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Adamts7-/- mice. Some of the parameters measured in the original phenotypic characterisation 
of Adamts7-/- mice by Bauer et al. were statistically significant (e.g. oxygen consumption and 
white blood cells in the blood) in specific sexes, whilst other measures were bordering on 
statistical significance (e.g. metabolic rate) (284). “Normality” in this study was established 
using 6 WT and 6 Adamts7-/- mice from each sex. In our current study "immunological 
normality" was established using 15 WT and 15 Adamts7-/- mice. Using this number of mice, 
we found that there was a trend for reduced DCs in the lung (p = 0.09) (Figure 5.2D) and 
reduced CD8+ T cells (p = 0.06) and CD4+ T cells (p = 0.12) in the spleen (Figure 5.1F). To 
fully establish normality of these immune cell types a greater number of WT and Adamts7-/- 
mice could be characterised. Increasing the number of mice used in naïve phenotyping would 
ascertain conclusive evidence that these mice are truly “immunologically normal”. 
 
 
5.11 Conclusion 
In summary, our data show that ADAMTS7 is important for normal DC function during 
influenza virus infection. In the absence of ADAMTS7, influenza-specific CD8+ T cell 
responses are compromised. In conclusion, interventions that facilitate increased ADAMTS7 
expression used in conjunction with current approved antivirals and/or vaccines offer a new 
approach to combating unexpected emerging influenza virus pandemic threats.  
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Chapter 6 - The role of ADAMTS enzymes in HeV infection 
6.1 Overview  
 Our studies presented herein used the well-characterised influenza virus infection 
model to assess the role of ADAMTS5 and ADAMTS7 in influenza virus immunity. Given the 
increased morbidity observed in influenza virus infected Adamts5-/- and Adamts7-/- mice, we 
wanted to further assess the role of these enzymes in the immune response to other viral 
diseases. This would allow us to determine if ADAMTS enzymes contribute to viral immunity 
in a broader context.  
Our research group has set up a collaboration with CSIRO AAHL investigators 
(Deborah Middleton and Linfa Wang) to establish and improve a mouse model for HeV 
infection. HeV is a RNA virus belonging to the paromyxoviradea family and was originally 
isolated from infected horses in Hendra, Queensland, Australia. Severe cases of HeV infection 
result in systemic disease, multiple organ failure and death (296, 297). Susceptibility to HeV 
infection has been observed in bats, ferrets, guinea pigs, pigs, cats, horses, dogs and humans 
(355-358). Infected horses display acute, febrile respiratory disease. Other symptoms include 
facial ataxia, swelling and frothing from the mouth. Horses display respiratory distress, 
neurological symptoms and vascular disease upon HeV infection (297). These symptoms are 
also observed in humans with the fatality rate of 57 % (4/7 human deaths) (359). Although 
most susceptible animals display clinical signs there is a paucity of immunological reagents 
(i.e. antibodies for flow cytometry) to define disease pathogenesis. Other small animal models, 
such as guinea pigs, require high dose inoculation to establish HeV infection but only develop 
severe encephalitis (360) and not fulminating disease. A robust small animal model for HeV 
infection that displays both respiratory and neurological symptoms, does not currently exist. 
Development of a consistent small animal model for the study of HeV or other henipavirus 
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infections, such as Nipah virus, would be an invaluable research tool. Unfortunately, mice are 
not readily susceptible to HeV as they are not a natural host and currently there are no mouse-
adapted HeV strains available to ensure consistent infection. Recently our CSIRO AAHL 
collaborators, demonstrated that C57BL/6 and BALB/C mice could be infected with HeV via 
the intranasal route (296). In these studies, HeV infected mice displayed acute, transient and 
asymptomatic virus replication in the respiratory tract along with clear encephalitis (although 
this did not occur consistently in all HeV infected mice) with older mice more susceptible than 
younger counterparts. 
In this results chapter we investigated the susceptibility of Adamts5-/- and Adamts7-/- 
mice to HeV in the context of establishing a model that fully reflects disease pathogenesis in 
humans and horses, as these mice were more susceptible to influenza virus infection as outlined 
in Chapters 3, 4 and 5.  
 
 
6.2 HeV infection of Adamts5-/- and Adamts7-/- mice 
WT, Adamts5-/- and Adamts7-/- mice were intranasally infected with 50,000 TCID50 
HEV (296). At 6 dpi, tissues (blood, brain, liver, lung, kidney and spleen) were harvested and 
RNA extracted for qPCR analysis to establish the presence of HeV N gene. Detection of HeV 
N gene in multiple organs would be indicative of a systemic infection. Table 6.1 demonstrates 
that the HeV N gene was detected in the lungs of all Adamts5-/- (8/8 infected mice) and 
Adamts7-/- mice (8/8 infected mice) and 7/8 WT mice. Adamts5-/- mice had a greater number 
of mice with increased HeV N gene expression in the brain (4/8) when compared to WT (1/8) 
and Adamts7-/- (1/8) mice. Adamts5-/- mice also had increased HeV N gene expression in the 
kidney (2/8) when compared to WT (0/8) and Adamts7-/- (1/8) mice. Adamts7-/- mice were the 
only mice group with confirmed expression of the HeV N gene in the spleen (1/8) and liver  
  
 
151 
 
 
 
 
 
 Blood Brain Kidney Liver Lung Spleen 
WT 0/8 1/8 0/8 0/8 7/8 0/8 
Adamts5-/- 0/8 4/8 2/8 0/8 8/8 0/8 
Adamts7-/- 0/8 1/8 1/8 1/8 8/8 1/8 
 
Table 6.1. HeV N gene expression in tissues.  
WT, Adamts5-/- and Adamts7-/- mice were intranasally infected with 50,000 TCID50 HeV. 
Tissues were removed at dpi and expression of HeV N gene assessed by qPCR. n = 8 
mice/group. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
152 
 
(1/8). This data suggests that Adamts5-/- and Adamts7-/- mice are generally more susceptible 
to HeV infection, although further confirmation is required. 
 
 
6.3 Immune responses in HeV infected Adamts5-/- and Adamts7-/- mice 
Given the increased expression of the HeV N gene observed in Adamts5-/- and Adamts7-
/- tissues when compared to WT mice (Table 6.1), we suspected that deficiencies in innate 
immune responses could be responsible for the increased presence of HeV N gene in these 
mice. We therefore enumerated neutrophils (Ly6GhiGR1hi), NK cells (CD3-CD314+), DCs 
(CD11bhiF4/80hi) and macrophages (CD11chiMHCIIhi) in the lungs and spleens of HeV 
infected WT, Adamts5-/- and Adamts7-/- mice under PC3/4 conditions. Overall, no statistically 
significant differences were observed in these cell types in WT, Adamts5-/- and Adamts7-/- in 
the spleen (Figure 6.1) or lung (Figure 6.2). Interestingly, small trends were observed in mice 
which were qPCR positive for the HeV N gene. Adamts7-/- mice had a higher average 
percentage of neutrophils, NK cells, DCs and macrophages in the spleen (Figure 6.1). In the 
lung, 4/8 Adamts5-/- mice showed a trend for higher percentages of neutrophils, (Figure 6.2A) 
but lower percentages for NK cells, macrophages and DCs (Figure 6.2B-D).  
We also assessed adaptive immune cell populations in these mice. Six days after HeV 
infection, the spleen and lung were removed, fixed, and stained with monoclonal antibodies 
targeting B cells (B220+), CD4+ T cells (CD3+CD4+) and CD8+ T cells (CD3+CD8+) in WT, 
Adamts5-/- and Adamts7-/- mice. In the spleen, no differences were observed in percentages of 
total B cells, CD4+ and CD8+ T cells in HeV infected WT, Adamts5-/- and Adamts7-/- mice 
(Figure 6.3). In the lung, the percentage of B cells and CD4+ and CD8+ T cells were comparable 
across all groups (Figure 6.4). These results suggest that there are no overt differences in 
adaptive immune cell populations in HeV infected WT, Adamts5-/- and Adamts7-/- mice. 
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Figure 6.1. Innate immunity in the spleen of HeV infected mice.  
WT, Adamts5-/- and Adamts7-/- mice were intranasally infected with 50,000 TCID50 HeV and 
spleens removed 6 dpi. Percentages of (A) neutrophils (Ly6GhiGR1hi), (B) NK cells (CD3-
CD314+), (C) macrophages (CD11bhiF4/80hi) and (D) DCs (CD11chiMHCIIhi) were 
enumerated. The results are expressed as means ± SEM (n = 8 mice/group). 
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Figure 6.2. Innate immunity in the lung of HeV infected mice.  
WT, Adamts5-/- and Adamts7-/- mice were intranasally infected with 50,000 TCID50 HeV and 
lung removed 6 dpi. Percentages of (A) neutrophils (Ly6GhiGR1hi), (B) NK cells (CD3-
CD314+), (C) macrophages (CD11bhiF4/80hi) and (D) DCs (CD11chiMHCIIhi) were 
enumerated. The results are expressed as means ± SEM (n = 8 mice/group). 
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Figure 6.3. Adaptive immunity in the spleen of HeV infected mice.  
WT, Adamts5-/- and Adamts7-/- mice were intranasally infected with 50,000 TCID50 HeV and 
spleens were removed 6 dpi. Percentages of total (A) B cells (B220+), (B) CD4+ T cells 
(CD4+CD3+) and (C) CD8+ T cells (CD8+CD3+) were measured. The results are expressed as 
means ± SEM (n = 8 mice/group). 
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Figure 6.4. Adaptive immunity in the lung of HeV infected mice.  
WT, Adamts5-/- and Adamts7-/- mice were intranasally infected with 50,000 TCID50 HeV and 
lungs removed 6 dpi. Percentages of total (A) B cells (B220+), (B) CD4+ T cells (CD4+CD3+) 
and (C) CD8+ T cells (CD8+CD3+) were measured. The results are expressed as means ± SEM 
(n = 8 mice/group). 
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6.4 Discussion 
  Our studies, and those of others have identified that the mouse may not be the most 
efficient model for HeV infection or that it indeed requires further development (296). This is 
similar for viral diseases such as Ebola virus, where knockout models (e.g. Ifnar-/- mice) display 
increased susceptibility to infection compared to WT mice (361, 362). Because of this our study 
endeavoured to find a knockout mouse model that promoted systemic HeV infection that 
represented disease pathogenesis as observed in humans and horses. We proposed that 
modulating ECM enzymes would lead to increased HeV susceptibility in mice, as the ECM a) 
contains receptors that bind viruses to enhance replication or b) given its role in immune cell 
responses and functions may influence the overall immunity to HeV infection. However, our 
preliminary studies require further detailed analysis to conclusively determine if Adamts5-/- and 
Adamts7-/- mice are more susceptible to HeV infection via virus isolation in cell culture.  
Our studies were not conclusive in highlighting differences in the immune responses 
between WT, Adamts5-/- and Adamts7-/- mice. This may have been because of the time point 
chosen to assess the immune response. Six dpi is generally considered to be an early time point 
in HeV infection (296). In the mouse model of HeV, encephalitis occurs at around 14 dpi (296), 
hence, it would be interesting to discover if encephalitis was more pronounced in Adamts5-/- 
and Adamts7-/- mice (given our observations in influenza virus infection) and if the immune 
response in these mice differed to that of WT controls at later dpi. We were however 
constrained by the need to handle the pathogen under PC4 conditions and had limited flexibility 
in terms of resourcing for this work. 
Finally, this study assessing the immune response to HeV infection using flow 
cytometry, whilst preliminary, is novel, because studies of BSL3/4 agents are generally limited 
to analyses involving molecular biology. To our knowledge flow cytometric analysis of this 
magnitude has never been performed previously on this BSL4 agent. Because of the strict 
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safety requirements for BSL4 agents, our studies involved antibody staining and fixing 
protocols at BSL4 (performed by staff in fully encapsulated suits) and flow cytometric analysis 
occurred at BSL3. In this study, we only determined percentages and did not use cell counts as 
in previous chapters. Future studies would benefit from determining cell numbers to establish 
whether true differences in these HeV infected mice exist, however this was not possible in 
this current study due to the time constraints and occupational health and safety requirements 
for individuals working under BSL4 conditions. 
 
 
6.5 Conclusion 
 The data presented in this chapter suggests that ADAMTS5 and ADAMTS7 may 
potentially be required for the control of systemic spread of HeV infection, although in depth 
studies need to be completed to validate these preliminary observations. 
 
 
 
 
 
 
 
 
  
 
159 
 
Chapter 7 - Discussion and Future Directions 
7.1 Discussion 
Since their initial discovery in 1997, the ADAMTS family of enzymes have been found 
to regulate or contribute to a vast array of diseases (363) including arthritis (213, 221, 364). 
Despite this knowledge, ADAMTS enzymes remain relatively uncharacterised compared to 
their MMP counterparts. Additionally, the inhibition of ADAMTS5 remains a key focus for 
the fields of rheumatology and matrix biology. Indeed, ADAMTS aggrecanase-specific 
inhibitors for arthritis are likely to be introduced to patients in the next few years following 
successful clinical trials which limited arthritis pathogenesis (365-367). Given the development 
of novel ADAMTS5 inhibitors for arthritis, it is important to understand the role ADAMTS5 
(and other ADAMTS family members) plays in other disease states before therapeutic 
inhibition is undertaken, especially as these arthritis interventions will generally target 
susceptible elderly populations. Despite a significant body of knowledge describing the role of 
ADAMTS5 in arthritis, very little information is available regarding infection or immunity.  
 The research described in Chapters 3 and 4 has generated a substantial body of data 
outlining the role of ADAMTS5 in influenza specific immunity. We demonstrated that 
ADAMTS5 was required for efficient primary and secondary immune responses. These 
responses were linked to the accumulation of influenza-specific CD8+ T cells in the MLN of 
Adamts5-/- mice during primary influenza virus infection. We believe that poor egress of CD8+ 
T cells from the MLN is associated with reduced enzymatic degradation of versican as depicted 
in Figure 7.1. In our model, ADAMTS5 must cleave versican in the MLN to facilitate egress 
from this tissue (Figure 7.1). Due to its localization, large size and substrate binding 
characteristics, versican significantly effects the outcome of many cellular processes, including 
normal immune cell migration (as described in this thesis). Although versican is beneficial in 
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a homeostatic environment (e.g. tissue stabilization), inflammation often results in the 
upregulation of versican (322, 330). This upregulation supports wound repair in the dermis and 
lung (277) and contributes to normal immune responses (e.g. IFNγ and TLR2 signaling) (322, 
368). However, without effective ECM turnover via enzymes, such as those in the ADAMTS 
family, the ECM can become an entangling web that prevents normal cell function.  
Unlike ADAMTS5, ADAMTS7 does not cleave versican and so its role in influenza 
virus immunity may not be closely associated with ADAMTS5 function. Our data in Chapter 
5 suggests that the total number of DCs (CD11chiMHCIIhi) in Adamts7-/- mice is perturbed 
leading to poor influenza-specific CD8+ T cell immunity (as depicted in Figure 7.2). As 
previously discussed, ADAMTS7 has been shown to form a positive feedback loop with TNFα. 
TNFα then drives expression of ADAMTS5. In our own studies, we observed increased 
ADAMTS7 expression in CD8+ T cells isolated from influenza virus-infected Adamts5-/- mice. 
This was not detected in CD8+ T cells from WT control mice (Figure 4.4B). We believe 
increased expression of ADAMTS7 in CD8+ T cells from Adamts5-/- mice may be a direct 
response to the lack of ADAMTS5. We propose in our model that ADAMTS7 is trying to 
promote ADAMTS5, which would in turn promote versican cleavage and egress of CD8+ T 
cells from the MLN to the lung. Further analysis is required to determine if this is indeed the 
case, however the study by Lai et al suggests that a therapeutic intervention that enhances 
ADAMTS7 may also enhance ADAMTS5 activity (285), which in our model would support 
DC activation (ADAMTS7 mediated) and T cell migration (ADAMTS5 mediated). 
Understanding a mechanism such as this would firstly benefit from analysing the immune 
responses in an Adamts5-/-xAdamts7-/- mouse model before any therapeutic studies were 
undertaken. 
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This dissertation also identified that the absence of ADAMTS5 and ADAMTS7 not 
only impacts influenza virus immunity but may also alter HeV pathogenesis. Unfortunately, it 
was outside the feasibility of this Ph.D. project to assess HeV infection in Adamts5-/- and 
Adamts7-/- mice in greater detail given the BSL4 nature of these experiments. However, these 
studies provide preliminary evidence supporting a generalised role for ADAMTS5 and 
ADAMTS7 in overall virus immunity and suggests that these knockout mice may be 
susceptible to several pathogens. Infection of Adamts5-/- and Adamts7-/- mice with viruses such 
as Herpes Simplex Virus (HSV) may also provide additional evidence given the importance of 
CD8+ T cells in controlling infection. HSV is a BSL2 agent with a well-characterised murine 
model (369, 370). As with influenza virus infection of Adamts5-/- and Adamts7-/- mice, we 
suspect HSV infection could lead to increased susceptibility, poor CD8+ T cell immunity and 
delayed healing of HSV dermal lesions, highlighting the broader significance of these ECM 
enzymes in viral immunity.  
Virus infections, such as influenza virus, may therefore benefit from increases in 
ADAMTS expression to improve immune cell migration and clearance of pathogens. Our 
laboratory has previously developed recombinant influenza viruses expressing microRNA’s 
(miR) to modulate host immunity. In these studies, miR-155 was incorporated into the NS gene 
segment (371). In vitro infection of MDCK’s cells with recombinant viruses resulted in 
increased cytokine expression (IL6 and IL1β) (371), whilst in vivo studies show enhanced 
CD8+ T cell immunity (personal communication – Leonard Izzard, Stambas Laboratory). This 
technology can be modified to modulate ADAMTS expression. Incorporating a miR that 
negatively regulates ADAMTS5 [miR-195 (372, 373)] or ADAMTS7 [miR-106b (161)] into 
the influenza virus NS segment could potentially improve vaccine efficiency when used as a 
LAIV. Alternatively, exogenous delivery of ADAMTS enzymes may also be beneficial as 
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ADAMTS13 has already been used in mice to prevent thrombotic thrombocytopenic purpura 
and reduced the severity of the disease (374).  
Some infectious diseases are characterised by uncontrolled infiltration of immune cells 
leading to exacerbated disease and increased mortality. For example, H5N1 highly pathogenic 
avian influenza viruses have a mortality rate of ~60% in infected individuals. Death is usually 
associated with a cytokine storm, dysregulated immune cell infiltration and increased lung 
pathology (19, 27, 375). Cerebral malaria, triggered by Plasmodium parasite, is responsible for 
500,000 deaths each year (376). Cerebral malaria manifests following sequestration of the 
parasite in the brain and the excessive release of pro-inflammatory cytokines (e.g. IFNγ) (377-
379), resulting in the infiltration of antigen-specific CD8+ T cells and brain pathology (380). 
Hence, inhibition of ADAMTS enzyme expression in these circumstances may be appropriate. 
The inhibition of ADAMTS4 and ADAMTS5 aggrecanases has been a key focus in the field 
of rheumatology. Two selective ADAMTS5 antibodies have already been developed: a 
recombinant monoclonal antibody directed towards the ancillary domain of ADAMTS5 
(CRB0017) and a humanised ADAMTS5 monoclonal antibody (GSK2394002) (366, 367). 
Additionally, a selective aggrecanase inhibitor is currently in clinical trials (365). The 
generation of ADAMTS5 specific inhibitors has provided a strong foundation from which other 
MMP and ADAMTS inhibitors might be generated in the future to assist not only in the 
treatment of arthritis, but also in infectious disease. However, the inhibition of ADAMTS7 is 
slightly more challenging given the dearth of information regarding its structure and function.  
Our study would suggest that inhibiting ADAMTS5 for arthritis treatment may make 
these individuals more susceptible to influenza virus infection. It is particularly important to 
understand this as it is generally the elderly who are afflicted with arthritis, and it is this 
population who is more likely to succumb to influenza virus infection. Assessing ADAMTS5 
inhibitors in an influenza virus/arthritis model would aid in our understanding of this effect, as 
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the inhibition of ADAMTS5 in arthritis may not affect the immune response to influenza virus 
infection given the different tissues. This could initially be tested in an arthritis and influenza 
virus mouse model with further studies undertaken to compare immune responses in influenza 
infected arthritis patients and non-arthritis patients. 
This study highlights a necessity for metalloproteinase activity in the immune response and 
suggests enhancing the expression of these enzymes would increase the immune response to 
influenza virus infection, resulting in the timely removal of disease. However, I believe this 
study establishes paradoxical and conflicting views in the ECM field. We know that 
dysregulation of metalloproteinases has a detrimental effect on ECM remodelling in arthritis. 
We also know that metalloproteinases in general cause exhaustive immune cell infiltration, 
excessive inflammation and unwarranted tissue destruction (227, 381-383). For example, 
excessive ECM remodelling by MMP9 in asthmatic patients can result in further tissue 
degradation, worsening the disease (384) suggesting that inhibition of MMP9 would provide a 
reliable therapeutic target to reduce asthma complications. Yet lack of MMP9 in Mmp9-/- mice 
results in delayed fracture repair indicating that MMP9 is required for cellular processes (385). 
Further, neutrophil infiltration into the lung and tissue destruction during influenza infection is 
directly correlated to MMP9 expression, hence inhibiting MMP9 seems necessary to prevent 
tissue destruction (91, 105). Following removal of MMP9 (Mmp9-/- mice) influenza infection 
was increased, due to reduced neutrophil infiltration and control of infection (105). Indeed, our 
study would suggest that presence of ADAMTS5 and ADAMTS7 is required for a functional 
immune response, although in other disease models the presence of ADAMTS5 and 
ADAMTS7 can have detrimental effects.  If therapeutics were created that could enhance the 
expression of ADAMTS5 (as described above) we would have to assess the longevity of 
increased ADAMTS5 expression in the body. Ideally, increased expression of ADAMTS5 
would be short-lived. However, if expression is enhanced over a longer period following the 
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removal of influenza virus infection one would expect tissue damage to occur, including the 
knee joint.  
These studies, and our current study, provide key indications that understanding the 
multiple and complex role metalloproteinases play in disease is essential before assessing their 
potential applications as pharmacological targets.  
 
 
7.2 Future Directions 
As previously discussed, ADAMTS5 and ADAMTS7 regulate influenza-specific 
immunity via different mechanisms, hence the future directions in this section will be addressed 
separately  
 
7.2.1 ADAMTS5 
Chapters 3 and 4 identified a key role for ADAMTS5 in influenza virus infection, 
whereby our results indicate that ADAMTS5 mediated cleavage of versican is involved in 
CD8+ T cell migration. To further assess the migration of CD8+ T cells from Adamts5-/- mice, 
we could use adoptive transfer experiments to determine if this phenomenon was T cell 
intrinsic or in some way associated with the MLN microenvironment (65, 386). In these studies, 
we would transfer CD8+ T cells from Adamts5-/- mice to WT recipients. Upon influenza virus 
infection, one would expect these cells to be at a migratory disadvantage given that they do not 
express ADAMTS5. Alternatively, CD8+ T cells from WT mice would be adoptively 
transferred into Adamts5-/- mice to confirm our hypothesis. In this scenario versican 
accumulation would still occur in the MLN of Adamts5-/- mice, but one would anticipate that 
ADAMTS5 expression from WT CD8+ T cells would facilitate versican cleavage in the MLN, 
and egress from this tissue.  
  
 
167 
 
Combinatorial mutant mice have been used previously to characterise the role of 
ADAMTS enzymes in versican cleavage, as single mutants have not always shown a fully 
penetrant phenotype. Adamts5-/-xAdamts9+/- and Adamts20-/-xAdamts9+/- mutant mice 
[Adamts9+/- mice were used in this study as Adamts9-/- mice are embryonic lethal (387)] have 
been used previously to identify the importance of versican cleavage in interdigital web 
regression (299). It would be of interest to examine the impact of influenza immunity in this 
model i.e. if a more severe phenotype is observed. Adamts-/-1, Adamts4-/- and Adamts15-/- mice 
are available and it would be of significant interest to assess the role these enzymes in influenza 
virus pathogenesis (alone or in combination) given that they all cleave versican. 
Finally, a topic that was not addressed fully in this study but is important in the matrix 
biology field, is the impact of versikine (the versican cleavage fragment) on overall immunity. 
Versikine acts as a damage associated molecular pattern, that triggers TLR2 signalling and 
activation of the NF-κB pathway that supports T cell activation through the release of type I 
cytokines (e.g. IL6) (258, 322, 388). We also know that the presence of versikine has been 
associated with a higher frequency of activated CD8+ T cells in myeloma patient samples (330). 
This suggests that versikine may have a crucial role in chemotactic signalling for CD8+ T cell 
migration and tissue infiltration. To further assess this our transwell assays used in this study 
can be modified by adding versikine to the lower chamber of the transwell in place of CXCL12 
chemoattractant medium. Inhibiting versikine signalling in vivo would be difficult, as it is not 
present until versican is cleaved, hence why Adamts5-/- mouse models, and other versicanase 
mouse models (e.g. Adamts4-/- mice), are assessed for versican degradation. It would be of 
interest to further extend this study towards how removing versikine affects cellular processes 
in the Adamts5-/- mouse through an in-depth immunohistochemical analysis.  
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7.2.2 ADAMTS7 
The matrix biology field would greatly benefit from understanding the enzymatic or 
non-enzymatic role of ADAMTS7 in cellular processes. ADAMTS7 is an extracellularly 
secreted, catalytically active enzyme, with very little information currently available about its 
substrates (195, 284). A highly novel study by Marchant et al. helped clarify the role of MMP12 
during cocksackie virus infection in mice (309). In this study chromatin immunoprecipitation 
DNA sequencing technology was used to identify the interactions of MMP12 with DNA 
intracellularly. In this study it was found that macrophage-secreted MMP12 enters cocksackie 
virus infected cells, where it then enters in the nucleus (309). In the nucleus, intracellular 
MMP12 binds to the NF-κB promoter allowing secretion of IFNα (309). Regulation of IFNα 
production by MMP12 following infection could not only limit pathogen replication, but also 
prevent excessive inflammation. Our study would benefit substantially from utilising this 
technology to further characterise ADAMTS7’s role in the intracellular environment.  
Chapter 5 described immunity in influenza virus infected Adamts7-/- mice. In these 
studies, we observed an increase in influenza virus lung titres and higher weight loss associated 
with perturbed influenza-specific CD8+ T cell responses. We speculated that this was caused 
by fewer activated DC populations in influenza virus infected Adamts7-/- mice resulting in 
impaired antigen presentation. We did not however fully establish defective antigen uptake by 
CD8+ T cells in Adamts7-/- mice. The use of endogenous influenza-specific CD8+ T cells may 
be beneficial in assessing antigen uptake in Adamts7-/- mice, although this is technically 
difficult due to the very low numbers of influenza-specific CD8+ T cells that can be isolated. 
Transgenic animals offer the ability to easily track pathogen-specific responses, although, 
transgenic animal models for influenza virus research are not available or are inappropriate. 
However, we have identified transgenic animals that could be used to test the migration of DCs 
and activation of T cells in the context of ADAMTS7/influenza virus infection. Transgenic 
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mice that express T cell receptors specific for glycoprotein B from HSV (369, 370) and 
modified to express allelic markers (e.g. CD45.1) or green fluorescent protein (to facilitate their 
detection in recipient mice) exist allowing efficient tracking of pathogen-specific responses. 
By crossing the Adamts7-/- mice with glycoprotein B HSV-specific transgenic mice we could 
generate transgenic T cells deficient in ADAMTS7 for use in transfer experiments with wild-
type mice as recipients. The use of these mice in transfer experiments would also allow us to 
better understand the role of ADAMTS7 in memory CD8+ T cell responses, given the 
deficiency in memory CD8+ T cell numbers observed in Adamts7-/- mice (Figure 5.10) 
Interestingly we also observed that older uninfected Adamts7-/- mice (+16 weeks of age) 
were heavier than their WT counterparts (Figure 5.11C). Although it has been reported that 
Adamts7-/- mice show no differences in weight when compared to WT littermates, the knockout 
mice used in these previous studies only reached 14 weeks of age (283, 284), whereas our 
studies assessed mice up to 20 weeks of ages. Additionally, ADAMTS7 expression has been 
detected in white fat tissue (283), suggesting a novel role for ADAMTS7 in fat storage or 
metabolism. It is important to note that obesity in humans has been associated with enhanced 
susceptibility to H1N1 infection (389-391). Similarly, obese mice show enhanced lung 
pathology, virus titres and mortality following infection (391, 392) that correlated with poor 
CD8+ T cell memory (391, 392). Future studies could investigate the effects obesity has on 
influenza immunity in Adamts7-/- mice through the analysis immune cell metabolism 
(metabolomics) during infection (393, 394).  
Finally, this dissertation has provided a thorough analysis of influenza-specific CD8+ 
T cell immunity in both Adamts5-/- and Adamts7-/- mice. Influenza-specific CD4+ T cell 
immunity, B cell activation and antibody responses were not assessed. Given poor total B and 
CD4+ T cell numbers observed in influenza virus infected Adamts5-/- and Adamts7-/- mice, we 
speculate antigen-specific immune cell subsets would also be affected. Complicating things is 
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the availability and effectiveness of MHCII tetrameric complexes for enumerating influenza-
specific CD4+ T cells as they are difficult to make and hard to access (395). Future studies 
should endeavour to assess these responses in Adamts5-/- and Adamts7-/- mice. 
 
 
Concluding remarks 
The environment outside of the cell is an essential mediator of development and homeostasis 
for cell types and tissues. Studying members of the metalloproteinase family in the context of 
the ECM is an essential part of cell biology research. There are significant gaps in our 
knowledge describing the functional roles of ADAMTS5 and ADAMTS7 enzymes. This 
knowledge is essential to underpin and develop specific pharmacological targets. The 
interactions between ECM components and the impact on infectious disease is a new and 
emerging field of research that requires further study, with the potential for significant 
advances both clinically and therapeutically. 
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